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Abstract
As a result of mutation in genes, which is a simple change in our DNA, we will have
undesirable phenotypes which are known as genetic diseases or disorders. These small
changes, which happen frequently, can have extreme results. Understanding and iden-
tifying these changes and associating these mutated genes with genetic diseases can
play an important role in our health, by making us able to find better diagnosis and
therapeutic strategies for these genetic diseases. As a result of years of experiments,
there is a vast amount of data regarding human genome and di↵erent genetic diseases
that they still need to be processed properly to extract useful information. This work
is an e↵ort to analyze some useful datasets and to apply di↵erent techniques to asso-
ciate genes with genetic diseases. Two genetic diseases were studied here: Parkinson’s
disease and breast cancer. Using genetic programming, we analyzed the complex net-
work around known disease genes of the aforementioned diseases, and based on that
we generated a ranking for genes, based on their relevance to these diseases. In order
to generate these rankings, centrality measures of all nodes in the complex network
surrounding the known disease genes of the given genetic disease were calculated.
Using genetic programming, all the nodes were assigned scores based on the simi-
larity of their centrality measures to those of the known disease genes. Obtained
results showed that this method is successful at finding these patterns in centrality
measures and the highly ranked genes are worthy as good candidate disease genes
for being studied. Using standard benchmark tests, we tested our approach against
ENDEAVOUR and CIPHER - two well known disease gene ranking frameworks - and
we obtained comparable results.
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Chapter 1
Introduction
The problem of associating diseases with the genes that cause them is referred in the
literature by di↵erent terms, such as disease-gene association problem or disease gene
prediction. It is one of the most important problems regarding human health. There
is a huge e↵ort in this field, in which di↵erent approaches are considered in order to
associate genes with disease phenotypes.
Despite the great amount of work and research in this area, there is a lot more
to discover, since only about 10% of human genes have been associated with disease
phenotypes [4]. With the completion of human genome sequencing and with vast
the amount of biological data sets, there is an unprecedented opportunity to find the
genetic basis of di↵erent diseases.
In order to elucidate the inherited basis of human disease, the genomic variations
should be linked to the phenotypes which can be challenging for a number of reasons.
First, the concept of disease phenotype is uncertain and it is di cult to discover all
of the phenotypes. This is especially because some of them can also be a↵ected by
environmental factors. The second reason is that the current techniques for genotyp-
ing are not certain and they can not provide comprehensive and reliable results for
disease genes. This is one of the reasons for the emergence of methods that propose
a prioritization or a set of candidate genes for disease phenotypes [29].
Despite all of these aforementioned challenges, human genetics has been successful
especially for Mendelian diseases. The Online Mendelian Inheritance in Man (OMIM)
[34] website says that as of August 2014, there are 5,297 phenotypes for which the
molecular basis is known and 3,267 genes with phenotype-causing mutations. This
success can be attributed to the available genetic tools and data sets, although as
mentioned before, there is much more to discover.
1
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1.1 The Problem of Disease-Gene Association and
the Role of Bioinformatics
Mutated genes are the reason for many di↵erent genetic diseases or disorders. Muta-
tion in genes occurs frequently in DNA. If the mutation is in the non-coding part of
the DNA we may not notice it. However, if the mutation happens in the functional
part of DNA it may have significant results and harmful consequences. SNP or Single
Nucleotide Polymorphism is a variation occurring in the genome sequence (a single
nucleotide —A, C, G or T— is mutated and replaced by another one). This is the
most common reason for genetic disease. Associating diseases and their phenotypes
with the genes that cause them is the e↵ort of finding the genes for which their muta-
tions lead to the disease. This can play an important role in human health. A better
understanding of the genetic basis of human diseases can be a great help in finding
better diagnosis and therapeutic strategies to treat these diseases. In bioinformatics
there are di↵erent computational methods which use di↵erent available resources such
as known disease genes, experiment results and other evidences in the literature (see
Section 3.1), in order to associate disease phenotypes with genes.
1.2 Thesis Structure
The organization of this thesis is as follows. In Chapter 2 we have defined a few basic
and important terms and concepts in biology, followed by the research fields in bioin-
formatics. One of these research fields is gene prediction which is the main subject
of this work and is fully reviewed in Chapter 3. Complexity is one the main concepts
that is used in this work. It is defined and explained in Chapter 4. The method-
ology, along with di↵erent databases and toolkits used in this work are described in
Chapter 5. Our method has been tested on two genetic diseases: breast cancer and
Parkinson’s disease. These two case studies with the results and comparisons with
other work are reported in Chapters 6 and 7 respectively. Chapter 8 concludes this
work and discusses the obtained results, followed by the ideas for future work.
Chapter 2
Background
2.1 Bioinformatics Terms and Concepts
Bioinformatics is an interdisciplinary scientific field, which uses many areas of com-
puter science, mathematics, statistics and engineering to process biological data. In
order to work with these biological data, one should have a general knowledge of the
terms and the concepts of biology. For a computer scientist who wants to work in the
field of bioinformatics, getting to know these concepts can be a starting point. The
aim of this chapter is to provide basic information about some important biological
terms and concepts.
2.1.1 DNA
Deoxyribonucleic acid, or as we know it, DNA, is the unit of heredity in humans and
other organisms. DNA is mostly located in the cell nucleus and if so is called nuclear
DNA. A small quantity is found in mitochondria and is called mtDNA. Almost all
of the DNA in body cells is the same, and even 99 percent of the DNA in di↵erent
persons is the same [64].
DNA is a huge molecule in the form of a double helix. Chemically, DNA is
made of three components: nitrogen-rich bases, deoxyribose sugars and phosphates.
The combination of these three form a nucleotide. The huge molecules of DNA are
thousands of these nucleotides which come together in pairs. The four nitrogen-rich
bases in DNA can be divided into two groups: purines and pyrimidines. The purine
bases are adenine (A) and guanine (G). Purine is a compound with two rings; hence,
because of the chemical structure of Adenine and Guanine, they fall into this category.
The other two bases are cytosine (C) and thymine (T), which because of their single
3
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Figure 2.1: Structure of Purines and Pyrimidines. Image from [63].
six sided ring structure, are called Pyrimidines. Figure 2.1 illustrates the structure
of these four bases.
Each DNA macromolecule contains thousands of these four bases. Because of
their ring structure, they are flat and they can easily stack on top of each other.
Therefore, the DNA molecules are compact and very strong (the reason for their
extreme durability). These four bases attach to each other in pairs and they create
the base pairs: adenine with thymine (A — T) and guanine with cytosine (G —
C). Each of these bases is attached to a deoxyribose sugar (a ribose without oxygen
atom at the 2’ site) and a phosphate molecule. The whole combination, as mentioned
before, is called a nucleotide. These nucleotides are arranged in long spiral strands
to form the double helix. The general form of DNA is like a ladder in which the base
pairs are ladder rungs and the phosphate and sugar molecules are vertical side pipes
of the ladder. Figure 2.2 illustrates the form of a DNA molecule.
There are many di↵erent combinations of each of these four bases in each strand
and they carry lots of information. Some portions of these strands (with a specific
order of bases), code for some traits in our body which is the reason for the e↵orts in
studying the order of these bases in DNA molecules. Note that because of the pairing
in these four bases, DNA strands are antiparallel and complementary. Therefore if
we have the order of bases in one strand, we can find out the base-pair sequence of
the other.
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Figure 2.2: DNA structure. Image from [12].
2.1.2 Chromosome
A chromosome is a thread like structure which contains DNA and protein. The
single DNA molecule in a chromosome is tightly coiled around the proteins called
histones, which support its structure and control its functions. The prokaryotic cells
(cells without a nucleus), usually have small circular chromosomes, while eukaryotic
cells (cells with a nucleus) have larger linear chromosomes. Chromosomes can be ei-
ther duplicated or unduplicated. Unduplicated chromosomes are single linear strands
whereas duplicated chromosomes are two identical copies (which are called chromatids
or sister chromatids) that are pinched together. The joining location of these two
chromatids is called the centromere and the shape of a chromosome is based on the
placement of the centromere (i.e. whether it is close to the middle, top or bottom of
the chromosome). Refer to the Figure 2.3 to see the building blocks of chromosome.
The ploidy number is the number of chromosome sets held by a particular organ-
ism. For example, humans are diploids, meaning they have two copies of each chro-
mosome. Organisms can be haploid (one copy of each chromosome), triploid (three
copy of each chromosome) and so on. In humans, as diploids, there are 22 pairs of
uniquely shaped autosomal (non-sex) chromosomes and one pair of sex chromosomes
(those chromosomes that determine our gender).
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Figure 2.3: Structure of Chromosome. Image from [95].
Chromosomes carry genes (Figure 2.3). Genes are sections of DNA molecules
that code for particular observed traits, called phenotypes. To pass these genetic
traits from one generation to the next, the chromosomes must be replicated. Each
pair of homologous chromosomes carries the same, but not necessarily identical genes
which are called alleles. Each gene can have one or more alleles. The combination of
alleles of all the various genes is called the genotype.
2.1.3 RNA
Ribonucleic acid, or RNA, is a macromolecule like DNA which is present in all living
cells. RNA is very similar to DNA in many aspects. Unlike DNA, RNA is single
stranded. The reason is that it is using ribose sugar instead of deoxyribose (deoxyri-
bose is a ribose which lacks oxygen on 2’ location). The four nucleotide bases in
RNA are adenine, guanine, cytosine, and uracil (instead of the thymine in DNA). A
RNA strand, has a backbone of alternating sugar (the ribose mentioned earlier) and
phosphate groups (see Figure 2.6). Unlike DNA, RNA molecules are very unstable
and they decompose very rapidly. Sometimes, complementary regions bond together
and form a secondary structure. These structures can be in di↵erent forms such as
stem-loop (Figure 2.4), internal loop (Figure 2.5) or pseudoknot. These secondary
structures can be important in the function of the RNA molecule. There are di↵erent
works that attempt to predict these structures such as CyloFold [33], KineFold [46]
and RNAfold [38].
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Figure 2.4: RNA stem-loop. It happens when there are complementary regions on
the same strand. Image from [15].
Figure 2.5: Example of internal loop in RNA strand. Image from [14].
There are di↵erent types of RNA in the cell which play an important role by
catalyzing biological reactions. These di↵erent types are messenger RNA (mRNA),
transfer RNA (tRNA) and ribosomal RNA (rRNA). mRNA regulates the expression
of genes, tRNA is for carrying the amino acids (building blocks of proteins) during
translation of genetic language of nucleic acid to the language of protein (the process
for generating the proteins, based on DNA genes). rRNA is for attaching the amino
acids in chains, during the process of aforementioned translation. In eukaryotic cells,
DNA is a vital part of the cell and it never leaves the cell. Therefore, RNA will act
like a copy of the DNA in the cell and during a process of transcription (copying
DNA’s message into RNA’s language), messages of genes will be transcribed into
RNA (mRNA). This transcribed RNA will leave the cell and it then goes through a
process which ends in generating proteins [65].
2.1.4 Proteins
Proteins are biological macromolecules which play many critical roles in the body.
Proteins are made of amino acids and in each protein molecule, there are hundreds
to thousands of amino acids, attached together. Since there are 20 di↵erent amino
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Figure 2.6: Structure of RNA molecule. Image from [16].
acids and because each molecule of proteins (polypeptides) usually has more than
100 amino acids, there is a huge variety of combinations. Proteins perform many
important tasks within cells and they are required for the structure, function and
regulation of di↵erent tissues and organs in the body. Proteins can be divided into
di↵erent groups, according to their function. In Table 2.1 you will see a list of di↵erent
tasks that they perform in the body.
The main di↵erence between proteins is their amino acid sequences which cause
the unique structure and function of di↵erent proteins. Determining the 3D structure
of proteins is an important issue in di↵erent fields such as bioinformatics. It will help
scientists to understand the functions of proteins at a molecular level. There are four
distinct levels of protein structure:
1- Primary Structure: the primary structure of protein refers to their linear se-
quence of amino acids. This primary structure is held together by covalent or
peptide bonds.
2- Secondary Structure: This structure refers to highly regular local sub-structures.
The two main types of this structure are alpha helix and beta strand which are
held together by hydrogen bonds.
3- Tertiary Structure: tertiary structure refers to the three-dimensional structure
of a protein molecule. The protein folding (which a↵ects its structure) is self
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Table 2.1: Protein Functions
Function Description Example
Antibody Antibodies bind to specific foreign particles, such Immunoglobulin
as viruses and bacteria, to help protect the body. G (IgG)
Enzyme Enzymes carry out almost all of the thousands of Phenylalanine
chemical reactions that take place in cells. They hydroxylase
also assist with the formation of new molecules by
reading the genetic information stored in DNA.
Messenger Messenger proteins, such as some types of Growth hormone
hormones, transmit signals to coordinate biological
processes between di↵erent cells, tissues, and
organs.
Structural These proteins provide structure and support for Actin
component cells. On a larger scale, they also allow the body to
move.
Transport/storage These proteins bind and carry atoms and small Ferritin
molecules within cells and throughout the body.
organizing and is highly a↵ected by the amino acid sequence (primary structure)
of that protein. However, the environment can also a↵ect the folding of a protein
and its final shape.
4- Quaternary Structure: if the protein is built of sub-units, the quaternary struc-
ture is concerned with how these subunits fit together.
Figure 2.7 illustrates the four levels of protein structure.
As it is explained in the previous sections, there is a natural flow of sequential
information from DNA to RNA, and from RNA to protein. This detailed transfer
of sequential information is known as the central dogma of microbiology [17] which
states that these data can not be transferred back from protein to another protein or
to a nucleic acid.
2.2 Research Fields in Bioinformatics
There is a huge amount of data in biology which needs to be organized and processed.
The two main e↵orts in bioinformatics are storage and analysis of data. Bioinformati-
cians try to construct a good infrastructure for storing data which will make it easy
to process the data and analyzing it. Most of the data is in the form of sequences of
nucleotides in DNA, or sequences of amino acids in protein chains. These sequences
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Figure 2.7: Four levels of protein structure. Image from [13].
can a↵ect the structure of their molecules. Bioinformaticians study these sequences
and try to determine the final structure of these molecules. If they know these struc-
tures, they can deduce di↵erent features of them. Another important issue in this
field is trying to find the genes in DNA sequences. Genes are coding parts of DNA
(exon) which code for something (i.e. they have the instructions for producing spe-
cific proteins). Bioinformaticians work on these sequences to determine these genes
and their e↵ects. Also there are other interesting topics such as interaction between
proteins (protein-protein interactions) or relationships between di↵erent genes (poly-
genic trait, a trait which is controlled by multiple genes). In the following sections, a
summary of some of the most important research topics in bioinformatics is provided.
It should be noted that bioinformatics is far broader than the following topics. For
more information refer to [32].
2.2.1 Sequencing
In sequencing, the aim is to determine the primary structure of a biopolymer (like
the order of nucleotides in DNA). The result of the sequencing is a linear order of the
elements which represents a great deal of information about the sequenced molecule.
These results are among the most important data in bioinformatics databases and can
be used and analyzed for di↵erent purposes. In genetics, di↵erent types of sequencing
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are DNA sequencing, RNA sequencing, protein sequencing, and polysaccharide se-
quencing. DNA sequencing has great importance and there are di↵erent methods for
sequencing DNA. The most commonly used method historically, is Sanger sequencing
[78] (the chain termination method), but there are other methods like pyrosequenc-
ing. In DNA sequencing, the DNA is first fractured into millions of small pieces.
Then, these small pieces will be read and after that they should be put together.
This process which is known as genome assembly has its own di culties. Di↵erent
methods exist for merging the small pieces of DNA.
2.2.2 Sequence Alignment
As sequencing technologies grow, there will be more data available each day. One of
the central challenges to analyze this data is sequence alignment. The aim of sequence
alignment is to arrange the sequences in such a way that areas of similarities can be
found. These similar areas can show some functional, structural or revolutionary
relations between the sequences. There are di↵erent possible ways of aligning two
sequences, assuming we can use gaps in these alignments, which means an insertion
of a letter in one sequence or deletion of a letter in the other sequence. The two most
important ways of aligning two sequences are local and global alignments. In local
alignment, it will be assumed that the query is a portion (substring) of the other
string, so the query will be matched with a substring of the main string. Whereas
in global alignment, an end to end alignment will be performed and there will be
many gaps in the final alignment, if the size of the two strings are dissimilar. The
Needleman-Wunsch algorithm is a general global alignment algorithm and the Smith-
Waterman algorithm is general local alignment method [51].
2.2.3 Gene Prediction
DNA sequences have two main parts: exon and intron. The exon is the part of the
sequence that codes for something (which is called coding DNA or gene) and the
intron is the part that does not code for anything (sometimes called “junk DNA”).
While working with the raw data of sequences, one of the main e↵orts is to find the
genes. Gene prediction is the process of finding the genes in sequences. It should be
distinguished with finding the function of a gene which is another important research
area with various methods. There are di↵erent methods for finding the genes. Some
are empirical methods, which try to find the known expressed sequence tags, mRNA
and protein products in the target genome. If the sequence is mRNA, the problem
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is only to find a gene sequence in that mRNA. If the given sequence is a protein
sequence, after reverse translating, a variety of possible candidates for coding DNA
sequences can be derived. Then the problem is trivial to search the given sequence
to find a match for a coding DNA (using di↵erent methods such as local sequence
alignment). Another method for finding the genes are ab initio methods. They look
up the sequence to find signals and evidence of existence of a protein coding gene.
Chapter 3
Literature Review of
Computational Methods
3.1 Computational Methods
In order to find the genes related to a genetic disease, there will be a search space
in which the methods look for the genes causing the diseases. The results of these
methods are usually a group of genes which are called candidate disease genes and
have a high probability of being involved in the genetic disease. Generally there are
two main approaches to represent the candidate genes: prioritization or selection. In
prioritization, genes will be ranked (or assigned values) based on the likelihood of
their involvement, and in selection, a reduced subset of genes with a higher likelihood
of involvement will be selected as the candidate disease genes [73].
One of the ways of determining the candidate genes is linkage analysis, which is the
study of the tendency of genes to be inherited together because of their close location
to each other on the chromosome [66]. Another recent methodology for disease gene
prediction is genome wide association studies (GWAS), an approach which scans the
markers across the complete sets of DNA or genomes in order to find genomic vari-
ations and SNPs associated with a particular disease [59]. A computational disease
gene prediction is a method which makes use of huge genomic databases and reposito-
ries of biomedical literature to identify the most likely disease gene candidates. These
candidate genes can be further studied by researchers for empirical analysis in order
to find diagnose, prognose and therapeutic treatments for genetic diseases [87]. In the
next few sections, di↵erent evidence types that are used by di↵erent computational
methods are explained and reviewed.
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3.1.1 Text Mining of Biomedical Literature
There are several di↵erent existing computational disease gene prediction methods in
the literature, one of which is text mining of the literature. PubMed [1] and OMIM
[34] are the two approaches based on natural language processing and text mining
of the biomedical literature [93]. It should be considered that although these data
resources o↵er worthwhile knowledge, they are inherently biased toward well-studied
genes [73].
3.1.2 Functional Annotations
Another group of disease gene prediction methods make use of functional annotations
in which they try to find the genes in the same pathway. These biological pathways
are a series of events which are the result of interactions within cells which lead to a
specific phenotype. In these methods, genes with the same functionality will be con-
sidered as a candidate disease gene. The Kyoto Encyclopedia of Genes and Genomes
(KEGG) [39], Gene Ontology (GO) [6] and Human Phenotype Ontology [43] are three
significant databases which connect genes with their functionality.
3.1.3 Gene Properties and Sequencing Data
Inherent gene or protein properties such as length, phylogenetic analysis of genes,
degree of conversation, and next generation sequencing data can be used for asso-
ciating genes with diseases. It should be noted that although these approaches can
be successful, due to lack of knowledge about the aforementioned information (es-
pecially gene sequences), they are not powerful enough to find many genetic causes
of diseases. The relationships between phenotypes of candidate genes with known
disease genes is another way of finding new candidate genes. Some data resources
such as MimMiner [89] and OMIM [34] can be used to connect genes with phenotypes.
3.1.4 Gene Expression
Data from gene expression is another useful resource which can be helpful toward find-
ing candidate genes. There are di↵erent factors such as cell type and environment
that a↵ect the expression of the genes. It is also obvious that the expression of disease
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genes is di↵erent than the normal ones. The methods which use gene expression data
compare the expression of the disease genes and normal genes. These methods are
capable of making a connection between the disease genes and new candidate genes
based on their similarity of expression on microarrays. It should be noted that the
data produced in this way is one of the least biased regarding disease gene prediction
[73].
3.1.5 Protein-Protein Interaction
One of the most e↵ective and powerful tools for predicting disease genes is Protein-
Protein Interaction networks or PPI [60]. In a PPI whose nodes are proteins, and the
links represent interactions between them, it has been shown that the genes related to
the same disease have protein products which physically interact [31]. Based on this,
these methods analyze the PPI networks in order to find proteins which physically
interact and then consider their producing genes as candidate disease genes.
At this point, it should be mentioned that there have been some e↵orts regarding
disease gene association which try to take advantage of several di↵erent methods
mentioned above. In this case there can be some problems with combining the ideas
which is mainly concerning how to combine all of them together as an integrated
computational module. If planned appropriately, these fusion methods are expected
to produce insightful results. The following section provides an overview of some of
the important computational methods.
3.2 Using a Fusion of Evidence Types in Di↵erent
Computational Methods
As mentioned earlier, there are some e↵orts in di↵erent computational methods to
take advantage of di↵erent evidence types. Using a fusion of evidence types has its
own challenges. For example which evidence types to use or how to combine and
integrate them into a single operational module. Also how to combine each generated
value of di↵erent evidence types into a final result is another challenge in here.
One of the methods that combines di↵erent evidence types is CIPHER [94]. In
this computational framework, in order to find the relations between phenotypes and
genotypes, they are looking at the similarities between disease phenotypes, known
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Table 3.1: Using a fusion of evidence types in some well-known disease-gene associa-
tion methods
Method Evidence Type Reference
CAESAR functional annotation, gene expression, inherent properties, text mining [27]
MAESTRO functional annotation, gene expression, inherent properties, text mining, PPI [8]
GFINDER gene expression, phenotype relationship [55]
GENESEEKER functional annotation, gene expression, text mining, phenotype relationship [88]
CGPRIO functional annotation, inherent properties, text mining, PPI [26]
associations between genes and phenotypes and also the interactions among proteins.
This is based on the assumption that functionally related genes can cause similar
diseases.
ENDEAVOUR [2] is another framework that provides gene prioritization through
fusion of genomic data. This prioritization is based on the similarity to the known
disease genes involved in these phenomena. ENDEAVOUR creates multiple distinct
prioritizations for heterogeneous data sources and then using order statistics, gener-
ates a global ranking. ENDEAVOUR has the flexibility for adding additional data
sources. Its accessible online tool [21] provides di↵erent evidence types such as PPI,
text mining and gene expression.
GPEC [50] is also a gene prioritization method that finds genes that are likely
to be associated with a disease or involved in a pathway. GPEC is a network based
approach that uses a random walk with restart algorithm (RWRA). It uses protein-
protein interaction network and functional annotations to find the candidate genes.
There are other frameworks that use a fusion of evidence types. Table 3.1 lists a few
of these methods.
Chapter 4
Complexity
The highly interconnected nature of the human interactome (see Section 4.2) makes
it di cult to consider single genes for diseases. In fact, these myriad number of
interactions will be processed in order to find functional and topological modules of
genes. Further studies showed that the e↵ects of a genetic abnormality is not only
restricted to the genes that carry it, but it can spread along the network in which
these genes interact and a↵ect the gene products of the normal genes as well [7].
Furthermore, it has been revealed that the same situation exists with the phenotypic
impacts of the mutated genes that their phenotypes are a result of the mutated genes
as well as the genes and gene products with which they interact [7]. Based on these
facts, the importance of the network based approaches in disease gene association
can be understood and the question would be “what types of networks should be
studied?”.
There are many organs in human body which interact in di↵erent ways. In the
past decade, there has been a huge growth in the amount of human specific interaction
data [35] which leaves us with di↵erent networks that can be studied. Among these
networks, protein-protein interaction networks or PPI are among the most important
networks to be studied [60]. There is also metabolic networks with the nodes repre-
senting metabolites and the links representing participation in the same biochemical
reactions [7]. Other important networks are regulatory networks, RNA networks,
co-expression networks and genetic networks [7].
4.1 Complex Networks
Considering the biological networks in the human body, it should be noted that
these networks are extremely huge with thousands of nodes and links among them.
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Figure 4.1: Human Interactome. Image from [18].
Refer to Figure 4.1 for an example. These networks have complex behaviour and
they are called complex networks. Many real world systems are complex networks,
including biological networks, transport networks, the Internet, and the World Wide
Web. When it comes to the complexity of these networks, the classic algorithms
for regular graphs will no longer work in a reasonable time, therefore these complex
networks should be studied and new algorithms should be used in order to process
these networks.
There are many common properties in complex networks such as small world
phenomena or community structure. These complex networks and their properties
need to be analyzed in order to extract di↵erent information.
4.2 The Modularity of Genetic Diseases
When it comes to the problem of disease gene association, there are several concepts
related to the modular nature of genetic diseases that should be considered and it
should be noted that almost all of the computational methods use a network based
approach in order to find candidate genes. One of these important concepts is that
there is not a one-to-one relationship between genes and genetic diseases or disorders.
This means that one gene can take part in several phenotypes of di↵erent diseases,
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and one disease can be a result of mutation in di↵erent genes [70]. There is a huge
network known as the human interactome which is a complex network of communi-
cations between di↵erent cells and organs. This network is extremely huge and has
around 25,000 protein coding genes, around a thousand metabolites and an undefined
number of proteins and RNA molecules. Nodes of this network are di↵erent cellular
components, and number more than 100,000. The links between these nodes, which
represent interactions between these components, are expected to be much larger in
number. Observing this huge network and excessive amount of interactions between
the genes and other components, it can be simply inferred that genetic diseases are not
the result of a single gene, but they are a result of di↵erent genes, closely interacting
with each other as modules in a complex network [7].
4.2.1 Guilt by Association
The principle known as guilt by association says that the genes interacting closely
with each other tend to share the same functionality, or from another point of view,
it can be said that the genes involved in a disease will closely interact with each other
in their underlying networks [30]. Based on this principle, the computational methods
for disease gene association take advantage of known disease genes (the genes that are
already known to be involved in the given genetic disease). First they will identify the
set of already known disease genes and then try to find the physical modules based
on the location and closeness in the network, or functional modules which contain
these known disease genes. They will then use this information to select the genes in
these modules as new candidate disease genes. These candidate disease genes are the
genes that are expected to be involved in a given genetic disease.
4.3 Centrality Measures
Centrality measures are important values for the nodes of a network which reveal the
key nodes that have significant roles in the network, relevant to the network topology
[24, 80]. In this section, several centrality measures are defined. For this, we assume
that we have a graph G = (V,E) in which:
• n is number of vertices and deg(v) is the degree of vertex v.
• dist(v, w) is the shortest path between v and w.
•  st indicates the number of shortest paths between s and t, and
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Figure 4.2: Graph G with 5 vertices and 5 edges.
•  st(v) is the number of shortest paths between s and t that pass through vertex
v.
The following explanations are based on the supplementary data of [80].
4.3.1 Degree
The degree of node v or deg(v) is simply the number of nodes adjacent to v. By
adjacent we mean those nodes that are directly connected or first neighbours, hence
it corresponds to adjacent edges as well. For example, in graph G (Figure 4.2), vertex
D has the highest degree which is 3. Vertices A, B and E all have a degree of 2 and
vertex C has a degree of 1.
One of the applications of degree is calculating the degree distribution P (k) which
is the probability that a node has exactly k links. P (k) can be calculated by counting
the number of nodes with k links, for k = 1, 2, 3, ... and then dividing it by the
total number of nodes which is n. Based on the degree distribution decisions can
be made about the structure of network. For example, a graph with power law
degree distribution indicates the existence of a few nodes with high degree (hubs). In
biological networks, a node with a high degree can suggest that it is a node with a
central regulatory role. For example proteins with high degree in signaling networks
can suggest that they are regulatory hubs of the network.
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4.3.2 Diameter
Diameter is defined as the longest distance between any pair of vertices of a graph.
Note that distance in here is the shortest path between the corresponding vertices.
In graph G of Figure 4.2, diameter is 3, which is the shortest path between vertex C
and vertex A. Note that there are two paths between vertex E and D, but we always
consider the shortest path. Therefore, dist(E,D) = 1 and dist(A,C) = 3.
This centrality measure indicates the distance between the two most distant nodes
of the network, hence, a high diameter in graph can imply low graph compactness.
However it should be considered that this doesn’t always work, as in a network that
has two distant nodes but other nodes are located close to each other. In this example,
although the diameter is high, the graph is still compact. In contrast with high
graph diameters, a low graph diameter is much more informative and implies high
compactness in the graph. It should be noted that in order to decide that the diameter
is low or high, we should consider the total number of nodes in the graph.
In biological networks, a low diameter, which implies compactness, can be a proof
of close interactions between nodes. For example, in a compact PPI (protein-protein
interaction) network, based on the principle of guilt by association (see 4.2.1), shared
functionalities can be implied.
4.3.3 Average Distance
This parameter is defined as the average of all shortest paths in a graph. This is
determined by dividing the summation of all shortest paths (between any pair of
vertices) by the total number of nodes.
AvDG =
P
v2V
P
w 6=v2V dist(v, w)
n
(4.1)
As with diameter, average distance can be used to imply graph compactness.
However, since average distance considers all nodes and shortest paths, the average
distance is more reliable than graph diameter. A high average distance implies a
sparse graph and vice versa. Again, in determining low or high, the size of the
network (total number of nodes) should be considered. In a large biological network,
a low average distance shows closeness and easiness of communications and indicates
existence of functional complexes and modules.
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4.3.4 Eigenvector
The eigenvector is a centrality measure that can be defined recursively. A node will
have high eigenvector value, if it has many neighbours with high eigenvector values.
The concept is to find nodes that not only have a high number of neighbours, but also
have important (high scoring) neighbours. Based on this, a node with high eigenvector
value can be said to be well-connected and that node will be visited frequently while
traversing the graph. Equation 4.2 shows one way to calculate eigenvector.
Eig(v) =
1
 
X
w2N(v)
Eig(w) (4.2)
In this equation,   is a constant and N(v) is the set of the neighbours of vertex v.
This recursive formula can begin by giving an initial eigen value of 1 to every node,
and it repeats until the values stop changing.
In biological networks, the eigenvector value can be an informative value for the
regulatory role of nodes in that network. A node with a high eigenvector value, has
several neighbours with high eigenvector values which regulate them or are regulated
by them. On the other hand, a node with a low Eigenvector value is a peripheral
node, and this node is not interacting with central nodes.
4.3.5 Eccentricity
Eccentricity, which is a node centrality index, is calculated by finding the shortest
path between the node v and all other nodes in the graph. The reciprocal of the
maximum value will be reported as the eccentricity value:
Cecc(v) =
1
max{dist(v, w) : w 2 V } (4.3)
Since we are finding the most distant node from a node, we can make assumptions
about node proximity and centrality role. In this sense, a high value for eccentricity
means that all nodes of the network are in proximity of that node, but a low value
for eccentricity means that other nodes are far from this node (or at least there is
one distant node from this node). Therefore, a high eccentricity value is much more
informative than a low value.
In biological networks, eccentricity of a node can be compared with the average
eccentricity of the network, a higher value indicates the easiness of that node to be
reached and influenced by other nodes of the network. A low value of eccentricity
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(compared to the average) can imply a marginal role for that node.
4.3.6 Closeness
Closeness is a centrality index that is computed by finding the reciprocal of summation
of shortest paths from a given node to all other nodes of that network. The closeness
of node v is calculated by the following formula:
Cclo(v) =
1
⌃w2V dist(v, w)
(4.4)
Based on this formula, a high value of closeness for a node shows the node proximity
in the network. Similarly, a low value of closeness implies that other nodes of the
network are distant from that node. While using this measure, it should be noted
that this value can be misleading. For example, a low value of closeness that can
be obtained by a few very distant nodes, while other nodes are close, and the same
thing can happen with a high closeness value. Therefore, this value is not very
informative by itself, but combined with other measures can be much more reliable
and informative. For example, a high eccentricity value along with a high closeness
value can imply that the node is central in the network.
If a node in a biological network is close to other nodes and has a higher closeness
value than the average of other nodes, this can imply that this node is functionally
relevant to other nodes. Also, nodes with low closeness can be of interest, since it
shows that these nodes are less relevant to this network and possibly they act as
intersecting boundaries with other networks. Based on this, if a biological network
has a high average closeness, it can be a sign of functional modules existing in that
network.
4.3.7 Radiality
Radiality is a centrality index with respect to graph diameter. In order to calculate
this value for a node v, summation of shortest paths from v to all other vertices will
be subtracted by graph diameter +1 ( G + 1). Then this value will be divided by
(n  1).
Crad(v) =
⌃w2V ( G + 1  dist(v, w))
n  1 (4.5)
Since graph diameter ( G) is the longest shortest distance, subtracting the distance
from v to its neighbour nodes from diameter gives a high value to the radiality of that
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node if the paths are short and vice versa. Therefore a high radiality value can imply
the proximity of that node, and if the radiality is low, that node would be peripheral.
Combining radiality with closeness and eccentricity can lead us to meaningful results
in terms of node centrality role: a high value for radiality, closeness and eccentricity
is a consistent sign that the node occupies a central position in the network. In
biological networks, a high radiality value compared to the average of graph, indicates
the existence of functional modules which can be helpful in obtaining the unknown
functionality of genes based on the functionality of close genes.
4.3.8 Centroid Value
Centroid value is the most complex centrality measure which is calculated by the
following formula:
Ccen(v) = min{f(v, w) : w 2 V } (4.6)
where f(v, w) =  v(w)    w(v) and  v(w) is the number of vertices that are closer
to v than to w. With this function, the number of nodes that are closer to v or w
(in terms of shortest path) is calculated and compared the node distance of all the
other nodes from the others. This means that this function is comparing the number
of neighbours (not necessarily immediate neighbours) between pairs of nodes. In this
sense, a high value for centroid score indicates that the node has a higher number
of neighbours (not only first neighbours). Again, here the centroid value is more
meaningful when it is compared with the average centroid value of all the nodes in
the graph. In a biological network, such as a protein signaling network, a high value
of centroid can imply the capability of a protein to functionally organize discrete
modules of proteins. Based on this, a network with a high average centroid value can
be organizing functional units.
4.3.9 Stress
This centrality measure is about the number of shortest paths passing through a
specific node. In order to calculate the stress of a node, all shortest paths in the
graph will be calculated and then the number of shortest paths passing through a
node v will be reported as its stress:
Cstr(v) =
X
s 6=v2V
X
t 6=v2V
 st(v) (4.7)
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A stressed node (a node with a high value for stress) is a node included in many short-
est paths which indicates an important role in the network. However, this doesn’t
mean that this node is crucial for those connections, because there can be other
shortest paths not passing through this node. Again this stress value is more infor-
mative when it is compared with the average stress value of the graph. In biological
networks, a stressed node shows the capability of holding communications between
nodes. Because of the nature of this measure, a stressed node may not be relevant in
holding the connections but it can be heavily involved in cellular processes.
4.3.10 Betweenness
Betweenness is a node centrality index similar to stress but much more informative.
In order to calculate betweenness, pairs of nodes s and p are considered, then the
number of shortest paths between them passing through a node v is divided by the
total number of shortest paths between them:
Cspb(v) =
X
s 6=v2V
X
t 6=v2V
 st(v) (4.8)
where
 st(v) =
 st(v)
 st
(4.9)
If the number of shortest paths between s and p is equal to (or close to) the number of
shortest paths between s and p that pass through v, the value of  st(v), and therefore
the value of betweenness, will be higher. This shows the importance of the node v in
maintaining the connections between other nodes. Therefore a high betweenness score
indicates the importance of that node to maintain the connections, and looking at the
stress value, the number of paths for which the node v is critical will be known. Hence,
betweenness and stress can be used together to obtain complementary information.
In biological networks, a high value of betweenness shows the capability of that node
in holding the communications of other nodes and organizing the regulatory modules.
Chapter 5
Methodology
Our approach to the disease-gene association problem combines several ideas. In
short this approach analyzes the complex network around the already known disease
genes and extracts several centrality measures for every node in this network. Based
on these measures, a GP program has been developed which aims at finding a pattern
in the known disease genes. It then tries to find this pattern in other genes of this
network and based on this, it will rank the genes. The outcome of this approach is
a ranking which prioritizes the genes based on the likelihood of their involvement in
the given genetic disease. In the following sections, an overview of the methods and
platforms used in this work is presented.
5.1 Genetic Programming
Artificial intelligence and machine learning try to bring the intelligence to machines
and software and give them the problem solving skills. As Arthur Samuel, one of
the pioneers in this field stated, the main goal of artificial intelligence and machine
learning is to make the machines to behave in such a way that if that task was being
done by a human, it should have involved the use of intelligence [77].
Genetic programming which is an evolutionary computation (EC) technique, is an-
swering one of the central questions in computer science (raised by Arthur Samuel in
1959), about how to have computers to learn and solve problems without giving them
explicit instructions and without explicitly programming them [45]. Genetic program-
ming (GP), is like a genetic algorithm (GA) but the individuals in the population
that are being evolved are computer programs. Every individual in the population
will be evolved in a random process, similar to Darwinian natural selection, in order
to breed a better (and fitter) population of individuals [44]. Although GP results
26
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can not be guaranteed since it uses a stochastic process, it has been very successful
in finding novel solutions for many di↵erent problems [74]. Prior to applying genetic
programming to a problem, terminals and functions set have to be determined. After
this, a function for measuring the fitness of individuals should be selected and then a
condition/criterion has to be defined in order to determine when to terminate the run.
Figure 5.1 shows the general flow of a GP. Genetic Programming generally follows
the following steps:
1. Create a random initial population of programs.
2. Execute each program, evaluate it and assign its fitness value.
3. Using a selection method which is based on the fitness values of the individuals,
select one or more individuals from the population, in order to breed the new
population.
4. Using a reproduction operation, generate the new individuals from the selected
ones in the last step.
5. If a solution is found or any terminating condition is met, go to (6); otherwise
go to (2).
6. Return the best individual so far.
There are a few terms that are used in the above GP description. These terms
are explained below.
5.1.1 Function and Terminal Sets
Defining functions and terminals is one of the most important parts of GP design.
As the name suggests, functions are the valid functions of the program. In most
cases they are simple primitive math operators such as addition and subtraction.
Terminals are random constants and independent variables that hold the external
inputs. Combining terminals and functions, expression trees are generated. In these
trees, functions are operators and terminals are operands. Therefore, each tree can
generate a value.
5.1.2 Selection Method
As explained above, GP has a number of generations. At the end of each generation,
the fitness values of the individuals in the population are calculated. At this step
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Figure 5.1: A fitness function is used to evaluate the individuals. There are two
reproduction operators (Crossover and Mutation) that will breed new population
based on the fitness of current individuals. Image from [74].
selection methods are used to select fitter individuals in order to breed new individuals
for the next generation. The di↵erence in selection methods is in the way they select
individuals for reproduction. In a GP program elitism can also be used in which
the best individuals will remain in the population of the next generation unchanged
(i.e. without being modified by reproduction operators). Two well-known selection
methods are Tournament Selection and Roulette-Wheel Selection.
5.1.3 Reproduction Operators
Reproduction operators are in charge of breeding new individuals for the next gen-
eration. At the end of each generation individuals will be evaluated using a fitness
function. Then, using a selection method, a number of individuals in the current
generation will be selected and passed to the reproduction methods to breed the in-
dividuals for the next generation. The two reproduction methods are mutation and
crossover. Mutation brings diversity to the population and makes it possible to ex-
plore the search space. In mutation, a node in the tree will be selected and the nodes
in that sub-tree will change their values to other valid values at random locations.
Crossover, which brings the ability to exploit the search space, works on two individ-
uals and produces two children. In crossover an entire sub-tree of the first individual
will be replaced with another sub-tree from the second individual. More accurately,
two sub-trees are swapped and generate two new individuals.
5.2 Databases, Toolkits and Platforms
In this work a variety of information from di↵erent databases has been used and
analyzed with di↵erent toolkits and platforms. The following sections explain these
data sources and platforms.
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5.2.1 Genotator
There is a huge amount of genetic data that is increasing over time. There are numer-
ous data resources that collect and organize di↵erent biological datasets. Researchers
often have to manually browse and integrate data from various sources to obtain in-
formation about a particular disease. Genotator [91] which is developed at Harvard
University, aims at collecting and integrating data from well known genetic resources.
Based on the information that Genotator collects, it generates reliable gene-to-disease
rankings for any disease. In this work, Genotator was used to obtain the set of known
disease genes for our diseases of interest.
5.2.2 Cytoscape
Cytoscape is a major computational platform that provides the means for analyzing
biological networks. Cytoscape is a free open source software and has accessible
API (application programming interface) which has made this possible for software
developers to develop their own plugins for this platform [76], which brings more
functionality to Cytoscape and makes it more flexible. Using these plugins, di↵erent
types of biological datasets can be obtained, analyzed and visualized [11]. For creating
the input datasets of our GP program, two plugins in Cytoscape have been used:
GeneMANIA and CentiScaPe.
5.2.3 GeneMANIA
GeneMANIA is a gene function prediction tool that analyzes a given list of genes (as
the input) and expands the list and prioritizes the genes based on the available pro-
teomic and genomic datasets [92]. The homo sapiens (human) interaction database
of GeneMANIA records di↵erent types of interactions (co-expression, protein–protein
interaction, pathway, co-localization etc.) based on 395 di↵erent interaction databases
developed to date. It contains the interactions among 21435 genes from the human
genome.
GeneMANIA produces a ranking of genes based on generated scores that are higher
for genes that share the same functionality or properties with the query genes. This
approach is based on the principle of guilt by association as described in Section
4.2.1. GeneMANIA is also freely available as a plugin for Cytoscape [58]. In this
work, GeneMANIA is used to extract a list of candidate genes that closely interact
with the known disease genes. This approach uses di↵erent evidence types, available
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for the users of GeneMANIA. Hence, it uses a composite network generated by Gen-
eMANIA that combines interaction networks of those evidence types. The genes in
this composite network are separated into training and testing datasets to be used
by the GP program; see Section 7.1 for further details. The evidence types used in
this work are co-expression, co-localization, genetic interactions, pathway, physical
interactions, predicted functional relationships and shared protein domains. These
evidence types are explained in the following sections based on the explanations pro-
vided by GeneMANIA [25].
Co-expression
Represents the data collected from the gene expression. In this sense, two genes that
have similar levels of expression are considered to be connected. Most of the data
from gene expression studies are collected from Gene Expression Omnibus (GEO)
[20].
Co-localization
This is mostly the location based data, such as proteins in proximity or genes that
are expressed in the same tissue. Based on this, two genes will be connected if they
are in a known module or in a same cellular tissue.
Genetic Interactions
This is the data collected from genetic interactions. This is mainly regarding func-
tionally related genes, which means modifications in one gene, can e↵ect the other
gene as well. BioGRID [84] is a repository for interaction datasets that is mainly used
by GeneMANIA for collecting interaction data.
Pathway
Data collected from di↵erent pathways in which gene products are linked to each
other if they are interacting in the same pathway. According to the definition in [37],
a pathway is a series of actions between di↵erent molecules that lead to a certain
product or a certain change. The pathway data in GeneMANIA are collected from
di↵erent data sources such as BioCyc and Reactome via PathwayCommons [9].
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Physical Interactions
Physical interaction is what is known as protein-protein interaction, described earlier
in Section 3.1.5. Based on this, genes will be linked if in a protein-protein interaction
study they are found to be interacting. GeneMANIA uses di↵erent protein interaction
databases to collect these data, two of which are BioGRID [84] and PathwayCommons
[9].
Predicted Functional Relationships
This evidence type is based on predicting relationships between genes, which is often
regarding protein interactions. The main source of these predictions is based on the
known functional interactions of the genes in other organisms.
Shared Protein Domains
Proteins have di↵erent domains and families. In these type of data, the gene products
that have the same protein data will be linked to each other. GeneMANIA uses
various databases for protein domains, such as InterPro [36], SMART [49] and Pfam
[48].
5.2.4 CentiScaPe
With the increasing amount of experimental data and large amount of available
datasets, there is an increasing need for analyzing them. These datasets are frequently
presented as huge biological networks, where nodes represent biological entities and
the links between them (edges) show interactions between those entities [11]. Analyz-
ing these complex networks can help to extract di↵erent information. For example,
the network around a known disease gene can be analyzed to find the genes that
closely interact with that known disease gene, and based on the aforementioned prin-
ciple of guilt by association, those genes can be identified as candidate disease genes
[86]. Here, a similar idea is used. In order to find the genes that closely interact with
the known disease genes, several centrality measures for the nodes in the network sur-
rounding the known disease genes is calculated. Analyzing these centrality measures
together can give us di↵erent information such as important nodes in that network.
In this work, CentiScaPe is used to compute the centrality measures for the nodes
of our composite network. CentiScaPe is a bioinformatics tool that is freely avail-
able as a plugin for Cytoscape. It computes di↵erent network centralities and inte-
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grates them into Cytoscape, so they can be used with other Cytoscape plugins. The
computed centrality parameters in CentiScaPe are Degree, Average Distance, Stress,
Diameter, Betweenness, Closeness, Radiality, Eccentricity and Centroid Value [80].
These centrality measures are described in Section 4.3.
5.2.5 ECJ
We use ECJ to implement genetic programming. ECJ is a Java based evolutionary
computation (EC) framework, developed by Sean Luke et al. in 1998 at George Mason
University [47]. ECJ was created after massive modifications on lil-gp [96] which
showed that it is not possible to further extend that platform. At this time, ECJ is a
strong and stable platform with lots of features (like island models, coevolution, multi
objective optimization algorithms, etc.) and is widely used for genetic programming
[54].
5.3 Experiment Description
In our GP approach we analyze the complex network around the already known
disease genes and extract several centrality measures for every node in this network.
Based on these measures, our GP approach works to find patterns in the known
disease genes and then tries to find these patterns in the other genes of this network.
Scores are assigned to genes based on the similarities of their patterns, and are used
for ranking. The output is a ranking that prioritizes the genes based on the likelihood
of their involvement in a given genetic disease.
In machine learning there are two main approaches to learning: supervised and
unsupervised. In supervised learning, data is divided into two groups, input and
output, and the goal is to predict the value of output based on the input data. In
order to achieve this goal, a training set (a set of input data with known output values)
will be used to assist the learning process. Two examples of supervised learning are
regression and classification. In the former there is a continuous output value, and
in the latter, a discrete output value to be predicted. In unsupervised learning, there
is no training or testing dataset (no dataset with known output) and the e↵ort is
on finding structures or relations in data [23]. One of the examples of unsupervised
learning is data clustering in which the goal is to find groups of data for which their
members are very similar. Our approach is an example of supervised learning.
Genetic Programing has great potential for classification and has been successfully
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Figure 5.2: A sample expression tree.
applied to many di↵erent supervised and unsupervised learning tasks [23, 69, 19].
Classification requires a training dataset, used to induce a classifier, and a testing
dataset, used to measure the quality of the classifier.
The input data, obtained from GeneMANIA, must be separated into training and
testing datasets (see Section 7.1). It is important that the training dataset is not
biased and includes the same number of members from di↵erent classes of data.
5.3.1 GP Language
Each GP program has a set of terminals and a function set, which it combines to gen-
erate the expression trees. Our terminal set contains 9 attributes corresponding to
the 9 centrality measures for each of the genes in the aforementioned training/testing
datasets. These 9 centrality measures are the ones computed in CentiScaPe, namely
degree, average distance, stress, diameter, betweenness, closeness, radiality, eccentric-
ity and centroid value (described in Section 4.3). There are 6 functions in the function
set, listed in Table 5.1. These function list covers the most basic math operators and
as reported in next two chapters, they were su cient for GP to perform well on the
input dataset.
Based on these, the GP expression tree is combined of the terminals which hold
values of centrality measures, and math operators (listed in Table 5.1). Hence, each
tree generates a value. These values will be considered as scores for genes and based
on them, genes are assigned a rank in the rank list. Figure 5.2 shows a sample
expression tree. These expression trees grow over generations and the evolved tree at
the final generation is much bigger in size than the depicted sample.
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Table 5.1: GP Functions
Name Function
Add Addition of two numbers
Sub Subtraction of two numbers
Div Division of two numbers, returns 0 if the 2nd number is 0
Mul Multiplication of two numbers
Min Minimum of two numbers
Max Maximum of two numbers
5.3.2 Fitness Evaluation
Defining a suitable fitness function and finding a proper way to evaluate the individ-
uals is one the most important aspects of GP application, that has significant impact
on the results. Fitness can be calculated in many di↵erent ways, such as number
of errors, number of hits, total time, etc. In this work the e↵ort is on generating
meaningful scores based on the centrality measures. One of the meaningful scores
that was available here, was the gene score from GeneMANIA. These are assigned to
genes based on their shared functionalities and properties with known disease genes.
Therefore, in the evaluation of generated individuals and the scores which they re-
turn, e↵ort is taken to see how close they get to the scores from GeneMANIA. An
ideal solution here: (i) finds the pattern in the centrality measures of the nodes in
our composite network, (ii) predicts the important nodes of this complex network;
and (iii) reports them as candidate disease genes.
Koza fitness was used in this program. This fitness holds the fitness of individuals,
as described in Koza I [44]. Standardized fitness ranges from 0 (best fitness) to infinity
(worst possible) and adjusted fitness is computed based on that:
fadj =
1
1 + fstn
(5.1)
where fadj is the adjusted fitness and fstn is the standard fitness. Although Koza
fitness prints out the adjusted fitness, it stores the standardized fitness, where lower
values are considered as better and fitter individuals.
As explained in previous section (Section 5.3.1), a rank list is created for the genes.
Rank of each gene in this rank list is compared with its origial rank in GeneMANIA’s
rank list. If the distance is less than 10, it will be considered as a hit, otherwise
the distance will be added to a sum of error parameter. This sum of error will be
passed to the fitness function as the standard fitness and then adjusted fitness will
be calculated based on that.
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5.4 Benchmark Tests
5.4.1 Leave-One-Out Cross Validation
In order to test the abilities of our method, we tested it using the leave-one-out cross
validation test. This is a standard and widely used procedure that tests the given
method against already known disease genes.
If we name the set of known disease genes K, we run this procedure |K| times,
each time for a di↵erent known disease gene in K. If we have a set of candidate
disease genes C, at each round of this procedure, a gene g will be removed from K
and will be added to C. Next, the method will run normally on C [ g and a ranking
will be generated for these genes. The goal is to see if the gene g will be ranked as a
highly associative gene (ranked lower than a predefined threshold)[50].
Considering the di culty of evaluating the generated rankings of di↵erent computa-
tional methods for candidate disease genes, leave-one-out gives a simple and e↵ective
approach to test these methods with known disease genes. Because of this, leave-one-
out is used elsewhere e.g. [94], [90] and [42].
5.4.2 Fold Enrichment Analysis
Following the leave-one-out cross-validation test, fold enrichment analysis is usually
used to report the results. Based on the provided explanations in [94], this analysis
simply says that if the method under study ranks n% of the known disease genes in
the top m% of the candidate genes (the aforementioned threshold), there would be a
n/m-fold enrichment on average.
As required by this analysis, a threshold must be defined to separate the two pre-
diction classes (highly associative genes and peripheral genes). There is no specific
rule to determine the threshold and as it is evident, it would be harder for the meth-
ods under study to perform well on smaller thresholds. It should be noted that for
comparison of several methods, the same threshold must be used in these tests.
5.4.3 Receiver-Operating Characteristic (ROC) Analysis
Receiver-operating characteristic or ROC analysis is another way to analyze the ob-
tained results via leave-one-out cross-validation test. This analysis basically measures
the performance of a binary classifier. In this analysis we define a threshold T for our
generated ranking for candidate disease genes (see Section 5.4.2). This threshold on
a generated rank list specifies the two prediction classes. Based on this, considering
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sets K and C and known disease gene g as defined in Section 5.4.1, if g is ranked
lower than T , it will be considered as a successfully identified known disease gene and
we call it a True-Positive or TP. If g is ranked higher than T , the method is failed
at identifying this known disease gene and we call it a False-Negative or FN. Based
on the computed values of TP and FN, the sensitivity of our computational method
will be defined as equation 5.2:
Sensitivity =
TP
TP + FN
(5.2)
The sensitivity value simply reports the success rate of our method (percentage of
identified genes) on the set of known disease genes.
Chapter 6
Case Study: Breast Cancer
In this chapter a case study of Breast Cancer based on our approach is presented.
Breast Cancer is the most common type of cancer among women which accounts for
22% of their cancers [94]. In the United States it accounts for more than 40000 deaths
per year [3] and in the United Kingdom it has been reported to be the most common
cause of death among women aged 40 to 50 [57].
Breast cancer is a genetic disease which is caused by mutation and alteration
in genes or their expression [41]. It is currently estimated that about 25% of the
risk of breast cancer is explained by the known susceptibility genes for this disease.
Moreover these genes explain less than 5% of breast cancer incidence [68], suggesting
a need for more studies on the genetic basis of this disease. Our method is applied to
the problem of finding Breast Cancer genes and in this chapter the experiments are
explained.
6.1 Input Data
Using OMIM [56], 15 susceptibility genes were selected to be involved in breast cancer
and they are used as the known disease genes in these experiments. Table 6.1 outlines
these known disease genes. These genes are the same as those used in [85] and [94].
The only exception was that these other works used an extra gene in addition to these
15 known disease genes. This additional gene could not be identified by GeneMANIA
which was the main reason that it was not used here.
The GeneMANIA plugin for Cytoscape was used to extract the top 2000 genes
interacting around these known disease genes and the composite network in which
they interact. This composite network was generated by GeneMANIA using the
following evidence types: co-expression, co-localization, genetic interactions, pathway,
37
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Table 6.1: Known Disease Genes for Breast Cancer
Gene NCBI ID
BRCA1 672
AR 367
ATM 472
CHEK2 11200
BRCA2 675
STK11 6794
RAD51 5888
PTEN 5728
BARD1 580
TP53 7157
RB1CC1 9821
NCOA3 8202
PIK3CA 5290
PPM1D 8493
CASP8 841
physical interactions (protein-protein interactions), predicted functional relationships
and shared protein domains. These 2000 genes and the set of our known disease genes
is used for training and testing of our GP program.
6.2 GP Design
The GP method has 4 separate working sets, each containing 4 islands that work
together. The purpose is to aid in dividing the computational e↵ort and making the
runs as fast as possible. Also, as will be explained later, in some experiments each set
is used to implement di↵erent settings and use di↵erent centrality measures as input
data, to compare the numerous possible setups of this problem. The experiments test
the following:
1. GP parameters settings
2. Fitness evaluation
3. Di↵erent sets of centrality measures to be analyzed for each node
One of the main goals is to improve the performance of the GP in the leave-one-out
cross validation test.
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The first experiment uses the following centrality measures: eccentricity, radial-
ity, closeness, degree and their averages. As explained in Section 4.3, these centrality
measures, when they are accompanied by their averages, are expected to generate
meaningful results. Table 6.2 shows the GP parameters of this experiment and Ta-
ble 6.3 shows the migration pattern of the island models. Islands were set to send
individuals every 4 generations.
Table 6.2: GP Parameters of First Experiment
Parameter Value
number of generations 50
number of jobs 20 (5 per set)
number of threads 8
population size 2500 (per island)
selection Tournament (Size = 7)
cross-over rate 90%
mutation rate 10%
size of training dataset 1014
size of testing dataset 1001
number of elite individuals 10
Table 6.3: Island Model Migration Pattern
From To No. of individuals
Island 1 Island 2 20
Island 2 Island 3 20
Island 3 Island 4, 1 50
Island 4 Island 1 25
In this experiment, each set had 5 jobs, but since everything (except the random
values) was the same for each set, we had a total of 20 runs. Figure 6.1 shows the
averages of mean fitness and best fitness values of the GP program for 20 runs, over
50 generations. In this experiment, GP was trying to generate scores for the genes,
based on the generated scores by GeneMANIA, and then rank each gene based on
the generated scores. The main problem in here was that the generated scores by
GeneMANIA were not normally distributed and the di↵erence of their scores, for
the last 1500 genes (out of 2015 genes in total) was less than 1, while for the top
genes there was a di↵erence of 100 for each gene. Based on this distribution GP was
trying to generate a score to cover those last 1500 genes, ignoring the top high-scoring
genes. As a result, the generated fitness values were better than they should be. This
brought us to the next experiment.
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Figure 6.1: Average of the mean fitness and best fitness of 20 runs over 50 generations.
Breast cancer, experiment 1.
6.3 Using GeneMANIA Ordering of the Genes
The next experiment was an e↵ort to value the order of the genes in the GeneMANIA
results instead of their scores. Based on this, in this experiment GP is trying to
generate an ordering of the genes based on their order in the GeneMANIA ranklist of
the top 2000 genes for breast cancer. If the distance between the generated order of a
gene with its original order in GeneMANIA list is less than 10, GP will count it as a
hit. Having this in mind, the second experiment uses the same parameters settings as
in Tables 6.2 and 6.3 with the new evaluation and scoring system. Figure 6.2 depicts
the convergence of mean fitness and best fitness of 20 jobs, over 50 generations.
In order to compare the fitness values of these two first experiments, an unpaired
two sample t-test assuming unequal variances was used. The null hypothesis was that
the means of the two experiments were equal and the P-value was 0.05. Table 6.4
shows the result of this test. Based on this, the great value of t-Stat shows a huge
di↵erence in the two groups. Also, if we check this value with the ‘t Critical two-
tail’ it is greater than this, which rejects our null hypothesis. By checking the mean
values, it can be seen that the first experiments had better fitness values. Please note
that these reported values are adjusted fitness values which should be in this range:
0 < fadj  1 with 0 being the worst and 1 the best fitness values.
Although in this new scoring system the fitness values are worse, we still kept it
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Figure 6.2: Average of the mean fitness and best fitness of 20 runs over 50 generations.
Breast cancer, experiment 2.
for the next experiments, since the results and the generated fitness values are more
realistic in this case.
Table 6.4: t-test assuming unequal variances over 20 runs of the first two experiments
of breast cancer. P-value was set to 0.05
Experiment 1 Experiment 2
Mean 4.20708E-05 4.11731E-06
Variance 1.25524E-12 1.88669E-16
Observations 20 20
Hypothesized Mean Di↵erence 0
df 19
t Stat 151.4854957
P(T<=t) one-tail 4.71714E-31
t Critical one-tail 1.729132792
P(T<=t) two-tail 9.43428E-31
t Critical two-tail 2.09302405
6.4 Di↵erent Centrality Measures
As explained earlier in Section 4.3, di↵erent centrality measures can be more mean-
ingful when they are accompanied with some other specific centrality measures. In
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the next experiment, di↵erent sets used di↵erent combinations of centrality measures,
in order to compare their output and decide about the best centrality measures to use.
Table 6.5 outlines the centrality measures used by each set in the third experiment.
Table 6.5: Centrality Measures Used in Third Experiment of Breast Cancer
Set No. Centrality Measures
Set 1 Eccentricity, Radiality, Closeness, Degree and their averages
Set 2 All Centrality Measures and their averages
Set 3 Stress, Betweenness and their averages
Set 4 Degree, Eigen Vector and their averages
Table 6.6 shows the GP parameters of this experiment. The migration pattern of
the island model is same as for the first experiment, outlined in Table 6.3.
Table 6.6: GP Parameters of Third Experiment, Breast Cancer
Parameter Value
number of generations 100
number of jobs 5
number of threads 2
population size 2500 (per island)
selection Tournament (Size = 5)
cross-over rate 90%
mutation rate 10%
size of training dataset 1014
size of testing dataset 1001
number of elite individuals 10
In order to get the results of the leave-one-out cross validation test, this experiment
was executed 15 times. Each time one of the known disease genes was given to the
testing set and the other 14 genes were given to the training set, making a testing set
of 1001 genes and a training set of 1014 genes. Each time the GP program generated a
ranking for the testing genes and the objective was to see if that single known disease
gene in the testing set can rank high.
As mentioned in Table 6.6, the number of jobs is 5 and each run of this experiment
generates 5 rankings (for each set). After running this experiment 15 times, we had
75 rankings for these 15 known disease genes for each set. The rank of each known
disease gene in these 75 rankings was extracted and compared with those of the other
sets to compare the performance of each set. It should be noted that in these rankings
lower is better and ideally all these 15 known disease genes should be ranked 1st in
their own separate run.
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Table 6.7: t-test assuming unequal variances to compare di↵erent sets of experiment
3 of breast cancer. P-value was 0.05 for all the tests.
t-test No. 1 Set 1 Set 2 t-test No. 2 Set 1 Set 3
Mean 125.94 286.9 Mean 125.94 69.56
Variance 22941.3376 94626.46 Variance 22941.33757 5714.628
Observations 75 75 Observations 75 75
Hypothesized Mean Di↵erence 0 Hypothesized Mean Di↵erence 0
df 108 df 109
t Stat -4.0654105 t Stat 2.884351465
P(T<=t) one-tail 4.5651E-05 P(T<=t) one-tail 0.002363794
t Critical one-tail 1.65908514 t Critical one-tail 1.658953459
P(T<=t) two-tail 9.1302E-05 P(T<=t) two-tail 0.004727589
t Critical two-tail 1.98217342 t Critical two-tail 1.98196743
t-test No. 3 Set 1 Set 4 t-test No. 4 Set 3 Set 4
Mean 125.94 116.1133 Mean 69.56 116.1133
Variance 22941.3376 22795.86 Variance 5714.628108 22795.86
Observations 75 75 Observations 75 75
Hypothesized Mean Di↵erence 0 Hypothesized Mean Di↵erence 0
df 148 df 109
t Stat 0.3979258 t Stat -2.38769651
P(T<=t) one-tail 0.34562914 P(T<=t) one-tail 0.009337583
t Critical one-tail 1.65521451 t Critical one-tail 1.658953459
P(T<=t) two-tail 0.69125827 P(T<=t) two-tail 0.018675166
t Critical two-tail 1.97612246 t Critical two-tail 1.98196743
We used 4 di↵erent t-tests (unpaired two sample t-test, assuming unequal vari-
ances) to compare ‘set 1 and set 2’, ‘set 1 and set 3’, ‘set 1 and set 4’, and ‘set 3 and
set 4’. Table 6.7 shows the results of these 4 t-tests. Based on these results, set 1
which is using eccentricity, radiality, closeness and degree performed better than set
2 which uses all 9 centrality measures listed in Section 5.2.4. One reason can be that
giving all of these centrality measures to the GP is overwhelming it with too much
information so that it is unable to generate good results compared to an experiment
in which we give it a selected number of centrality measures. Furthermore, the tests
show that set 3, using stress and betweenness, outperforms sets 1 and 4 with a no-
ticeable di↵erence in the mean values of its generated rankings, compared to sets 1
and 4. Also the t-test on sets 1 and 4 shows that their performance is almost similar
and the di↵erences in their mean values are negligible. Therefore set 3, using stress
and betweenness, generated the best ranks and set 2, using all centrality measures,
was the worst. Set 1 using radiality, eccentricity, closeness, degree and set 4 using
degree and eigenvector had the same performance.
It should be mentioned that in these series of 15 runs for the leave-one-out cross
validation test, the threshold for the known disease gene to be considered as identified
in our GP ranking was set to 25 (top 2.5%, as in [85]) and 4 out of 15 known disease
genes were successfully identified in this experiment.
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6.5 Improving the Results
Based on the previous experiments, we implemented the last experiment to get the
best possible results. As we see in the previous section (6.4), the best combination of
centrality measures was stress, betweenness and their averages. For this experiment
we used these centrality measures for all the sets. Table 6.8 outlines the parameter
settings of the last experiment and Table 6.9 shows the migration patterns of islands
which is the same for all four sets. The mail-box capacity was set to 200.
Table 6.8: GP Parameters of Last/Best Experiment, Breast Cancer
Parameter Value
number of generations 100
number of jobs 20 (5 per set)
number of threads 4
population size 1024 (256 per island)
selection Tournament (Size = 3)
cross-over rate 90%
mutation rate 10%
size of training dataset 214
size of testing dataset 1801
number of elite individuals 5
Table 6.9: Island Model Migration Pattern
From To No. of individuals
Island 1 Island 2, 3, 4 20
Island 2 Island 1, 3, 4 20
Island 3 Island 1, 2, 4 20
Island 4 Island 1, 2, 3 20
Figure 6.3 shows the convergence of average mean fitness and best fitness for
this experiment over 100 generations, for all 20 runs of this experiment. Another
important change in this experiment was the number of training and testing sets.
The reason for this change was to make sure that the size of the training set is not
too large for GP, so it can perform well. Hence, out of 2015 genes for breast cancer,
214 were given to the training set and the rest were given to the testing set.
In order to check the e↵ect of smaller training size on the fitness values, we used
a two sample t-test on this experiment and the previous one (experiment 3). Table
6.10 shows the result of this t-test. As we can see, the t-Stat shows a huge di↵erence
in the mean fitness values of the best runs of these experiments. As we see in this
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Figure 6.3: Average of the mean fitness and best fitness of 20 runs over 100 genera-
tions. Breast cancer, final experiment
table, the mean value of experiment 4 is about 24 times greater than the previous
one which shows a huge improvement in the fitness values.
Table 6.10: Two sample t-test assuming unequal variances, comparing third and
fourth experiments of breast cancer.
Experiment 3 Experiment 4
Mean 4.139838E-06 9.95502E-05
Variance 2.75799E-15 1.66538E-12
Observations 20 20
Hypothesized Mean Di↵erence 0
df 19
t Stat -330.3670629
P(T<=t) one-tail 1.74726E-37
t Critical one-tail 1.729132792
P(T<=t) two-tail 3.49453E-37
t Critical two-tail 2.09302405
6.5.1 Leave-One-Out Cross Validation
As mentioned earlier in Section 5.4.1, in order to run this test we have to run our
GP program 15 times and each time we give one of the known disease genes to the
testing set and the other 14 known disease genes to the training set. Each time our
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GP generates a ranking for the genes in the testing set and if that known disease gene
is ranked lower than a certain threshold, we count it as a successfully identified gene.
There is no specific rule to set this threshold, but in order to be able to make a fair
comparison with other work, we set the threshold to be the top 2.5% of the genes,
which is the same threshold that is used in [85] and in [94].
Our method, using stress and betweenness as the centrality measures for each
gene, successfully predicted 9 out of 15 known disease genes. These genes are listed
in Table 6.11.
Table 6.11: Successfully Predicted Genes via GP from the 15 Known Disease Genes
for Breast Cancer listed in Table 6.1
Gene Median Ranking Best Ranking Standard Deviation
TP53 4 2.5 4.98
BARD1 5 3 19.39
BRCA1 6.75 6 22.42
PIK3CA 9.75 7 8.81
ATM 15.75 14 9.08
NCOA3 24 19 13.11
RAD51 34 29 36.30
CASP8 42 32 21.75
RB1CC1 45.25 42 15.84
6.5.2 Comparison with Other Works
We compared these results with the earlier work performed in [85] and also with
CIPHER [94], on the same set of candidate disease genes and same set of known
disease genes. Note that as mentioned in Section 6.1, both these previous works had
an extra known disease gene in addition to those of this experiment. Table 6.12 shows
the results of the benchmark tests.
The GA approach has the best performance here, identifying 12 out of 16 known
disease genes. Our GP approach has the same performance as CIPHER with the
same percentage of identified known disease genes (same sensitivity values).
6.5.3 Predicting novel disease genes for breast cancer
After running the benchmark tests on our method and comparing it with other work,
we analyzed the generated ranklists for the candidate genes. Some of the genes that
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Table 6.12: Analysis and Comparison to Other Frameworks
Framework Fold enrich. Leave-one-out Sensitivity
CIPHER 25 10/16 0.625
GA approach 30 12/16 0.75
GP approach 24 9/15 0.60
were consistently ranked high in most of ranklists, found to be mentioned in di↵erent
works to be involved in breast cancer. It shows that these genes and also other highly
ranked genes are worthy of being further studied.
One of these genes is APP (Amyloid-  precursor protein) that in a recent study
([53]) the pathological role of this gene in breast cancer has been studied. This gene
has been reported to be related for di↵erent types of cancer, but this recent study
showed its role in pathogenesis of breast cancer. There is also CYP19A1 (cytochrome
P450) and XRCC3 ( X-ray repair complementing defective repair in Chinese hamster
cells 3) that they are both reported by genetics home reference [67] that changes in
these genes are associated with breast cancer.
SNURF (SNRPN upstream reading frame) is another highly ranked gene in most
of our rankings that is studied in [79] and [75]. It is mentioned that this gene cooper-
ates with other genes and can cause a breast cancer. Another highly ranked protein
coding gene is TSPY1 (testis specific protein, Y-linked 1). This gene is reported in
di↵erent studies such as [28] and [22] to be related to breast cancer. There are also
two genes ESR1 (estrogen receptor 1) and EP300 (E1A binding protein p300) that
both were ranked high in earlier work done in [85] and they are reported to have some
supporting evidence of involvement in breast cancer, based on di↵erent data resource
according to Genotator.
Chapter 7
Case Study: Parkinson’s Disease
The methodology was applied to the problem of finding genes involved in Parkinson’s
Disease, a neurological condition that in most cases is due to an interaction between
many genes and environmental risk factors [81]. Due to the complicated nature of
these interactions, it is thus a particularly worthwhile but challenging disease to study
for disease-gene association.
7.1 Input Data
Using Genotator, we extracted 15 genes known to be involved in Parkinson’s disease.
They are the same set of known disease genes that are used in [85] and they are
listed in Table 7.1. These are high-scoring genes scored by Genotator based on their
involvement in Parkinson’s disease.
Using the GeneMANIA plugin for Cytoscape, a list of the 3000 top-scoring genes
that closely interact with the 15 known disease genes for Parkinson’s disease, and the
composite network in which they interact, was extracted. The composite network
from GeneMANIA is based on di↵erent evidence types that are available for users of
this software, namely: co-expression, co-localization, genetic interactions, pathway,
physical interactions (protein-protein interactions), predicted functional relationships
and shared protein domains. Using CentiScaPe, the nine centrality measures were
generated for each node of this network.
The 3015 genes (15 known disease genes from Genotator, and 3000 genes from
GeneMANIA) were divided into two groups, one for training and the other for testing.
If the genes in each dataset were to have similar scores (for example, if all genes with
high scores were in one dataset and all genes with lower scores in the other), then
there would be a high probability that GP would produce biased results. Having this
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Table 7.1: Known Disease Genes
Gene NCBI ID
LRRK2 120892
SNCA 6622
PARK2 5071
MAPT 4137
APOE 348
GBA 2629
GAK 2580
BST1 683
DRD2 1813
PINK1 65018
MAOB 4129
BDNF 627
CYP2D6 1565
PON1 5444
COMT 1312
in mind, the genes for the training and testing datasets were selected so that both
datasets have genes with high scores and low scores. Note that the sizes of training
and testing datasets vary in di↵erent experiments and they will be mentioned for each
experiment.
7.2 GP Design
Similar to the design of our GP method for the previous case study (see Section
6.2), our GP has 4 separate working sets, each containing four asynchronous islands.
This special implementation drastically reduced the running time of the experiments,
making us able to run more di↵erent experiments. Also because of having di↵erent
separate working sets, it was possible to use di↵erent approaches in each set for
research purposes.
For the first experiment, we used the parameters listed in Table 7.2. The islands
of all four sets use the migration pattern mentioned in Table 7.3, and based on this
pattern, every four generations they send their individuals to other islands. For this
experiment, we used all the available centrality measures listed in Section 5.2.4, to
see the power of them all together for this problem. Note that in this experiment
everything except the random values remained the same for each set.
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Table 7.2: GP Parameters of First Experiment, Parkinson’s Disease
Parameter Value
number of generations 51
number of jobs 20 (5 per set)
number of threads 8
population size 2500 (per island)
selection Tournament (Size = 7)
cross-over rate 90%
mutation rate 10%
size of training dataset 1514
size of testing dataset 1501
number of elite individuals 10
Table 7.3: Island Model Migration Pattern
From To No. of individuals
Island 1 Island 2 20
Island 2 Island 3 20
Island 3 Island 4, 1 50
Island 4 Island 1 25
Figure 7.1 illustrates the convergence of average mean fitness and best fitness
for this experiment over 51 generations. In order to see the performance of this
experiment on the genes, we performed the leave-one-out cross validation test on our
set of 15 known disease genes. The threshold was set to the top 1.8%, the same
threshold used to report and compare other methods in Section 7.12. Out of the 15
known disease genes, this method identified two of them (SNCA and APOE) and
showed a potential for further improvement.
Unexpectedly, using all available centrality measures did not result in an out-
standing performance in the leave-one-out cross validation test. The concern here is
to check whether changing centrality measures can actually help with these results or
not. Having this in mind, the next experiment is an attempt to see the e↵ect of using
a di↵erent set of centrality measures in analyzing our composite network of genes’
interactions. Based on this, for the second experiment everything was the same as
the first one (see Tables 7.2 and 7.3), but this time a new set of centrality measures
was used: radiality, eccentricity, closeness, degree and their averages. Based on the
studies on the centrality measures and explanations in Section 4.3, and also based on
the results of the Breast Cancer case study, these centrality measures were expected
to work better together.
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Figure 7.1: Average of the mean fitness and best fitness of 20 runs over 51 generations.
Parkinson’s disease, experiment 1.
After running this experiment 15 times, each time for a known disease gene of
our known disease genes set, this method successfully identified 4 out of 15 known
disease genes. In order to have a comprehensive comparison of this experiment and
the previous one, we used a two sample t-test on all 15 known disease genes, in which
lower is better. As Table 7.4 shows, the t-test shows that there is a di↵erence between
the two experiments in favour of the second experiment. Based on this result, it can
be inferred that the second experiment not only outperformed the first experiment
on the four identified known disease genes, but it performed better on the rest of the
known disease genes as well. Considering that the second experiment was identical
to the first one, except for the set of centrality measures that was used, this proves
that using a selected set of centrality measures can actually have a great e↵ect on the
final results of our method.
7.3 Di↵erent Sets of Centrality Measures
The results of the second experiment showed the importance of having the right set of
centrality measures to analyze the composite network of genes interactions. The next
experiment was designed to compare the performance of di↵erent sets of centrality
measures on identifying known disease genes. Based on the explanations in Section
4.3 and based on the results of the Breast Cancer case study, we used di↵erent sets of
centrality measures for our third experiment. The centrality measures used by each
set are outlined in Table 7.5.
This experiment was performed using a slightly di↵erent set of parameter settings
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Table 7.4: Unpaired two sample t-test assuming unequal variances, comparing first
and second experiments of Parkinson’s disease. P-value is 0.05.
Experiment 1 Experiment 2
Mean 519.6733333 228.9
Variance 231272.6182 94352.54054
Observations 75 75
Hypothesized Mean Di↵erence 0
df 126
t Stat 4.412921791
P(T<=t) one-tail 1.08316E-05
t Critical one-tail 1.657036982
P(T<=t) two-tail 2.16631E-05
t Critical two-tail 1.978970576
Table 7.5: Centrality Measures Used in Third Experiment of Parkinson’s Disease
Set No. Centrality Measures
Set 1 Eccentricity, Radiality, Closeness, Degree and their averages
Set 2 Stress, Betweenness and their averages
Set 3 Stress, Betweenness and their averages
Set 4 Degree, Eigen-Vector and their averages
and also used a di↵erent migration pattern for the island models, as reported in Tables
7.6 and Table 7.7 respectively.
After running the experiment, an unpaired two sample t-test was used to com-
pare the performance of each set, using di↵erent sets of centrality measures. The
comparison was based on each of the 15 known disease genes, in the leave-one-out
cross validation test to see which set produced lower ranks for these known disease
genes. Table 7.8 shows the results of these t-tests. As we see, and as was expected,
sets 2 and 3 had the same results with a small non-significant di↵erence. Set 1 and
set 4 also had the same performance and the di↵erence in their mean values was
non-significant. Moreover, set 2, which used stress and betweenness, showed a bet-
ter performance compared to set 1, which used radiality, eccentricity, closeness and
degree. Finally, the result of the t-test comparing sets 2 and 4 suggests that there
is no significant di↵erence between these two (although the ‘t-stat’ is very close to
the critical value). However, if we consider the results of one-tail, the di↵erence is
significant in favour of set 2. Based on these results, it can be inferred that the com-
bination of stress, betweenness and their averages, outperformed other combinations
of centrality measures. These combination of centrality measures were expected to
work well together (see Section 4.3) and they also worked well for our Breast Cancer
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Table 7.6: GP Parameters of Third Experiment, Parkinson’s Disease
Parameter Value
number of generations 100
number of jobs 5
number of threads 4
population size 3000 (per island)
selection Tournament (Size = 3)
cross-over rate 90%
mutation rate 10%
size of training dataset 1514
size of testing dataset 1501
number of elite individuals 10
Table 7.7: Island Model Migration Pattern
From To No. of individuals
Island 1 Island 2, 3, 4 20
Island 2 Island 1, 3, 4 20
Island 3 Island 1, 2, 4 20
Island 4 Island 1, 2, 3 20
case study.
7.4 Improving the Results
The final experiment was designed and implemented based on the results of previous
experiments to obtain the best possible output of this method. As we experienced
in previous sections, centrality measures play an important role in the success of
our method. Based on the result of the previous experiment (Section 7.3), stress,
betweenness and their averages were used by all sets. There were also a few changes
in parameter settings. The important change in here was the reduced size of the
training set, as it was expected to improve the fitness values in our experiment. Table
7.9 shows these parameters for the last experiment. Islands used the same pattern
as for the previous example (Table 7.7) to send individuals to each other. Figure 7.2
shows the convergence of the average mean fitness and best fitness for this experiment
over 100 generations, for all 20 runs of this experiment.
The fitness values of this experiment were compared with the previous one using
a t-test. Table 7.10 shows the result of this t-test. Based on this, there was a huge
improvement in the fitness values of the fourth experiment. This shows the e↵ect of
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Table 7.8: t-test assuming unequal variances to compare di↵erent sets of experiment
3 of Parkinson’s disease. P-value is 0.05 for all of the tests.
t-test No. 1 Set 2 Set 3 t-test No. 2 Set 2 Set 1
Mean 174.4933333 168.8866667 Mean 174.4933333 319.98
Variance 102591.7128 102641.7268 Variance 102591.7128 113245.753
Observations 75 75 Observations 75 75
Hypothesized Mean Di↵erence 0 Hypothesized Mean Di↵erence 0
df 148 df 148
t Stat 0.107179396 t Stat -2.712004518
P(T<=t) one-tail 0.457395906 P(T<=t) one-tail 0.003739975
t Critical one-tail 1.655214507 t Critical one-tail 1.655214507
P(T<=t) two-tail 0.914791813 P(T<=t) two-tail 0.007479949
t Critical two-tail 1.976459531 t Critical two-tail 1.976122461
t-test No. 3 Set 2 Set 4 t-test No. 4 Set 1 Set 4
Mean 174.4933333 276.5466667 Mean 319.98 276.5466667
Variance 102591.7128 133995.4877 Variance 113245.753 133995.4877
Observations 75 75 Observations 75 75
Hypothesized Mean Di↵erence 0 Hypothesized Mean Di↵erence 0
df 145 df 147
t Stat -1.81703044 t Stat 0.756472832
P(T<=t) one-tail 0.35638687 P(T<=t) one-tail 0.225288203
t Critical one-tail 1.655430252 t Critical one-tail 1.655285437
P(T<=t) two-tail 0.071277374 P(T<=t) two-tail 0.450576405
t Critical two-tail 1.97645931 t Critical two-tail 1.976233277
choosing a smaller training set.
7.4.1 Leave-One-Out Cross Validation Test
For this test, we performed our method 15 separate times. Each time one of the known
disease genes was given to the testing set and the other 14 were given to the training
set. Each time, the GP method produced a ranking for the genes in training set. If
that known disease gene in the testing set was ranked lower than a certain threshold,
it was counted as a successfully identified known disease gene. The threshold in this
Table 7.9: GP Parameters of Last Experiment, Parkinson’s Disease
Parameter Value
number of generations 100
number of jobs 20
number of threads 4
population size 1024 (256 per island)
selection Tournament (Size = 3)
cross-over rate 90%
mutation rate 10%
size of training dataset 314
size of testing dataset 2701
number of elite individuals 5
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Figure 7.2: Average of the mean fitness and best fitness of 20 runs over 100 genera-
tions. Parkinson’s disease, last experiment.
experiment was set to the top 50 genes (the same threshold that is used to report
and compare other methodologies in Section 7.12).
Our method using stress, betweenness and their averages successfully identified 6
out of 15 known disease genes. These genes and their ranks are reported in Table
7.11.
7.4.2 Comparison with Other Works
We compared the obtained results with the earlier work performed in [85] and also
with ENDEAVOUR [2] on the same set of known disease genes. Table 7.12 shows
the result of this comparison. Based on these results, our GP approach outperformed
the other two approaches, identifying 6 out of 15 known disease genes. It should be
noted that as expected, our approach has di↵erent performance on di↵erent diseases.
In the breast cancer case study, GA performed better than the GP approach but for
the Parkinson’s disease, GP outperformed the GA approach.
7.4.3 Predicting novel Parkinson’s disease genes
After leave-one-out cross-validation on the known disease genes, we analyzed the
ranklist generated by our GP program to look at its prediction of novel disease genes.
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Table 7.10: An unpaired two sample t-test, assuming unequal variances comparing
fitness values of third and fourth experiments.
Experiment 3 Experiment 4
Mean 1.81952E-06 4.42633E-05
Variance 8.09145E-17 1.05503E-13
Observations 20 20
Hypothesized Mean Di↵erence 0
df 19
t Stat -584.158556
P(T<=t) one-tail 3.46483E-42
t Critical one-tail 1.729132792
P(T<=t) two-tail 6.92966E-42
t Critical two-tail 2.09302405
Table 7.11: Successfully Predicted Genes via GP from the 15 Known Disease Genes
for Parkinson’s Disease listed in Table 7.1
Gene Median Ranking Best Ranking Standard Deviation
PARK2 5 4.5 21.24
PINK1 5.75 4.5 184.00
BST1 5.75 5 54.72
SNCA 20.75 8 263.60
PON1 49 35 181.33
MAOB 50.5 34.5 110.70
Interestingly, some of the top ranked genes of our GP program are mentioned in
di↵erent works and studies to be relevant to Parkinson’s disease.
Epidermal Growth Factor Receptor (EGFR)
The epidermal growth factor receptor was one of the highest ranked genes in all of the
runs of our program. In studying the literature, we found that Chen-Plotkin et al.
[10] and Pellecchia et al. [72] have observed this gene to be related to some cognitive
inabilities of Parkinson’s disease patients. Putting all of this evidence together, it
makes EGFR gene a good candidate disease gene for Parkinson’s disease that should
be further studied.
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Table 7.12: Analysis and Comparison to Other Frameworks
Framework Fold enrich. Leave-one-out Sensitivity
ENDEAVOUR 11.11 3/15 0.2
GA approach 18.33 5/15 0.33
GP approach 22.22 6/15 0.4
Complement Component 8, alpha polypeptide (C8A)
C8A is a component of the complement system which encodes the alpha subunit of
C8, and mutations in this gene can lead to complement C8 alpha-gamma deficiency
[61]. This gene is ranked among the top genes in di↵erent runs of our GP method
and is reported in di↵erent works to be related to Parkinson’s disease. In PDbase,
a database for Parkinson’s Disease-related genes, it is mentioned that this gene is in
the Parkinson’s disease pathway, along with 8 other genes [71]. BioGraph [52] which
integrates heterogeneous knowledge bases, has ranked C8A 4th out of 18180 genes
(top 0.02%) in the context of Parkinson’s disease pathway [5].
Growth Associated Protein 43 (GAP-43)
GAP-43 is a protein associated with nerve growth, and is generated by the GAP-
43 gene in humans (NCBI gene ID: 2596) [62, 82]. There are some studies about
this gene and its protein being involved in Parkinson’s disease (in both humans
and animals). Seth et al. in [83] have studied the molecular events, triggered by
6-Hydroxydopamine (6-OHDA) exposure and the expression of growth associated
protein GAP-43. 6-OHDA has been implicated in the pathogenesis of Parkinson’s
disease [40]. Interestingly, GAP-43 is one of the highly ranked genes in di↵erent runs
of our GP method, which makes it a good candidate gene for Parkinson’s disease to
be further investigated.
Chapter 8
Conclusion and Future Work
The increasing amount of data in biological datasets brings with it the requirement
for analyzing the data to extract useful information. These datasets are often pre-
sented in the form of complex networks. Due to the complexity of these networks,
classic algorithms for graphs will no longer work in a reasonable time, therefore other
approaches should be used.
In this work, a GP approach is used to analyze the complex network around the
known disease genes. Using di↵erent sets of centrality measures, GP tries to extract
useful information, and based on them it generates a ranking for the genes. A lower
rank for a gene means that it has a higher probability of being involved in the disease
under study.
We presented two case studies for breast cancer and Parkinson’s disease. We per-
formed our method on a set of known disease genes for breast cancer and Parkinson’s
disease and then we used two well known and reliable frameworks to compare the re-
sults. The results of both experiments showed the great potential of GP in processing
complex networks and for the problem of disease-gene association. As outlined in Ta-
bles 6.12 and 7.12, our method compares favourably to results obtained by CIPHER,
ENDEAVOUR and also the earlier work done with GA in [85].
As it was expected for the GP to find patterns in known disease genes and use them
to find candidate disease genes, our method was successful in generating acceptable
and meaningful results. As an example, although this method sometimes fails to
identify some known disease genes, for the well known disease genes such as SNCA
and PARK2 for Parkinson’s disease or TP53, BRCA1 and ATM for Breast Cancer
it always performs well, as it consistently ranks them among the top 10 genes for
all of the runs. Another example is the e↵ect of di↵erent centrality measures on
the outcome of our method. As elaborated earlier in Section 4.3, some centrality
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measures are expected to work better and generate more meaningful results when
they are combined. Based on the experiments explained in our case studies (Chapters
6 and 7), as we expected, centrality measures had significant impact on the results.
For both genetic diseases that we studied (breast cancer and Parkinson’s disease), the
best combination of centrality measures were stress, betweenness and their averages.
It should be noted that these centrality measures may not be the best combination
for other genetic diseases and also there are still some other possible combinations
to test out of the 9 available centrality measures. Furthermore, there are some other
powerful centrality measures that are not available in CentiScaPe. Analyzing gene
interaction networks with those centrality measures may help GP in making better
decisions for candidate disease genes.
Although the results are satisfactory, there is still a need for improvement. GP
parameters were determined empirically in this work, and it is possible to find better
parameter settings for the GP program. Also the GP language can be modified and
enhanced as it may make a huge di↵erence in GP performance. Fitness evaluation
is another important part of every GP program that can have a significant e↵ect on
the results. Di↵erent criteria should be considered and studied in order to find more
powerful fitness functions.
As mentioned before, this GP method is based on the island models. The archi-
tecture of these islands and their migration patterns and parameter settings are other
important factors that can be improved. This work is generic and disease centred,
which means that it can be applied to almost any genetic disease with some mod-
ifications. Hence, applying this method to more genetic diseases can be considered
in the future, especially since we expect di↵erent performance and accuracy for this
method on di↵erent genetic diseases.
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Appendix A
Leave-One-Out Cross-Validation
Results
As mentioned before in Section 5.4, leave-one-out cross validation test was used to test
the performance of our computational method. For both case studies (Parkinson’s
disease and Breast Cancer) this test was performed 15 times for each of the known
disease genes. The results of the final (and the best) experiment are reported in here
for both diseases.
Note that for each known disease gene, there are five paragraphs representing each
of the five jobs. In each paragraph, ranking of that specific gene is extracted for each
“set–island”. Inside the parentheses job number, set number and island number is
reported respectively followed by the known disease gene name and its rank in the
generated ranklist for candidate disease genes. Also median of generated ranks by all
four islands in each set, is reported in a bold text, right after the ranks of four islands
in each set.
A.1 Breast Cancer
A.1.1 AR
Job # 0
(Job.0.S1.I1) AR - 80; (Job.0.S1.I2) AR - 83; (Job.0.S1.I3) AR - 80; (Job.0.S1.I4)
AR - 82 : 81.0 (Job.0.S2.I1) AR - 77; (Job.0.S2.I2) AR - 75; (Job.0.S2.I3) AR
- 76; (Job.0.S2.I4) AR - 75 : 75.5 (Job.0.S3.I1) AR - 58; (Job.0.S3.I2) AR - 48;
(Job.0.S3.I3) AR - 45; (Job.0.S3.I4) AR - 48 : 48.0 (Job.0.S4.I1) AR - 82; (Job.0.S4.I2)
AR - 83; (Job.0.S4.I3) AR - 85; (Job.0.S4.I4) AR - 82 : 82.5
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Job # 1
(Job.1.S1.I1) AR - 67; (Job.1.S1.I2) AR - 67; (Job.1.S1.I3) AR - 67; (Job.1.S1.I4)
AR - 67 : 67.0 (Job.1.S2.I1) AR - 209; (Job.1.S2.I2) AR - 220; (Job.1.S2.I3) AR
- 1314; (Job.1.S2.I4) AR - 220 : 220.0 (Job.1.S3.I1) AR - 107; (Job.1.S3.I2) AR -
104; (Job.1.S3.I3) AR - 102; (Job.1.S3.I4) AR - 157 : 105.5 (Job.1.S4.I1) AR - 86;
(Job.1.S4.I2) AR - 86; (Job.1.S4.I3) AR - 152; (Job.1.S4.I4) AR - 86 : 86.0
Job # 2
(Job.2.S1.I1) AR - 94; (Job.2.S1.I2) AR - 95; (Job.2.S1.I3) AR - 94; (Job.2.S1.I4)
AR - 95 : 94.5 (Job.2.S2.I1) AR - 53; (Job.2.S2.I2) AR - 48; (Job.2.S2.I3) AR
- 53; (Job.2.S2.I4) AR - 55 : 53.0 (Job.2.S3.I1) AR - 68; (Job.2.S3.I2) AR - 70;
(Job.2.S3.I3) AR - 65; (Job.2.S3.I4) AR - 68 : 68.0 (Job.2.S4.I1) AR - 56; (Job.2.S4.I2)
AR - 86; (Job.2.S4.I3) AR - 82; (Job.2.S4.I4) AR - 43 : 69.0
Job # 3
(Job.3.S1.I1) AR - 100; (Job.3.S1.I2) AR - 100; (Job.3.S1.I3) AR - 101; (Job.3.S1.I4)
AR - 93 : 100.0 (Job.3.S2.I1) AR - 86; (Job.3.S2.I2) AR - 84; (Job.3.S2.I3) AR
- 87; (Job.3.S2.I4) AR - 87 : 86.5 (Job.3.S3.I1) AR - 88; (Job.3.S3.I2) AR - 90;
(Job.3.S3.I3) AR - 87; (Job.3.S3.I4) AR - 95 : 89.0 (Job.3.S4.I1) AR - 87; (Job.3.S4.I2)
AR - 84; (Job.3.S4.I3) AR - 84; (Job.3.S4.I4) AR - 87 : 85.5
Job # 4
(Job.4.S1.I1) AR - 71; (Job.4.S1.I2) AR - 779; (Job.4.S1.I3) AR - 783; (Job.4.S1.I4)
AR - 780 : 779.5 (Job.4.S2.I1) AR - 88; (Job.4.S2.I2) AR - 88; (Job.4.S2.I3) AR
- 91; (Job.4.S2.I4) AR - 86 : 88.0 (Job.4.S3.I1) AR - 68; (Job.4.S3.I2) AR - 83;
(Job.4.S3.I3) AR - 69; (Job.4.S3.I4) AR - 71 : 70.0 (Job.4.S4.I1) AR - 109; (Job.4.S4.I2)
AR - 110; (Job.4.S4.I3) AR - 115; (Job.4.S4.I4) AR - 82 : 109.5
Best ranks of each set–island : 80 - 75 - 45 - 82 - 67 - 209 - 102 - 86 - 94 - 48 -
65 - 43 - 93 - 84 - 87 - 84 - 71 - 86 - 68 - 82 -
Median: 85.75
Median of best : 82.0
APPENDIX A. LEAVE-ONE-OUT CROSS-VALIDATION RESULTS 72
A.1.2 ATM
Job # 0
(Job.0.S1.I1) ATM - 26; (Job.0.S1.I2) ATM - 28; (Job.0.S1.I3) ATM - 26; (Job.0.S1.I4)
ATM - 26 : 26.0 (Job.0.S2.I1) ATM - 22; (Job.0.S2.I2) ATM - 22; (Job.0.S2.I3)
ATM - 22; (Job.0.S2.I4) ATM - 22 : 22.0 (Job.0.S3.I1) ATM - 5; (Job.0.S3.I2) ATM
- 2; (Job.0.S3.I3) ATM - 5; (Job.0.S3.I4) ATM - 2 : 3.5 (Job.0.S4.I1) ATM - 7;
(Job.0.S4.I2) ATM - 7; (Job.0.S4.I3) ATM - 9; (Job.0.S4.I4) ATM - 8 : 7.5
Job # 1
(Job.1.S1.I1) ATM - 18; (Job.1.S1.I2) ATM - 17; (Job.1.S1.I3) ATM - 17; (Job.1.S1.I4)
ATM - 17 : 17.0 (Job.1.S2.I1) ATM - 21; (Job.1.S2.I2) ATM - 16; (Job.1.S2.I3) ATM
- 14; (Job.1.S2.I4) ATM - 17 : 16.5 (Job.1.S3.I1) ATM - 10; (Job.1.S3.I2) ATM -
10; (Job.1.S3.I3) ATM - 10; (Job.1.S3.I4) ATM - 7 : 10.0 (Job.1.S4.I1) ATM - 6;
(Job.1.S4.I2) ATM - 6; (Job.1.S4.I3) ATM - 6; (Job.1.S4.I4) ATM - 6 : 6.0
Job # 2
(Job.2.S1.I1) ATM - 15; (Job.2.S1.I2) ATM - 14; (Job.2.S1.I3) ATM - 14; (Job.2.S1.I4)
ATM - 14 : 14.0 (Job.2.S2.I1) ATM - 7; (Job.2.S2.I2) ATM - 8; (Job.2.S2.I3) ATM
- 7; (Job.2.S2.I4) ATM - 8 : 7.5 (Job.2.S3.I1) ATM - 27; (Job.2.S3.I2) ATM - 45;
(Job.2.S3.I3) ATM - 27; (Job.2.S3.I4) ATM - 25 : 27.0 (Job.2.S4.I1) ATM - 13;
(Job.2.S4.I2) ATM - 13; (Job.2.S4.I3) ATM - 13; (Job.2.S4.I4) ATM - 13 : 13.0
Job # 3
(Job.3.S1.I1) ATM - 19; (Job.3.S1.I2) ATM - 7; (Job.3.S1.I3) ATM - 11; (Job.3.S1.I4)
ATM - 11 : 11.0 (Job.3.S2.I1) ATM - 18; (Job.3.S2.I2) ATM - 18; (Job.3.S2.I3)
ATM - 18; (Job.3.S2.I4) ATM - 18 : 18.0 (Job.3.S3.I1) ATM - 5; (Job.3.S3.I2) ATM
- 6; (Job.3.S3.I3) ATM - 5; (Job.3.S3.I4) ATM - 5 : 5.0 (Job.3.S4.I1) ATM - 5;
(Job.3.S4.I2) ATM - 24; (Job.3.S4.I3) ATM - 23; (Job.3.S4.I4) ATM - 22 : 22.5
Job # 4
(Job.4.S1.I1) ATM - 19; (Job.4.S1.I2) ATM - 26; (Job.4.S1.I3) ATM - 20; (Job.4.S1.I4)
ATM - 29 : 23.0 (Job.4.S2.I1) ATM - 16; (Job.4.S2.I2) ATM - 15; (Job.4.S2.I3) ATM
- 14; (Job.4.S2.I4) ATM - 15 : 15.0 (Job.4.S3.I1) ATM - 37; (Job.4.S3.I2) ATM -
35; (Job.4.S3.I3) ATM - 36; (Job.4.S3.I4) ATM - 37 : 36.5 (Job.4.S4.I1) ATM - 38;
(Job.4.S4.I2) ATM - 27; (Job.4.S4.I3) ATM - 24; (Job.4.S4.I4) ATM - 38 : 32.5
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Best ranks of each set–island : 26 - 22 - 2 - 7 - 17 - 14 - 7 - 6 - 14 - 7 - 25 - 13
- 7 - 18 - 5 - 5 - 19 - 14 - 35 - 24 -
Median: 15.75
Median of best : 14.0
A.1.3 BARD1
Job # 0
(Job.0.S1.I1) BARD1 - 3; (Job.0.S1.I2) BARD1 - 11; (Job.0.S1.I3) BARD1 - 6;
(Job.0.S1.I4) BARD1 - 4 : 5.0 (Job.0.S2.I1) BARD1 - 7; (Job.0.S2.I2) BARD1 -
6; (Job.0.S2.I3) BARD1 - 3; (Job.0.S2.I4) BARD1 - 4 : 5.0 (Job.0.S3.I1) BARD1
- 4; (Job.0.S3.I2) BARD1 - 2; (Job.0.S3.I3) BARD1 - 2; (Job.0.S3.I4) BARD1 - 4 :
3.0 (Job.0.S4.I1) BARD1 - 10; (Job.0.S4.I2) BARD1 - 10; (Job.0.S4.I3) BARD1 - 10;
(Job.0.S4.I4) BARD1 - 12 : 10.0
Job # 1
(Job.1.S1.I1) BARD1 - 5; (Job.1.S1.I2) BARD1 - 10; (Job.1.S1.I3) BARD1 - 10;
(Job.1.S1.I4) BARD1 - 5 : 7.5 (Job.1.S2.I1) BARD1 - 3; (Job.1.S2.I2) BARD1 -
3; (Job.1.S2.I3) BARD1 - 3; (Job.1.S2.I4) BARD1 - 3 : 3.0 (Job.1.S3.I1) BARD1
- 4; (Job.1.S3.I2) BARD1 - 4; (Job.1.S3.I3) BARD1 - 3; (Job.1.S3.I4) BARD1 - 4 :
4.0 (Job.1.S4.I1) BARD1 - 5; (Job.1.S4.I2) BARD1 - 5; (Job.1.S4.I3) BARD1 - 5;
(Job.1.S4.I4) BARD1 - 5 : 5.0
Job # 2
(Job.2.S1.I1) BARD1 - 4; (Job.2.S1.I2) BARD1 - 3; (Job.2.S1.I3) BARD1 - 2; (Job.2.S1.I4)
BARD1 - 2 : 2.5 (Job.2.S2.I1) BARD1 - 5; (Job.2.S2.I2) BARD1 - 5; (Job.2.S2.I3)
BARD1 - 5; (Job.2.S2.I4) BARD1 - 5 : 5.0 (Job.2.S3.I1) BARD1 - 7; (Job.2.S3.I2)
BARD1 - 10; (Job.2.S3.I3) BARD1 - 4; (Job.2.S3.I4) BARD1 - 7 : 7.0 (Job.2.S4.I1)
BARD1 - 3; (Job.2.S4.I2) BARD1 - 3; (Job.2.S4.I3) BARD1 - 3; (Job.2.S4.I4) BARD1
- 3 : 3.0
Job # 3
(Job.3.S1.I1) BARD1 - 2; (Job.3.S1.I2) BARD1 - 2; (Job.3.S1.I3) BARD1 - 2; (Job.3.S1.I4)
BARD1 - 2 : 2.0 (Job.3.S2.I1) BARD1 - 3; (Job.3.S2.I2) BARD1 - 89; (Job.3.S2.I3)
BARD1 - 84; (Job.3.S2.I4) BARD1 - 84 : 84.0 (Job.3.S3.I1) BARD1 - 3; (Job.3.S3.I2)
BARD1 - 3; (Job.3.S3.I3) BARD1 - 3; (Job.3.S3.I4) BARD1 - 3 : 3.0 (Job.3.S4.I1)
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BARD1 - 8; (Job.3.S4.I2) BARD1 - 4; (Job.3.S4.I3) BARD1 - 6; (Job.3.S4.I4) BARD1
- 6 : 6.0
Job # 4
(Job.4.S1.I1) BARD1 - 4; (Job.4.S1.I2) BARD1 - 3; (Job.4.S1.I3) BARD1 - 4; (Job.4.S1.I4)
BARD1 - 3 : 3.5 (Job.4.S2.I1) BARD1 - 15; (Job.4.S2.I2) BARD1 - 64; (Job.4.S2.I3)
BARD1 - 10; (Job.4.S2.I4) BARD1 - 73 : 39.5 (Job.4.S3.I1) BARD1 - 10; (Job.4.S3.I2)
BARD1 - 6; (Job.4.S3.I3) BARD1 - 9; (Job.4.S3.I4) BARD1 - 10 : 9.5 (Job.4.S4.I1)
BARD1 - 7; (Job.4.S4.I2) BARD1 - 7; (Job.4.S4.I3) BARD1 - 3; (Job.4.S4.I4) BARD1
- 5 : 6.0
Best ranks of each set–island : 3 - 3 - 2 - 10 - 5 - 3 - 3 - 5 - 2 - 5 - 4 - 3 - 2 - 3
- 3 - 4 - 3 - 10 - 6 - 3 -
Median: 5.0
Median of best : 3.0
A.1.4 BRCA1
Job # 0
(Job.0.S1.I1) BRCA1 - 6; (Job.0.S1.I2) BRCA1 - 6; (Job.0.S1.I3) BRCA1 - 6; (Job.0.S1.I4)
BRCA1 - 6 : 6.0 (Job.0.S2.I1) BRCA1 - 9; (Job.0.S2.I2) BRCA1 - 9; (Job.0.S2.I3)
BRCA1 - 9; (Job.0.S2.I4) BRCA1 - 10 : 9.0 (Job.0.S3.I1) BRCA1 - 7; (Job.0.S3.I2)
BRCA1 - 5; (Job.0.S3.I3) BRCA1 - 13; (Job.0.S3.I4) BRCA1 - 6 : 6.5 (Job.0.S4.I1)
BRCA1 - 14; (Job.0.S4.I2) BRCA1 - 4; (Job.0.S4.I3) BRCA1 - 4; (Job.0.S4.I4)
BRCA1 - 4 : 4.0
Job # 1
(Job.1.S1.I1) BRCA1 - 12; (Job.1.S1.I2) BRCA1 - 16; (Job.1.S1.I3) BRCA1 - 8;
(Job.1.S1.I4) BRCA1 - 19 : 14.0 (Job.1.S2.I1) BRCA1 - 13; (Job.1.S2.I2) BRCA1 -
7; (Job.1.S2.I3) BRCA1 - 7; (Job.1.S2.I4) BRCA1 - 7 : 7.0 (Job.1.S3.I1) BRCA1 -
11; (Job.1.S3.I2) BRCA1 - 10; (Job.1.S3.I3) BRCA1 - 11; (Job.1.S3.I4) BRCA1 - 10
: 10.5 (Job.1.S4.I1) BRCA1 - 5; (Job.1.S4.I2) BRCA1 - 5; (Job.1.S4.I3) BRCA1 - 5;
(Job.1.S4.I4) BRCA1 - 5 : 5.0
Job # 2
(Job.2.S1.I1) BRCA1 - 6; (Job.2.S1.I2) BRCA1 - 6; (Job.2.S1.I3) BRCA1 - 6; (Job.2.S1.I4)
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BRCA1 - 6 : 6.0 (Job.2.S2.I1) BRCA1 - 6; (Job.2.S2.I2) BRCA1 - 4; (Job.2.S2.I3)
BRCA1 - 7; (Job.2.S2.I4) BRCA1 - 4 : 5.0 (Job.2.S3.I1) BRCA1 - 3; (Job.2.S3.I2)
BRCA1 - 6; (Job.2.S3.I3) BRCA1 - 3; (Job.2.S3.I4) BRCA1 - 3 : 3.0 (Job.2.S4.I1)
BRCA1 - 13; (Job.2.S4.I2) BRCA1 - 11; (Job.2.S4.I3) BRCA1 - 12; (Job.2.S4.I4)
BRCA1 - 16 : 12.5
Job # 3
(Job.3.S1.I1) BRCA1 - 3; (Job.3.S1.I2) BRCA1 - 3; (Job.3.S1.I3) BRCA1 - 3; (Job.3.S1.I4)
BRCA1 - 3 : 3.0 (Job.3.S2.I1) BRCA1 - 12; (Job.3.S2.I2) BRCA1 - 12; (Job.3.S2.I3)
BRCA1 - 12; (Job.3.S2.I4) BRCA1 - 12 : 12.0 (Job.3.S3.I1) BRCA1 - 3; (Job.3.S3.I2)
BRCA1 - 2; (Job.3.S3.I3) BRCA1 - 14; (Job.3.S3.I4) BRCA1 - 3 : 3.0 (Job.3.S4.I1)
BRCA1 - 41; (Job.3.S4.I2) BRCA1 - 102; (Job.3.S4.I3) BRCA1 - 108; (Job.3.S4.I4)
BRCA1 - 105 : 103.5
Job # 4
(Job.4.S1.I1) BRCA1 - 18; (Job.4.S1.I2) BRCA1 - 33; (Job.4.S1.I3) BRCA1 - 53;
(Job.4.S1.I4) BRCA1 - 22 : 27.5 (Job.4.S2.I1) BRCA1 - 21; (Job.4.S2.I2) BRCA1 -
6; (Job.4.S2.I3) BRCA1 - 13; (Job.4.S2.I4) BRCA1 - 18 : 15.5 (Job.4.S3.I1) BRCA1
- 6; (Job.4.S3.I2) BRCA1 - 6; (Job.4.S3.I3) BRCA1 - 6; (Job.4.S3.I4) BRCA1 - 6 :
6.0 (Job.4.S4.I1) BRCA1 - 7; (Job.4.S4.I2) BRCA1 - 9; (Job.4.S4.I3) BRCA1 - 9;
(Job.4.S4.I4) BRCA1 - 7 : 8.0
Best ranks of each set–island : 6 - 9 - 5 - 4 - 8 - 7 - 10 - 5 - 6 - 4 - 3 - 11 - 3 -
12 - 2 - 41 - 18 - 6 - 6 - 7 -
Median: 6.75
Median of best : 6.0
A.1.5 BRCA2
Job # 0
(Job.0.S1.I1) BRCA2 - 129; (Job.0.S1.I2) BRCA2 - 129; (Job.0.S1.I3) BRCA2 - 129;
(Job.0.S1.I4) BRCA2 - 128 : 129.0 (Job.0.S2.I1) BRCA2 - 77; (Job.0.S2.I2) BRCA2
- 98; (Job.0.S2.I3) BRCA2 - 102; (Job.0.S2.I4) BRCA2 - 91 : 94.5 (Job.0.S3.I1)
BRCA2 - 128; (Job.0.S3.I2) BRCA2 - 127; (Job.0.S3.I3) BRCA2 - 128; (Job.0.S3.I4)
BRCA2 - 127 : 127.5 (Job.0.S4.I1) BRCA2 - 185; (Job.0.S4.I2) BRCA2 - 190;
(Job.0.S4.I3) BRCA2 - 130; (Job.0.S4.I4) BRCA2 - 187 : 186.0
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Job # 1
(Job.1.S1.I1) BRCA2 - 130; (Job.1.S1.I2) BRCA2 - 121; (Job.1.S1.I3) BRCA2 - 121;
(Job.1.S1.I4) BRCA2 - 121 : 121.0 (Job.1.S2.I1) BRCA2 - 192; (Job.1.S2.I2) BRCA2
- 118; (Job.1.S2.I3) BRCA2 - 212; (Job.1.S2.I4) BRCA2 - 265 : 202.0 (Job.1.S3.I1)
BRCA2 - 482; (Job.1.S3.I2) BRCA2 - 473; (Job.1.S3.I3) BRCA2 - 161; (Job.1.S3.I4)
BRCA2 - 477 : 475.0 (Job.1.S4.I1) BRCA2 - 135; (Job.1.S4.I2) BRCA2 - 134;
(Job.1.S4.I3) BRCA2 - 135; (Job.1.S4.I4) BRCA2 - 135 : 135.0
Job # 2
(Job.2.S1.I1) BRCA2 - 169; (Job.2.S1.I2) BRCA2 - 185; (Job.2.S1.I3) BRCA2 - 167;
(Job.2.S1.I4) BRCA2 - 161 : 168.0 (Job.2.S2.I1) BRCA2 - 112; (Job.2.S2.I2) BRCA2
- 117; (Job.2.S2.I3) BRCA2 - 127; (Job.2.S2.I4) BRCA2 - 127 : 122.0 (Job.2.S3.I1)
BRCA2 - 119; (Job.2.S3.I2) BRCA2 - 204; (Job.2.S3.I3) BRCA2 - 241; (Job.2.S3.I4)
BRCA2 - 195 : 199.5 (Job.2.S4.I1) BRCA2 - 119; (Job.2.S4.I2) BRCA2 - 143;
(Job.2.S4.I3) BRCA2 - 143; (Job.2.S4.I4) BRCA2 - 130 : 136.5
Job # 3
(Job.3.S1.I1) BRCA2 - 151; (Job.3.S1.I2) BRCA2 - 151; (Job.3.S1.I3) BRCA2 - 22;
(Job.3.S1.I4) BRCA2 - 161 : 151.0 (Job.3.S2.I1) BRCA2 - 173; (Job.3.S2.I2) BRCA2
- 194; (Job.3.S2.I3) BRCA2 - 182; (Job.3.S2.I4) BRCA2 - 191 : 186.5 (Job.3.S3.I1)
BRCA2 - 189; (Job.3.S3.I2) BRCA2 - 557; (Job.3.S3.I3) BRCA2 - 194; (Job.3.S3.I4)
BRCA2 - 194 : 194.0 (Job.3.S4.I1) BRCA2 - 207; (Job.3.S4.I2) BRCA2 - 222;
(Job.3.S4.I3) BRCA2 - 341; (Job.3.S4.I4) BRCA2 - 183 : 214.5
Job # 4
(Job.4.S1.I1) BRCA2 - 174; (Job.4.S1.I2) BRCA2 - 178; (Job.4.S1.I3) BRCA2 -
188; (Job.4.S1.I4) BRCA2 - 184 : 181.0 (Job.4.S2.I1) BRCA2 - 136; (Job.4.S2.I2)
BRCA2 - 130; (Job.4.S2.I3) BRCA2 - 137; (Job.4.S2.I4) BRCA2 - 136 : 136.0
(Job.4.S3.I1) BRCA2 - 121; (Job.4.S3.I2) BRCA2 - 122; (Job.4.S3.I3) BRCA2 - 140;
(Job.4.S3.I4) BRCA2 - 122 : 122.0 (Job.4.S4.I1) BRCA2 - 76; (Job.4.S4.I2) BRCA2
- 72; (Job.4.S4.I3) BRCA2 - 98; (Job.4.S4.I4) BRCA2 - 72 : 74.0
Best ranks of each set–island : 128 - 77 - 127 - 130 - 121 - 118 - 161 - 134 - 161
- 112 - 119 - 119 - 22 - 173 - 189 - 183 - 174 - 130 - 121 - 72 -
Median: 143.75
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Median of best : 127.5
A.1.6 CASP8
Job # 0
(Job.0.S1.I1) CASP8 - 24; (Job.0.S1.I2) CASP8 - 21; (Job.0.S1.I3) CASP8 - 27;
(Job.0.S1.I4) CASP8 - 28 : 25.5 (Job.0.S2.I1) CASP8 - 31; (Job.0.S2.I2) CASP8 -
30; (Job.0.S2.I3) CASP8 - 30; (Job.0.S2.I4) CASP8 - 38 : 30.5 (Job.0.S3.I1) CASP8
- 47; (Job.0.S3.I2) CASP8 - 50; (Job.0.S3.I3) CASP8 - 47; (Job.0.S3.I4) CASP8 - 55
: 48.5 (Job.0.S4.I1) CASP8 - 88; (Job.0.S4.I2) CASP8 - 98; (Job.0.S4.I3) CASP8 -
98; (Job.0.S4.I4) CASP8 - 98 : 98.0
Job # 1
(Job.1.S1.I1) CASP8 - 29; (Job.1.S1.I2) CASP8 - 23; (Job.1.S1.I3) CASP8 - 29;
(Job.1.S1.I4) CASP8 - 29 : 29.0 (Job.1.S2.I1) CASP8 - 103; (Job.1.S2.I2) CASP8 -
30; (Job.1.S2.I3) CASP8 - 29; (Job.1.S2.I4) CASP8 - 108 : 66.5 (Job.1.S3.I1) CASP8
- 52; (Job.1.S3.I2) CASP8 - 32; (Job.1.S3.I3) CASP8 - 49; (Job.1.S3.I4) CASP8 - 35
: 42.0 (Job.1.S4.I1) CASP8 - 44; (Job.1.S4.I2) CASP8 - 45; (Job.1.S4.I3) CASP8 -
45; (Job.1.S4.I4) CASP8 - 45 : 45.0
Job # 2
(Job.2.S1.I1) CASP8 - 38; (Job.2.S1.I2) CASP8 - 60; (Job.2.S1.I3) CASP8 - 38;
(Job.2.S1.I4) CASP8 - 38 : 38.0 (Job.2.S2.I1) CASP8 - 42; (Job.2.S2.I2) CASP8 -
38; (Job.2.S2.I3) CASP8 - 18; (Job.2.S2.I4) CASP8 - 16 : 28.0 (Job.2.S3.I1) CASP8
- 43; (Job.2.S3.I2) CASP8 - 41; (Job.2.S3.I3) CASP8 - 32; (Job.2.S3.I4) CASP8 - 43
: 42.0 (Job.2.S4.I1) CASP8 - 4; (Job.2.S4.I2) CASP8 - 5; (Job.2.S4.I3) CASP8 - 7;
(Job.2.S4.I4) CASP8 - 5 : 5.0
Job # 3
(Job.3.S1.I1) CASP8 - 50; (Job.3.S1.I2) CASP8 - 49; (Job.3.S1.I3) CASP8 - 50;
(Job.3.S1.I4) CASP8 - 50 : 50.0 (Job.3.S2.I1) CASP8 - 26; (Job.3.S2.I2) CASP8 -
25; (Job.3.S2.I3) CASP8 - 26; (Job.3.S2.I4) CASP8 - 23 : 25.5 (Job.3.S3.I1) CASP8
- 45; (Job.3.S3.I2) CASP8 - 55; (Job.3.S3.I3) CASP8 - 44; (Job.3.S3.I4) CASP8 - 34 :
44.5 (Job.3.S4.I1) CASP8 - 8; (Job.3.S4.I2) CASP8 - 13; (Job.3.S4.I3) CASP8 - 10;
(Job.3.S4.I4) CASP8 - 15 : 11.5
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Job # 4
(Job.4.S1.I1) CASP8 - 53; (Job.4.S1.I2) CASP8 - 54; (Job.4.S1.I3) CASP8 - 50;
(Job.4.S1.I4) CASP8 - 55 : 53.5 (Job.4.S2.I1) CASP8 - 56; (Job.4.S2.I2) CASP8 -
42; (Job.4.S2.I3) CASP8 - 46; (Job.4.S2.I4) CASP8 - 44 : 45.0 (Job.4.S3.I1) CASP8
- 40; (Job.4.S3.I2) CASP8 - 32; (Job.4.S3.I3) CASP8 - 32; (Job.4.S3.I4) CASP8 - 39
: 35.5 (Job.4.S4.I1) CASP8 - 84; (Job.4.S4.I2) CASP8 - 64; (Job.4.S4.I3) CASP8 -
91; (Job.4.S4.I4) CASP8 - 115 : 87.5
Best ranks of each set–island : 21 - 30 - 47 - 88 - 23 - 29 - 32 - 44 - 38 - 16 - 32
- 4 - 49 - 23 - 34 - 8 - 50 - 42 - 32 - 64 -
Median: 42.0
Median of best : 32.0
A.1.7 CHEK2
Job # 0
(Job.0.S1.I1) CHEK2 - 47; (Job.0.S1.I2) CHEK2 - 45; (Job.0.S1.I3) CHEK2 - 45;
(Job.0.S1.I4) CHEK2 - 50 : 46.0 (Job.0.S2.I1) CHEK2 - 74; (Job.0.S2.I2) CHEK2 -
76; (Job.0.S2.I3) CHEK2 - 76; (Job.0.S2.I4) CHEK2 - 74 : 75.0 (Job.0.S3.I1) CHEK2
- 67; (Job.0.S3.I2) CHEK2 - 69; (Job.0.S3.I3) CHEK2 - 65; (Job.0.S3.I4) CHEK2 - 62
: 66.0 (Job.0.S4.I1) CHEK2 - 153; (Job.0.S4.I2) CHEK2 - 138; (Job.0.S4.I3) CHEK2
- 153; (Job.0.S4.I4) CHEK2 - 151 : 152.0
Job # 1
(Job.1.S1.I1) CHEK2 - 79; (Job.1.S1.I2) CHEK2 - 54; (Job.1.S1.I3) CHEK2 - 65;
(Job.1.S1.I4) CHEK2 - 65 : 65.0 (Job.1.S2.I1) CHEK2 - 85; (Job.1.S2.I2) CHEK2 -
88; (Job.1.S2.I3) CHEK2 - 83; (Job.1.S2.I4) CHEK2 - 88 : 86.5 (Job.1.S3.I1) CHEK2
- 107; (Job.1.S3.I2) CHEK2 - 121; (Job.1.S3.I3) CHEK2 - 124; (Job.1.S3.I4) CHEK2
- 107 : 114.0 (Job.1.S4.I1) CHEK2 - 63; (Job.1.S4.I2) CHEK2 - 70; (Job.1.S4.I3)
CHEK2 - 63; (Job.1.S4.I4) CHEK2 - 63 : 63.0
Job # 2
(Job.2.S1.I1) CHEK2 - 91; (Job.2.S1.I2) CHEK2 - 111; (Job.2.S1.I3) CHEK2 - 111;
(Job.2.S1.I4) CHEK2 - 116 : 111.0 (Job.2.S2.I1) CHEK2 - 84; (Job.2.S2.I2) CHEK2 -
83; (Job.2.S2.I3) CHEK2 - 84; (Job.2.S2.I4) CHEK2 - 83 : 83.5 (Job.2.S3.I1) CHEK2
- 68; (Job.2.S3.I2) CHEK2 - 67; (Job.2.S3.I3) CHEK2 - 68; (Job.2.S3.I4) CHEK2 - 67
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: 67.5 (Job.2.S4.I1) CHEK2 - 99; (Job.2.S4.I2) CHEK2 - 145; (Job.2.S4.I3) CHEK2
- 128; (Job.2.S4.I4) CHEK2 - 82 : 113.5
Job # 3
(Job.3.S1.I1) CHEK2 - 68; (Job.3.S1.I2) CHEK2 - 70; (Job.3.S1.I3) CHEK2 - 72;
(Job.3.S1.I4) CHEK2 - 68 : 69.0 (Job.3.S2.I1) CHEK2 - 63; (Job.3.S2.I2) CHEK2 -
63; (Job.3.S2.I3) CHEK2 - 74; (Job.3.S2.I4) CHEK2 - 63 : 63.0 (Job.3.S3.I1) CHEK2
- 78; (Job.3.S3.I2) CHEK2 - 100; (Job.3.S3.I3) CHEK2 - 55; (Job.3.S3.I4) CHEK2 -
90 : 84.0 (Job.3.S4.I1) CHEK2 - 47; (Job.3.S4.I2) CHEK2 - 76; (Job.3.S4.I3) CHEK2
- 2; (Job.3.S4.I4) CHEK2 - 1 : 24.5
Job # 4
(Job.4.S1.I1) CHEK2 - 69; (Job.4.S1.I2) CHEK2 - 70; (Job.4.S1.I3) CHEK2 - 71;
(Job.4.S1.I4) CHEK2 - 68 : 69.5 (Job.4.S2.I1) CHEK2 - 74; (Job.4.S2.I2) CHEK2 -
71; (Job.4.S2.I3) CHEK2 - 73; (Job.4.S2.I4) CHEK2 - 68 : 72.0 (Job.4.S3.I1) CHEK2
- 72; (Job.4.S3.I2) CHEK2 - 121; (Job.4.S3.I3) CHEK2 - 59; (Job.4.S3.I4) CHEK2 -
68 : 70.0 (Job.4.S4.I1) CHEK2 - 77; (Job.4.S4.I2) CHEK2 - 76; (Job.4.S4.I3) CHEK2
- 76; (Job.4.S4.I4) CHEK2 - 77 : 76.5
Best ranks of each set–island : 45 - 74 - 62 - 138 - 54 - 83 - 107 - 63 - 91 - 83 -
67 - 82 - 68 - 63 - 55 - 1 - 68 - 68 - 59 - 76 -
Median: 71.0
Median of best : 68.0
A.1.8 NCOA3
Job # 0
(Job.0.S1.I1) NCOA3 - 15; (Job.0.S1.I2) NCOA3 - 13; (Job.0.S1.I3) NCOA3 - 25;
(Job.0.S1.I4) NCOA3 - 25 : 20.0 (Job.0.S2.I1) NCOA3 - 4; (Job.0.S2.I2) NCOA3 -
17; (Job.0.S2.I3) NCOA3 - 18; (Job.0.S2.I4) NCOA3 - 4 : 10.5 (Job.0.S3.I1) NCOA3
- 38; (Job.0.S3.I2) NCOA3 - 40; (Job.0.S3.I3) NCOA3 - 40; (Job.0.S3.I4) NCOA3 - 24
: 39.0 (Job.0.S4.I1) NCOA3 - 14; (Job.0.S4.I2) NCOA3 - 14; (Job.0.S4.I3) NCOA3 -
14; (Job.0.S4.I4) NCOA3 - 14 : 14.0
Job # 1
(Job.1.S1.I1) NCOA3 - 36; (Job.1.S1.I2) NCOA3 - 35; (Job.1.S1.I3) NCOA3 - 36;
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(Job.1.S1.I4) NCOA3 - 34 : 35.5 (Job.1.S2.I1) NCOA3 - 18; (Job.1.S2.I2) NCOA3 -
20; (Job.1.S2.I3) NCOA3 - 18; (Job.1.S2.I4) NCOA3 - 21 : 19.0 (Job.1.S3.I1) NCOA3
- 36; (Job.1.S3.I2) NCOA3 - 77; (Job.1.S3.I3) NCOA3 - 27; (Job.1.S3.I4) NCOA3 - 33
: 34.5 (Job.1.S4.I1) NCOA3 - 18; (Job.1.S4.I2) NCOA3 - 16; (Job.1.S4.I3) NCOA3 -
16; (Job.1.S4.I4) NCOA3 - 17 : 16.5
Job # 2
(Job.2.S1.I1) NCOA3 - 45; (Job.2.S1.I2) NCOA3 - 31; (Job.2.S1.I3) NCOA3 - 31;
(Job.2.S1.I4) NCOA3 - 48 : 38.0 (Job.2.S2.I1) NCOA3 - 27; (Job.2.S2.I2) NCOA3 -
34; (Job.2.S2.I3) NCOA3 - 27; (Job.2.S2.I4) NCOA3 - 27 : 27.0 (Job.2.S3.I1) NCOA3
- 3; (Job.2.S3.I2) NCOA3 - 3; (Job.2.S3.I3) NCOA3 - 3; (Job.2.S3.I4) NCOA3 - 3 :
3.0 (Job.2.S4.I1) NCOA3 - 34; (Job.2.S4.I2) NCOA3 - 29; (Job.2.S4.I3) NCOA3 - 34;
(Job.2.S4.I4) NCOA3 - 39 : 34.0
Job # 3
(Job.3.S1.I1) NCOA3 - 15; (Job.3.S1.I2) NCOA3 - 15; (Job.3.S1.I3) NCOA3 - 15;
(Job.3.S1.I4) NCOA3 - 15 : 15.0 (Job.3.S2.I1) NCOA3 - 28; (Job.3.S2.I2) NCOA3 -
39; (Job.3.S2.I3) NCOA3 - 20; (Job.3.S2.I4) NCOA3 - 39 : 33.5 (Job.3.S3.I1) NCOA3
- 34; (Job.3.S3.I2) NCOA3 - 27; (Job.3.S3.I3) NCOA3 - 33; (Job.3.S3.I4) NCOA3 - 31
: 32.0 (Job.3.S4.I1) NCOA3 - 44; (Job.3.S4.I2) NCOA3 - 48; (Job.3.S4.I3) NCOA3 -
53; (Job.3.S4.I4) NCOA3 - 34 : 46.0
Job # 4
(Job.4.S1.I1) NCOA3 - 4; (Job.4.S1.I2) NCOA3 - 4; (Job.4.S1.I3) NCOA3 - 2; (Job.4.S1.I4)
NCOA3 - 4 : 4.0 (Job.4.S2.I1) NCOA3 - 21; (Job.4.S2.I2) NCOA3 - 21; (Job.4.S2.I3)
NCOA3 - 18; (Job.4.S2.I4) NCOA3 - 25 : 21.0 (Job.4.S3.I1) NCOA3 - 42; (Job.4.S3.I2)
NCOA3 - 48; (Job.4.S3.I3) NCOA3 - 46; (Job.4.S3.I4) NCOA3 - 45 : 45.5 (Job.4.S4.I1)
NCOA3 - 8; (Job.4.S4.I2) NCOA3 - 8; (Job.4.S4.I3) NCOA3 - 6; (Job.4.S4.I4) NCOA3
- 13 : 8.0
Best ranks of each set–island : 13 - 4 - 24 - 14 - 34 - 18 - 27 - 16 - 31 - 27 - 3 -
29 - 15 - 20 - 27 - 34 - 2 - 18 - 42 - 6 -
Median: 24.0
Median of best : 19.0
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A.1.9 PIK3CA
Job # 0
(Job.0.S1.I1) PIK3CA - 28; (Job.0.S1.I2) PIK3CA - 28; (Job.0.S1.I3) PIK3CA - 28;
(Job.0.S1.I4) PIK3CA - 28 : 28.0 (Job.0.S2.I1) PIK3CA - 25; (Job.0.S2.I2) PIK3CA
- 19; (Job.0.S2.I3) PIK3CA - 22; (Job.0.S2.I4) PIK3CA - 18 : 20.5 (Job.0.S3.I1)
PIK3CA - 3; (Job.0.S3.I2) PIK3CA - 3; (Job.0.S3.I3) PIK3CA - 3; (Job.0.S3.I4)
PIK3CA - 3 : 3.0 (Job.0.S4.I1) PIK3CA - 16; (Job.0.S4.I2) PIK3CA - 14; (Job.0.S4.I3)
PIK3CA - 16; (Job.0.S4.I4) PIK3CA - 16 : 16.0
Job # 1
(Job.1.S1.I1) PIK3CA - 6; (Job.1.S1.I2) PIK3CA - 6; (Job.1.S1.I3) PIK3CA - 6;
(Job.1.S1.I4) PIK3CA - 6 : 6.0 (Job.1.S2.I1) PIK3CA - 6; (Job.1.S2.I2) PIK3CA -
5; (Job.1.S2.I3) PIK3CA - 6; (Job.1.S2.I4) PIK3CA - 6 : 6.0 (Job.1.S3.I1) PIK3CA
- 25; (Job.1.S3.I2) PIK3CA - 29; (Job.1.S3.I3) PIK3CA - 25; (Job.1.S3.I4) PIK3CA
- 25 : 25.0 (Job.1.S4.I1) PIK3CA - 12; (Job.1.S4.I2) PIK3CA - 13; (Job.1.S4.I3)
PIK3CA - 12; (Job.1.S4.I4) PIK3CA - 12 : 12.0
Job # 2
(Job.2.S1.I1) PIK3CA - 18; (Job.2.S1.I2) PIK3CA - 9; (Job.2.S1.I3) PIK3CA - 18;
(Job.2.S1.I4) PIK3CA - 14 : 16.0 (Job.2.S2.I1) PIK3CA - 3; (Job.2.S2.I2) PIK3CA -
3; (Job.2.S2.I3) PIK3CA - 2; (Job.2.S2.I4) PIK3CA - 2 : 2.5 (Job.2.S3.I1) PIK3CA
- 6; (Job.2.S3.I2) PIK3CA - 4; (Job.2.S3.I3) PIK3CA - 6; (Job.2.S3.I4) PIK3CA - 4
: 5.0 (Job.2.S4.I1) PIK3CA - 14; (Job.2.S4.I2) PIK3CA - 16; (Job.2.S4.I3) PIK3CA
- 16; (Job.2.S4.I4) PIK3CA - 8 : 15.0
Job # 3
(Job.3.S1.I1) PIK3CA - 5; (Job.3.S1.I2) PIK3CA - 9; (Job.3.S1.I3) PIK3CA - 6;
(Job.3.S1.I4) PIK3CA - 9 : 7.5 (Job.3.S2.I1) PIK3CA - 5; (Job.3.S2.I2) PIK3CA -
4; (Job.3.S2.I3) PIK3CA - 4; (Job.3.S2.I4) PIK3CA - 5 : 4.5 (Job.3.S3.I1) PIK3CA
- 29; (Job.3.S3.I2) PIK3CA - 24; (Job.3.S3.I3) PIK3CA - 29; (Job.3.S3.I4) PIK3CA
- 29 : 29.0 (Job.3.S4.I1) PIK3CA - 19; (Job.3.S4.I2) PIK3CA - 14; (Job.3.S4.I3)
PIK3CA - 16; (Job.3.S4.I4) PIK3CA - 19 : 17.5
Job # 4
(Job.4.S1.I1) PIK3CA - 1; (Job.4.S1.I2) PIK3CA - 3; (Job.4.S1.I3) PIK3CA - 1;
(Job.4.S1.I4) PIK3CA - 1 : 1.0 (Job.4.S2.I1) PIK3CA - 17; (Job.4.S2.I2) PIK3CA
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- 13; (Job.4.S2.I3) PIK3CA - 13; (Job.4.S2.I4) PIK3CA - 14 : 13.5 (Job.4.S3.I1)
PIK3CA - 1; (Job.4.S3.I2) PIK3CA - 3; (Job.4.S3.I3) PIK3CA - 6; (Job.4.S3.I4)
PIK3CA - 3 : 3.0 (Job.4.S4.I1) PIK3CA - 6; (Job.4.S4.I2) PIK3CA - 6; (Job.4.S4.I3)
PIK3CA - 6; (Job.4.S4.I4) PIK3CA - 6 : 6.0
Best ranks of each set–island : 28 - 18 - 3 - 14 - 6 - 5 - 25 - 12 - 9 - 2 - 4 - 8 -
5 - 4 - 24 - 14 - 1 - 13 - 1 - 6 -
Median: 9.75
Median of best : 7.0
A.1.10 PPM1D
Job # 0
(Job.0.S1.I1) PPM1D - 215; (Job.0.S1.I2) PPM1D - 169; (Job.0.S1.I3) PPM1D -
224; (Job.0.S1.I4) PPM1D - 231 : 219.5 (Job.0.S2.I1) PPM1D - 249; (Job.0.S2.I2)
PPM1D - 308; (Job.0.S2.I3) PPM1D - 234; (Job.0.S2.I4) PPM1D - 236 : 242.5
(Job.0.S3.I1) PPM1D - 162; (Job.0.S3.I2) PPM1D - 160; (Job.0.S3.I3) PPM1D -
161; (Job.0.S3.I4) PPM1D - 160 : 160.5 (Job.0.S4.I1) PPM1D - 530; (Job.0.S4.I2)
PPM1D - 530; (Job.0.S4.I3) PPM1D - 546; (Job.0.S4.I4) PPM1D - 546 : 538.0
Job # 1
(Job.1.S1.I1) PPM1D - 415; (Job.1.S1.I2) PPM1D - 162; (Job.1.S1.I3) PPM1D -
161; (Job.1.S1.I4) PPM1D - 416 : 288.5 (Job.1.S2.I1) PPM1D - 932; (Job.1.S2.I2)
PPM1D - 355; (Job.1.S2.I3) PPM1D - 932; (Job.1.S2.I4) PPM1D - 879 : 905.5
(Job.1.S3.I1) PPM1D - 595; (Job.1.S3.I2) PPM1D - 603; (Job.1.S3.I3) PPM1D -
595; (Job.1.S3.I4) PPM1D - 572 : 595.0 (Job.1.S4.I1) PPM1D - 259; (Job.1.S4.I2)
PPM1D - 589; (Job.1.S4.I3) PPM1D - 513; (Job.1.S4.I4) PPM1D - 329 : 421.0
Job # 2
(Job.2.S1.I1) PPM1D - 218; (Job.2.S1.I2) PPM1D - 196; (Job.2.S1.I3) PPM1D -
207; (Job.2.S1.I4) PPM1D - 207 : 207.0 (Job.2.S2.I1) PPM1D - 226; (Job.2.S2.I2)
PPM1D - 441; (Job.2.S2.I3) PPM1D - 400; (Job.2.S2.I4) PPM1D - 227 : 313.5
(Job.2.S3.I1) PPM1D - 1065; (Job.2.S3.I2) PPM1D - 1686; (Job.2.S3.I3) PPM1D -
1618; (Job.2.S3.I4) PPM1D - 1407 : 1512.5 (Job.2.S4.I1) PPM1D - 159; (Job.2.S4.I2)
PPM1D - 162; (Job.2.S4.I3) PPM1D - 165; (Job.2.S4.I4) PPM1D - 165 : 163.5
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Job # 3
(Job.3.S1.I1) PPM1D - 330; (Job.3.S1.I2) PPM1D - 321; (Job.3.S1.I3) PPM1D -
330; (Job.3.S1.I4) PPM1D - 213 : 325.5 (Job.3.S2.I1) PPM1D - 296; (Job.3.S2.I2)
PPM1D - 191; (Job.3.S2.I3) PPM1D - 270; (Job.3.S2.I4) PPM1D - 1054 : 283.0
(Job.3.S3.I1) PPM1D - 2; (Job.3.S3.I2) PPM1D - 2; (Job.3.S3.I3) PPM1D - 2;
(Job.3.S3.I4) PPM1D - 2 : 2.0 (Job.3.S4.I1) PPM1D - 167; (Job.3.S4.I2) PPM1D -
215; (Job.3.S4.I3) PPM1D - 175; (Job.3.S4.I4) PPM1D - 161 : 171.0
Job # 4
(Job.4.S1.I1) PPM1D - 1718; (Job.4.S1.I2) PPM1D - 1699; (Job.4.S1.I3) PPM1D -
1722; (Job.4.S1.I4) PPM1D - 1721 : 1719.5 (Job.4.S2.I1) PPM1D - 125; (Job.4.S2.I2)
PPM1D - 125; (Job.4.S2.I3) PPM1D - 125; (Job.4.S2.I4) PPM1D - 172 : 125.0
(Job.4.S3.I1) PPM1D - 182; (Job.4.S3.I2) PPM1D - 199; (Job.4.S3.I3) PPM1D -
230; (Job.4.S3.I4) PPM1D - 214 : 206.5 (Job.4.S4.I1) PPM1D - 171; (Job.4.S4.I2)
PPM1D - 171; (Job.4.S4.I3) PPM1D - 191; (Job.4.S4.I4) PPM1D - 189 : 180.0
Best ranks of each set–island : 169 - 234 - 160 - 530 - 161 - 355 - 572 - 259 - 196
- 226 - 1065 - 159 - 213 - 191 - 2 - 161 - 1699 - 125 - 182 - 171 -
Median: 262.75
Median of best : 193.5
A.1.11 PTEN
Job # 0
(Job.0.S1.I1) PTEN - 165; (Job.0.S1.I2) PTEN - 165; (Job.0.S1.I3) PTEN - 134;
(Job.0.S1.I4) PTEN - 174 : 165.0 (Job.0.S2.I1) PTEN - 130; (Job.0.S2.I2) PTEN -
130; (Job.0.S2.I3) PTEN - 211; (Job.0.S2.I4) PTEN - 172 : 151.0 (Job.0.S3.I1) PTEN
- 138; (Job.0.S3.I2) PTEN - 139; (Job.0.S3.I3) PTEN - 139; (Job.0.S3.I4) PTEN - 141
: 139.0 (Job.0.S4.I1) PTEN - 139; (Job.0.S4.I2) PTEN - 146; (Job.0.S4.I3) PTEN -
130; (Job.0.S4.I4) PTEN - 128 : 134.5
Job # 1
(Job.1.S1.I1) PTEN - 93; (Job.1.S1.I2) PTEN - 94; (Job.1.S1.I3) PTEN - 94; (Job.1.S1.I4)
PTEN - 92 : 93.5 (Job.1.S2.I1) PTEN - 107; (Job.1.S2.I2) PTEN - 107; (Job.1.S2.I3)
PTEN - 107; (Job.1.S2.I4) PTEN - 111 : 107.0 (Job.1.S3.I1) PTEN - 141; (Job.1.S3.I2)
PTEN - 140; (Job.1.S3.I3) PTEN - 141; (Job.1.S3.I4) PTEN - 140 : 140.5 (Job.1.S4.I1)
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PTEN - 214; (Job.1.S4.I2) PTEN - 149; (Job.1.S4.I3) PTEN - 138; (Job.1.S4.I4)
PTEN - 142 : 145.5
Job # 2
(Job.2.S1.I1) PTEN - 141; (Job.2.S1.I2) PTEN - 138; (Job.2.S1.I3) PTEN - 142;
(Job.2.S1.I4) PTEN - 143 : 141.5 (Job.2.S2.I1) PTEN - 193; (Job.2.S2.I2) PTEN -
193; (Job.2.S2.I3) PTEN - 143; (Job.2.S2.I4) PTEN - 142 : 168.0 (Job.2.S3.I1) PTEN
- 336; (Job.2.S3.I2) PTEN - 428; (Job.2.S3.I3) PTEN - 428; (Job.2.S3.I4) PTEN - 356
: 392.0 (Job.2.S4.I1) PTEN - 151; (Job.2.S4.I2) PTEN - 155; (Job.2.S4.I3) PTEN -
145; (Job.2.S4.I4) PTEN - 151 : 151.0
Job # 3
(Job.3.S1.I1) PTEN - 42; (Job.3.S1.I2) PTEN - 42; (Job.3.S1.I3) PTEN - 43; (Job.3.S1.I4)
PTEN - 57 : 42.5 (Job.3.S2.I1) PTEN - 285; (Job.3.S2.I2) PTEN - 280; (Job.3.S2.I3)
PTEN - 296; (Job.3.S2.I4) PTEN - 291 : 288.0 (Job.3.S3.I1) PTEN - 108; (Job.3.S3.I2)
PTEN - 97; (Job.3.S3.I3) PTEN - 99; (Job.3.S3.I4) PTEN - 100 : 99.5 (Job.3.S4.I1)
PTEN - 107; (Job.3.S4.I2) PTEN - 112; (Job.3.S4.I3) PTEN - 119; (Job.3.S4.I4)
PTEN - 115 : 113.5
Job # 4
(Job.4.S1.I1) PTEN - 159; (Job.4.S1.I2) PTEN - 159; (Job.4.S1.I3) PTEN - 155;
(Job.4.S1.I4) PTEN - 169 : 159.0 (Job.4.S2.I1) PTEN - 767; (Job.4.S2.I2) PTEN -
768; (Job.4.S2.I3) PTEN - 791; (Job.4.S2.I4) PTEN - 791 : 779.5 (Job.4.S3.I1) PTEN
- 146; (Job.4.S3.I2) PTEN - 140; (Job.4.S3.I3) PTEN - 139; (Job.4.S3.I4) PTEN - 129
: 139.5 (Job.4.S4.I1) PTEN - 113; (Job.4.S4.I2) PTEN - 216; (Job.4.S4.I3) PTEN -
212; (Job.4.S4.I4) PTEN - 246 : 214.0
Best ranks of each set–island : 134 - 130 - 138 - 128 - 92 - 107 - 140 - 138 - 138
- 142 - 336 - 145 - 42 - 280 - 97 - 107 - 155 - 767 - 129 - 113 -
Median: 143.5
Median of best : 136.0
A.1.12 RAD51
Job # 0
(Job.0.S1.I1) RAD51 - 12; (Job.0.S1.I2) RAD51 - 35; (Job.0.S1.I3) RAD51 - 35;
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(Job.0.S1.I4) RAD51 - 36 : 35.0 (Job.0.S2.I1) RAD51 - 25; (Job.0.S2.I2) RAD51 -
25; (Job.0.S2.I3) RAD51 - 26; (Job.0.S2.I4) RAD51 - 25 : 25.0 (Job.0.S3.I1) RAD51
- 160; (Job.0.S3.I2) RAD51 - 157; (Job.0.S3.I3) RAD51 - 157; (Job.0.S3.I4) RAD51
- 142 : 157.0 (Job.0.S4.I1) RAD51 - 35; (Job.0.S4.I2) RAD51 - 32; (Job.0.S4.I3)
RAD51 - 33; (Job.0.S4.I4) RAD51 - 35 : 34.0
Job # 1
(Job.1.S1.I1) RAD51 - 13; (Job.1.S1.I2) RAD51 - 13; (Job.1.S1.I3) RAD51 - 5;
(Job.1.S1.I4) RAD51 - 15 : 13.0 (Job.1.S2.I1) RAD51 - 37; (Job.1.S2.I2) RAD51 -
28; (Job.1.S2.I3) RAD51 - 37; (Job.1.S2.I4) RAD51 - 37 : 37.0 (Job.1.S3.I1) RAD51
- 28; (Job.1.S3.I2) RAD51 - 28; (Job.1.S3.I3) RAD51 - 28; (Job.1.S3.I4) RAD51 - 28
: 28.0 (Job.1.S4.I1) RAD51 - 31; (Job.1.S4.I2) RAD51 - 31; (Job.1.S4.I3) RAD51 -
30; (Job.1.S4.I4) RAD51 - 29 : 30.5
Job # 2
(Job.2.S1.I1) RAD51 - 29; (Job.2.S1.I2) RAD51 - 35; (Job.2.S1.I3) RAD51 - 66;
(Job.2.S1.I4) RAD51 - 61 : 48.0 (Job.2.S2.I1) RAD51 - 37; (Job.2.S2.I2) RAD51 -
36; (Job.2.S2.I3) RAD51 - 36; (Job.2.S2.I4) RAD51 - 37 : 36.5 (Job.2.S3.I1) RAD51
- 35; (Job.2.S3.I2) RAD51 - 34; (Job.2.S3.I3) RAD51 - 34; (Job.2.S3.I4) RAD51 - 35
: 34.5 (Job.2.S4.I1) RAD51 - 7; (Job.2.S4.I2) RAD51 - 6; (Job.2.S4.I3) RAD51 - 7;
(Job.2.S4.I4) RAD51 - 7 : 7.0
Job # 3
(Job.3.S1.I1) RAD51 - 30; (Job.3.S1.I2) RAD51 - 47; (Job.3.S1.I3) RAD51 - 29;
(Job.3.S1.I4) RAD51 - 30 : 30.0 (Job.3.S2.I1) RAD51 - 126; (Job.3.S2.I2) RAD51 -
25; (Job.3.S2.I3) RAD51 - 32; (Job.3.S2.I4) RAD51 - 25 : 28.5 (Job.3.S3.I1) RAD51
- 28; (Job.3.S3.I2) RAD51 - 25; (Job.3.S3.I3) RAD51 - 26; (Job.3.S3.I4) RAD51 - 27
: 26.5 (Job.3.S4.I1) RAD51 - 31; (Job.3.S4.I2) RAD51 - 22; (Job.3.S4.I3) RAD51 -
31; (Job.3.S4.I4) RAD51 - 31 : 31.0
Job # 4
(Job.4.S1.I1) RAD51 - 35; (Job.4.S1.I2) RAD51 - 37; (Job.4.S1.I3) RAD51 - 35;
(Job.4.S1.I4) RAD51 - 37 : 36.0 (Job.4.S2.I1) RAD51 - 93; (Job.4.S2.I2) RAD51 -
95; (Job.4.S2.I3) RAD51 - 95; (Job.4.S2.I4) RAD51 - 93 : 94.0 (Job.4.S3.I1) RAD51
- 94; (Job.4.S3.I2) RAD51 - 109; (Job.4.S3.I3) RAD51 - 114; (Job.4.S3.I4) RAD51
- 116 : 111.5 (Job.4.S4.I1) RAD51 - 34; (Job.4.S4.I2) RAD51 - 34; (Job.4.S4.I3)
APPENDIX A. LEAVE-ONE-OUT CROSS-VALIDATION RESULTS 86
RAD51 - 34; (Job.4.S4.I4) RAD51 - 34 : 34.0
Best ranks of each set–island : 12 - 25 - 142 - 32 - 5 - 28 - 28 - 29 - 29 - 36 - 34
- 6 - 29 - 25 - 25 - 22 - 35 - 93 - 94 - 34 -
Median: 34.0
Median of best : 29.0
A.1.13 RB1CC1
Job # 0
(Job.0.S1.I1) RB1CC1 - 53; (Job.0.S1.I2) RB1CC1 - 52; (Job.0.S1.I3) RB1CC1 - 55;
(Job.0.S1.I4) RB1CC1 - 54 : 53.5 (Job.0.S2.I1) RB1CC1 - 31; (Job.0.S2.I2) RB1CC1
- 25; (Job.0.S2.I3) RB1CC1 - 29; (Job.0.S2.I4) RB1CC1 - 31 : 30.0 (Job.0.S3.I1)
RB1CC1 - 42; (Job.0.S3.I2) RB1CC1 - 44; (Job.0.S3.I3) RB1CC1 - 43; (Job.0.S3.I4)
RB1CC1 - 44 : 43.5 (Job.0.S4.I1) RB1CC1 - 59; (Job.0.S4.I2) RB1CC1 - 59; (Job.0.S4.I3)
RB1CC1 - 56; (Job.0.S4.I4) RB1CC1 - 62 : 59.0
Job # 1
(Job.1.S1.I1) RB1CC1 - 23; (Job.1.S1.I2) RB1CC1 - 23; (Job.1.S1.I3) RB1CC1 -
23; (Job.1.S1.I4) RB1CC1 - 23 : 23.0 (Job.1.S2.I1) RB1CC1 - 1790; (Job.1.S2.I2)
RB1CC1 - 1779; (Job.1.S2.I3) RB1CC1 - 1790; (Job.1.S2.I4) RB1CC1 - 1791 : 1790.0
(Job.1.S3.I1) RB1CC1 - 40; (Job.1.S3.I2) RB1CC1 - 43; (Job.1.S3.I3) RB1CC1 - 39;
(Job.1.S3.I4) RB1CC1 - 43 : 41.5 (Job.1.S4.I1) RB1CC1 - 14; (Job.1.S4.I2) RB1CC1
- 14; (Job.1.S4.I3) RB1CC1 - 34; (Job.1.S4.I4) RB1CC1 - 20 : 17.0
Job # 2
(Job.2.S1.I1) RB1CC1 - 62; (Job.2.S1.I2) RB1CC1 - 58; (Job.2.S1.I3) RB1CC1 - 53;
(Job.2.S1.I4) RB1CC1 - 58 : 58.0 (Job.2.S2.I1) RB1CC1 - 9; (Job.2.S2.I2) RB1CC1
- 6; (Job.2.S2.I3) RB1CC1 - 6; (Job.2.S2.I4) RB1CC1 - 5 : 6.0 (Job.2.S3.I1) RB1CC1
- 46; (Job.2.S3.I2) RB1CC1 - 49; (Job.2.S3.I3) RB1CC1 - 48; (Job.2.S3.I4) RB1CC1
- 42 : 47.0 (Job.2.S4.I1) RB1CC1 - 40; (Job.2.S4.I2) RB1CC1 - 35; (Job.2.S4.I3)
RB1CC1 - 38; (Job.2.S4.I4) RB1CC1 - 37 : 37.5
Job # 3
(Job.3.S1.I1) RB1CC1 - 62; (Job.3.S1.I2) RB1CC1 - 62; (Job.3.S1.I3) RB1CC1 - 63;
(Job.3.S1.I4) RB1CC1 - 61 : 62.0 (Job.3.S2.I1) RB1CC1 - 59; (Job.3.S2.I2) RB1CC1
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- 59; (Job.3.S2.I3) RB1CC1 - 59; (Job.3.S2.I4) RB1CC1 - 59 : 59.0 (Job.3.S3.I1)
RB1CC1 - 50; (Job.3.S3.I2) RB1CC1 - 53; (Job.3.S3.I3) RB1CC1 - 55; (Job.3.S3.I4)
RB1CC1 - 50 : 51.5 (Job.3.S4.I1) RB1CC1 - 22; (Job.3.S4.I2) RB1CC1 - 23; (Job.3.S4.I3)
RB1CC1 - 28; (Job.3.S4.I4) RB1CC1 - 27 : 25.0
Job # 4
(Job.4.S1.I1) RB1CC1 - 59; (Job.4.S1.I2) RB1CC1 - 59; (Job.4.S1.I3) RB1CC1 - 59;
(Job.4.S1.I4) RB1CC1 - 59 : 59.0 (Job.4.S2.I1) RB1CC1 - 53; (Job.4.S2.I2) RB1CC1
- 53; (Job.4.S2.I3) RB1CC1 - 54; (Job.4.S2.I4) RB1CC1 - 50 : 53.0 (Job.4.S3.I1)
RB1CC1 - 32; (Job.4.S3.I2) RB1CC1 - 45; (Job.4.S3.I3) RB1CC1 - 155; (Job.4.S3.I4)
RB1CC1 - 30 : 38.5 (Job.4.S4.I1) RB1CC1 - 40; (Job.4.S4.I2) RB1CC1 - 41; (Job.4.S4.I3)
RB1CC1 - 48; (Job.4.S4.I4) RB1CC1 - 40 : 40.5
Best ranks of each set–island : 52 - 25 - 42 - 56 - 23 - 1779 - 39 - 14 - 53 - 5 -
42 - 35 - 61 - 59 - 50 - 22 - 59 - 50 - 30 - 40 -
Median: 45.25
Median of best : 42.0
A.1.14 STK11
Job # 0
(Job.0.S1.I1) STK11 - 497; (Job.0.S1.I2) STK11 - 484; (Job.0.S1.I3) STK11 - 605;
(Job.0.S1.I4) STK11 - 730 : 551.0 (Job.0.S2.I1) STK11 - 602; (Job.0.S2.I2) STK11
- 796; (Job.0.S2.I3) STK11 - 583; (Job.0.S2.I4) STK11 - 566 : 592.5 (Job.0.S3.I1)
STK11 - 1693; (Job.0.S3.I2) STK11 - 1595; (Job.0.S3.I3) STK11 - 1718; (Job.0.S3.I4)
STK11 - 784 : 1644.0 (Job.0.S4.I1) STK11 - 357; (Job.0.S4.I2) STK11 - 358; (Job.0.S4.I3)
STK11 - 374; (Job.0.S4.I4) STK11 - 176 : 357.5
Job # 1
(Job.1.S1.I1) STK11 - 317; (Job.1.S1.I2) STK11 - 399; (Job.1.S1.I3) STK11 - 485;
(Job.1.S1.I4) STK11 - 537 : 442.0 (Job.1.S2.I1) STK11 - 324; (Job.1.S2.I2) STK11
- 336; (Job.1.S2.I3) STK11 - 228; (Job.1.S2.I4) STK11 - 336 : 330.0 (Job.1.S3.I1)
STK11 - 786; (Job.1.S3.I2) STK11 - 979; (Job.1.S3.I3) STK11 - 814; (Job.1.S3.I4)
STK11 - 1626 : 896.5 (Job.1.S4.I1) STK11 - 152; (Job.1.S4.I2) STK11 - 151; (Job.1.S4.I3)
STK11 - 151; (Job.1.S4.I4) STK11 - 612 : 151.5
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Job # 2
(Job.2.S1.I1) STK11 - 1587; (Job.2.S1.I2) STK11 - 1587; (Job.2.S1.I3) STK11 - 1587;
(Job.2.S1.I4) STK11 - 1587 : 1587.0 (Job.2.S2.I1) STK11 - 454; (Job.2.S2.I2) STK11
- 585; (Job.2.S2.I3) STK11 - 592; (Job.2.S2.I4) STK11 - 594 : 588.5 (Job.2.S3.I1)
STK11 - 152; (Job.2.S3.I2) STK11 - 152; (Job.2.S3.I3) STK11 - 151; (Job.2.S3.I4)
STK11 - 160 : 152.0 (Job.2.S4.I1) STK11 - 603; (Job.2.S4.I2) STK11 - 605; (Job.2.S4.I3)
STK11 - 159; (Job.2.S4.I4) STK11 - 556 : 579.5
Job # 3
(Job.3.S1.I1) STK11 - 135; (Job.3.S1.I2) STK11 - 169; (Job.3.S1.I3) STK11 - 131;
(Job.3.S1.I4) STK11 - 133 : 134.0 (Job.3.S2.I1) STK11 - 190; (Job.3.S2.I2) STK11
- 171; (Job.3.S2.I3) STK11 - 243; (Job.3.S2.I4) STK11 - 182 : 186.0 (Job.3.S3.I1)
STK11 - 195; (Job.3.S3.I2) STK11 - 195; (Job.3.S3.I3) STK11 - 215; (Job.3.S3.I4)
STK11 - 200 : 197.5 (Job.3.S4.I1) STK11 - 171; (Job.3.S4.I2) STK11 - 168; (Job.3.S4.I3)
STK11 - 171; (Job.3.S4.I4) STK11 - 176 : 171.0
Job # 4
(Job.4.S1.I1) STK11 - 221; (Job.4.S1.I2) STK11 - 128; (Job.4.S1.I3) STK11 - 221;
(Job.4.S1.I4) STK11 - 116 : 174.5 (Job.4.S2.I1) STK11 - 29; (Job.4.S2.I2) STK11 -
27; (Job.4.S2.I3) STK11 - 32; (Job.4.S2.I4) STK11 - 29 : 29.0 (Job.4.S3.I1) STK11
- 394; (Job.4.S3.I2) STK11 - 403; (Job.4.S3.I3) STK11 - 200; (Job.4.S3.I4) STK11 -
179 : 297.0 (Job.4.S4.I1) STK11 - 1366; (Job.4.S4.I2) STK11 - 1371; (Job.4.S4.I3)
STK11 - 1369; (Job.4.S4.I4) STK11 - 1304 : 1367.5
Best ranks of each set–island : 484 - 566 - 784 - 176 - 317 - 228 - 786 - 151 - 1587 -
454 - 151 - 159 - 131 - 171 - 195 - 168 - 116 - 27 - 179 - 1304 -
Median: 343.75
Median of best : 187.0
A.1.15 TP53
Job # 0
(Job.0.S1.I1) TP53 - 3; (Job.0.S1.I2) TP53 - 2; (Job.0.S1.I3) TP53 - 3; (Job.0.S1.I4)
TP53 - 4 : 3.0 (Job.0.S2.I1) TP53 - 6; (Job.0.S2.I2) TP53 - 33; (Job.0.S2.I3) TP53
- 6; (Job.0.S2.I4) TP53 - 45 : 19.5 (Job.0.S3.I1) TP53 - 4; (Job.0.S3.I2) TP53 -
3; (Job.0.S3.I3) TP53 - 4; (Job.0.S3.I4) TP53 - 4 : 4.0 (Job.0.S4.I1) TP53 - 3;
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(Job.0.S4.I2) TP53 - 5; (Job.0.S4.I3) TP53 - 3; (Job.0.S4.I4) TP53 - 2 : 3.0
Job # 1
(Job.1.S1.I1) TP53 - 11; (Job.1.S1.I2) TP53 - 14; (Job.1.S1.I3) TP53 - 15; (Job.1.S1.I4)
TP53 - 2 : 12.5 (Job.1.S2.I1) TP53 - 5; (Job.1.S2.I2) TP53 - 4; (Job.1.S2.I3) TP53
- 4; (Job.1.S2.I4) TP53 - 6 : 4.5 (Job.1.S3.I1) TP53 - 9; (Job.1.S3.I2) TP53 -
3; (Job.1.S3.I3) TP53 - 9; (Job.1.S3.I4) TP53 - 8 : 8.5 (Job.1.S4.I1) TP53 - 5;
(Job.1.S4.I2) TP53 - 2; (Job.1.S4.I3) TP53 - 5; (Job.1.S4.I4) TP53 - 3 : 4.0
Job # 2
(Job.2.S1.I1) TP53 - 28; (Job.2.S1.I2) TP53 - 28; (Job.2.S1.I3) TP53 - 3; (Job.2.S1.I4)
TP53 - 3 : 15.5 (Job.2.S2.I1) TP53 - 1; (Job.2.S2.I2) TP53 - 3; (Job.2.S2.I3) TP53
- 3; (Job.2.S2.I4) TP53 - 1 : 2.0 (Job.2.S3.I1) TP53 - 2; (Job.2.S3.I2) TP53 -
4; (Job.2.S3.I3) TP53 - 4; (Job.2.S3.I4) TP53 - 1 : 3.0 (Job.2.S4.I1) TP53 - 5;
(Job.2.S4.I2) TP53 - 5; (Job.2.S4.I3) TP53 - 5; (Job.2.S4.I4) TP53 - 5 : 5.0
Job # 3
(Job.3.S1.I1) TP53 - 7; (Job.3.S1.I2) TP53 - 7; (Job.3.S1.I3) TP53 - 6; (Job.3.S1.I4)
TP53 - 8 : 7.0 (Job.3.S2.I1) TP53 - 2; (Job.3.S2.I2) TP53 - 2; (Job.3.S2.I3) TP53
- 15; (Job.3.S2.I4) TP53 - 2 : 2.0 (Job.3.S3.I1) TP53 - 3; (Job.3.S3.I2) TP53 -
3; (Job.3.S3.I3) TP53 - 3; (Job.3.S3.I4) TP53 - 3 : 3.0 (Job.3.S4.I1) TP53 - 2;
(Job.3.S4.I2) TP53 - 2; (Job.3.S4.I3) TP53 - 2; (Job.3.S4.I4) TP53 - 2 : 2.0
Job # 4
(Job.4.S1.I1) TP53 - 5; (Job.4.S1.I2) TP53 - 5; (Job.4.S1.I3) TP53 - 5; (Job.4.S1.I4)
TP53 - 5 : 5.0 (Job.4.S2.I1) TP53 - 4; (Job.4.S2.I2) TP53 - 4; (Job.4.S2.I3) TP53
- 4; (Job.4.S2.I4) TP53 - 4 : 4.0 (Job.4.S3.I1) TP53 - 2; (Job.4.S3.I2) TP53 -
2; (Job.4.S3.I3) TP53 - 2; (Job.4.S3.I4) TP53 - 2 : 2.0 (Job.4.S4.I1) TP53 - 3;
(Job.4.S4.I2) TP53 - 3; (Job.4.S4.I3) TP53 - 4; (Job.4.S4.I4) TP53 - 2 : 3.0
Best ranks of each set–island : 2 - 6 - 3 - 2 - 2 - 4 - 3 - 2 - 3 - 1 - 1 - 5 - 6 - 2 -
3 - 2 - 5 - 4 - 2 - 2 -
Median: 4.0
Median of best : 2.5
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A.2 Parkinson’s Disease
A.2.1 APOE
Job # 0
(Job.0.S1.I1) APOE - 285; (Job.0.S1.I2) APOE - 285; (Job.0.S1.I3) APOE - 285;
(Job.0.S1.I4) APOE - 63 : 285.0 (Job.0.S2.I1) APOE - 43; (Job.0.S2.I2) APOE -
43; (Job.0.S2.I3) APOE - 46; (Job.0.S2.I4) APOE - 43 : 43.0 (Job.0.S3.I1) APOE -
105; (Job.0.S3.I2) APOE - 98; (Job.0.S3.I3) APOE - 120; (Job.0.S3.I4) APOE - 105
: 105.0 (Job.0.S4.I1) APOE - 287; (Job.0.S4.I2) APOE - 213; (Job.0.S4.I3) APOE -
253; (Job.0.S4.I4) APOE - 293 : 270.0
Job # 1
(Job.1.S1.I1) APOE - 29; (Job.1.S1.I2) APOE - 8; (Job.1.S1.I3) APOE - 124; (Job.1.S1.I4)
APOE - 15 : 22.0 (Job.1.S2.I1) APOE - 10; (Job.1.S2.I2) APOE - 57; (Job.1.S2.I3)
APOE - 24; (Job.1.S2.I4) APOE - 34 : 29.0 (Job.1.S3.I1) APOE - 97; (Job.1.S3.I2)
APOE - 400; (Job.1.S3.I3) APOE - 156; (Job.1.S3.I4) APOE - 400 : 278.0 (Job.1.S4.I1)
APOE - 173; (Job.1.S4.I2) APOE - 173; (Job.1.S4.I3) APOE - 173; (Job.1.S4.I4)
APOE - 173 : 173.0
Job # 2
(Job.2.S1.I1) APOE - 178; (Job.2.S1.I2) APOE - 171; (Job.2.S1.I3) APOE - 72;
(Job.2.S1.I4) APOE - 170 : 170.5 (Job.2.S2.I1) APOE - 102; (Job.2.S2.I2) APOE
- 115; (Job.2.S2.I3) APOE - 102; (Job.2.S2.I4) APOE - 109 : 105.5 (Job.2.S3.I1)
APOE - 83; (Job.2.S3.I2) APOE - 183; (Job.2.S3.I3) APOE - 80; (Job.2.S3.I4) APOE
- 82 : 82.5 (Job.2.S4.I1) APOE - 63; (Job.2.S4.I2) APOE - 61; (Job.2.S4.I3) APOE
- 73; (Job.2.S4.I4) APOE - 67 : 65.0
Job # 3
(Job.3.S1.I1) APOE - 67; (Job.3.S1.I2) APOE - 65; (Job.3.S1.I3) APOE - 66; (Job.3.S1.I4)
APOE - 67 : 66.5 (Job.3.S2.I1) APOE - 18; (Job.3.S2.I2) APOE - 9; (Job.3.S2.I3)
APOE - 18; (Job.3.S2.I4) APOE - 8 : 13.5 (Job.3.S3.I1) APOE - 12; (Job.3.S3.I2)
APOE - 20; (Job.3.S3.I3) APOE - 12; (Job.3.S3.I4) APOE - 20 : 16.0 (Job.3.S4.I1)
APOE - 108; (Job.3.S4.I2) APOE - 110; (Job.3.S4.I3) APOE - 110; (Job.3.S4.I4)
APOE - 108 : 109.0
Job # 4
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(Job.4.S1.I1) APOE - 585; (Job.4.S1.I2) APOE - 603; (Job.4.S1.I3) APOE - 587;
(Job.4.S1.I4) APOE - 566 : 586.0 (Job.4.S2.I1) APOE - 26; (Job.4.S2.I2) APOE -
32; (Job.4.S2.I3) APOE - 26; (Job.4.S2.I4) APOE - 72 : 29.0 (Job.4.S3.I1) APOE -
35; (Job.4.S3.I2) APOE - 38; (Job.4.S3.I3) APOE - 131; (Job.4.S3.I4) APOE - 38 :
38.0 (Job.4.S4.I1) APOE - 135; (Job.4.S4.I2) APOE - 98; (Job.4.S4.I3) APOE - 101;
(Job.4.S4.I4) APOE - 135 : 118.0
Best ranks of each set–island : 63 - 43 - 98 - 213 - 8 - 10 - 97 - 173 - 72 - 102 -
80 - 61 - 65 - 8 - 12 - 108 - 566 - 26 - 35 - 98 -
Median: 93.75
Median of best : 68.5
A.2.2 BDNF
Job # 0
(Job.0.S1.I1) BDNF - 502; (Job.0.S1.I2) BDNF - 479; (Job.0.S1.I3) BDNF - 474;
(Job.0.S1.I4) BDNF - 462 : 476.5 (Job.0.S2.I1) BDNF - 116; (Job.0.S2.I2) BDNF
- 220; (Job.0.S2.I3) BDNF - 112; (Job.0.S2.I4) BDNF - 225 : 168.0 (Job.0.S3.I1)
BDNF - 1003; (Job.0.S3.I2) BDNF - 695; (Job.0.S3.I3) BDNF - 960; (Job.0.S3.I4)
BDNF - 879 : 919.5 (Job.0.S4.I1) BDNF - 12; (Job.0.S4.I2) BDNF - 14; (Job.0.S4.I3)
BDNF - 52; (Job.0.S4.I4) BDNF - 14 : 14.0
Job # 1
(Job.1.S1.I1) BDNF - 189; (Job.1.S1.I2) BDNF - 190; (Job.1.S1.I3) BDNF - 189;
(Job.1.S1.I4) BDNF - 189 : 189.0 (Job.1.S2.I1) BDNF - 2692; (Job.1.S2.I2) BDNF -
2693; (Job.1.S2.I3) BDNF - 2693; (Job.1.S2.I4) BDNF - 2694 : 2693.0 (Job.1.S3.I1)
BDNF - 116; (Job.1.S3.I2) BDNF - 163; (Job.1.S3.I3) BDNF - 163; (Job.1.S3.I4)
BDNF - 184 : 163.0 (Job.1.S4.I1) BDNF - 8; (Job.1.S4.I2) BDNF - 8; (Job.1.S4.I3)
BDNF - 8; (Job.1.S4.I4) BDNF - 8 : 8.0
Job # 2
(Job.2.S1.I1) BDNF - 800; (Job.2.S1.I2) BDNF - 12; (Job.2.S1.I3) BDNF - 747;
(Job.2.S1.I4) BDNF - 519 : 633.0 (Job.2.S2.I1) BDNF - 40; (Job.2.S2.I2) BDNF -
40; (Job.2.S2.I3) BDNF - 40; (Job.2.S2.I4) BDNF - 40 : 40.0 (Job.2.S3.I1) BDNF -
150; (Job.2.S3.I2) BDNF - 149; (Job.2.S3.I3) BDNF - 150; (Job.2.S3.I4) BDNF - 149
: 149.5 (Job.2.S4.I1) BDNF - 198; (Job.2.S4.I2) BDNF - 194; (Job.2.S4.I3) BDNF -
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200; (Job.2.S4.I4) BDNF - 149 : 196.0
Job # 3
(Job.3.S1.I1) BDNF - 15; (Job.3.S1.I2) BDNF - 55; (Job.3.S1.I3) BDNF - 27; (Job.3.S1.I4)
BDNF - 15 : 21.0 (Job.3.S2.I1) BDNF - 59; (Job.3.S2.I2) BDNF - 59; (Job.3.S2.I3)
BDNF - 51; (Job.3.S2.I4) BDNF - 61 : 59.0 (Job.3.S3.I1) BDNF - 941; (Job.3.S3.I2)
BDNF - 859; (Job.3.S3.I3) BDNF - 930; (Job.3.S3.I4) BDNF - 936 : 933.0 (Job.3.S4.I1)
BDNF - 111; (Job.3.S4.I2) BDNF - 111; (Job.3.S4.I3) BDNF - 111; (Job.3.S4.I4)
BDNF - 111 : 111.0
Job # 4
(Job.4.S1.I1) BDNF - 72; (Job.4.S1.I2) BDNF - 72; (Job.4.S1.I3) BDNF - 72; (Job.4.S1.I4)
BDNF - 57 : 72.0 (Job.4.S2.I1) BDNF - 56; (Job.4.S2.I2) BDNF - 109; (Job.4.S2.I3)
BDNF - 112; (Job.4.S2.I4) BDNF - 118 : 110.5 (Job.4.S3.I1) BDNF - 7; (Job.4.S3.I2)
BDNF - 7; (Job.4.S3.I3) BDNF - 99; (Job.4.S3.I4) BDNF - 7 : 7.0 (Job.4.S4.I1)
BDNF - 213; (Job.4.S4.I2) BDNF - 213; (Job.4.S4.I3) BDNF - 213; (Job.4.S4.I4)
BDNF - 213 : 213.0
Best ranks of each set–island : 462 - 112 - 695 - 12 - 189 - 2692 - 116 - 8 - 12 -
40 - 149 - 149 - 15 - 51 - 859 - 111 - 57 - 56 - 7 - 213 -
Median: 156.25
Median of best : 111.5
A.2.3 BST1
Job # 0
(Job.0.S1.I1) BST1 - 10; (Job.0.S1.I2) BST1 - 10; (Job.0.S1.I3) BST1 - 55; (Job.0.S1.I4)
BST1 - 108 : 32.5 (Job.0.S2.I1) BST1 - 7; (Job.0.S2.I2) BST1 - 6; (Job.0.S2.I3) BST1
- 5; (Job.0.S2.I4) BST1 - 5 : 5.5 (Job.0.S3.I1) BST1 - 44; (Job.0.S3.I2) BST1 - 64;
(Job.0.S3.I3) BST1 - 37; (Job.0.S3.I4) BST1 - 35 : 40.5 (Job.0.S4.I1) BST1 - 4;
(Job.0.S4.I2) BST1 - 4; (Job.0.S4.I3) BST1 - 4; (Job.0.S4.I4) BST1 - 4 : 4.0
Job # 1
(Job.1.S1.I1) BST1 - 5; (Job.1.S1.I2) BST1 - 5; (Job.1.S1.I3) BST1 - 5; (Job.1.S1.I4)
BST1 - 5 : 5.0 (Job.1.S2.I1) BST1 - 31; (Job.1.S2.I2) BST1 - 31; (Job.1.S2.I3) BST1
- 34; (Job.1.S2.I4) BST1 - 34 : 32.5 (Job.1.S3.I1) BST1 - 3; (Job.1.S3.I2) BST1 -
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13; (Job.1.S3.I3) BST1 - 5; (Job.1.S3.I4) BST1 - 6 : 5.5 (Job.1.S4.I1) BST1 - 17;
(Job.1.S4.I2) BST1 - 5; (Job.1.S4.I3) BST1 - 5; (Job.1.S4.I4) BST1 - 5 : 5.0
Job # 2
(Job.2.S1.I1) BST1 - 6; (Job.2.S1.I2) BST1 - 6; (Job.2.S1.I3) BST1 - 6; (Job.2.S1.I4)
BST1 - 5 : 6.0 (Job.2.S2.I1) BST1 - 19; (Job.2.S2.I2) BST1 - 13; (Job.2.S2.I3) BST1
- 22; (Job.2.S2.I4) BST1 - 36 : 20.5 (Job.2.S3.I1) BST1 - 4; (Job.2.S3.I2) BST1 -
4; (Job.2.S3.I3) BST1 - 4; (Job.2.S3.I4) BST1 - 4 : 4.0 (Job.2.S4.I1) BST1 - 14;
(Job.2.S4.I2) BST1 - 14; (Job.2.S4.I3) BST1 - 12; (Job.2.S4.I4) BST1 - 13 : 13.5
Job # 3
(Job.3.S1.I1) BST1 - 38; (Job.3.S1.I2) BST1 - 19; (Job.3.S1.I3) BST1 - 27; (Job.3.S1.I4)
BST1 - 19 : 23.0 (Job.3.S2.I1) BST1 - 18; (Job.3.S2.I2) BST1 - 5; (Job.3.S2.I3)
BST1 - 5; (Job.3.S2.I4) BST1 - 5 : 5.0 (Job.3.S3.I1) BST1 - 5; (Job.3.S3.I2) BST1
- 5; (Job.3.S3.I3) BST1 - 5; (Job.3.S3.I4) BST1 - 5 : 5.0 (Job.3.S4.I1) BST1 - 5;
(Job.3.S4.I2) BST1 - 5; (Job.3.S4.I3) BST1 - 5; (Job.3.S4.I4) BST1 - 12 : 5.0
Job # 4
(Job.4.S1.I1) BST1 - 342; (Job.4.S1.I2) BST1 - 145; (Job.4.S1.I3) BST1 - 376; (Job.4.S1.I4)
BST1 - 9 : 243.5 (Job.4.S2.I1) BST1 - 8; (Job.4.S2.I2) BST1 - 8; (Job.4.S2.I3) BST1
- 21; (Job.4.S2.I4) BST1 - 6 : 8.0 (Job.4.S3.I1) BST1 - 18; (Job.4.S3.I2) BST1 -
15; (Job.4.S3.I3) BST1 - 27; (Job.4.S3.I4) BST1 - 18 : 18.0 (Job.4.S4.I1) BST1 - 6;
(Job.4.S4.I2) BST1 - 6; (Job.4.S4.I3) BST1 - 5; (Job.4.S4.I4) BST1 - 5 : 5.5
Best ranks of each set–island : 10 - 5 - 35 - 4 - 5 - 31 - 3 - 5 - 5 - 13 - 4 - 12 -
19 - 5 - 5 - 5 - 9 - 6 - 15 - 5 -
Median: 5.75
Median of best : 5.0
A.2.4 COMT
Job # 0
(Job.0.S1.I1) COMT - 756; (Job.0.S1.I2) COMT - 753; (Job.0.S1.I3) COMT - 771;
(Job.0.S1.I4) COMT - 749 : 754.5 (Job.0.S2.I1) COMT - 47; (Job.0.S2.I2) COMT -
23; (Job.0.S2.I3) COMT - 11; (Job.0.S2.I4) COMT - 60 : 35.0 (Job.0.S3.I1) COMT
- 22; (Job.0.S3.I2) COMT - 48; (Job.0.S3.I3) COMT - 612; (Job.0.S3.I4) COMT - 25
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: 36.5 (Job.0.S4.I1) COMT - 698; (Job.0.S4.I2) COMT - 698; (Job.0.S4.I3) COMT -
698; (Job.0.S4.I4) COMT - 698 : 698.0
Job # 1
(Job.1.S1.I1) COMT - 656; (Job.1.S1.I2) COMT - 876; (Job.1.S1.I3) COMT - 874;
(Job.1.S1.I4) COMT - 656 : 765.0 (Job.1.S2.I1) COMT - 270; (Job.1.S2.I2) COMT
- 286; (Job.1.S2.I3) COMT - 273; (Job.1.S2.I4) COMT - 295 : 279.5 (Job.1.S3.I1)
COMT - 362; (Job.1.S3.I2) COMT - 358; (Job.1.S3.I3) COMT - 341; (Job.1.S3.I4)
COMT - 372 : 360.0 (Job.1.S4.I1) COMT - 204; (Job.1.S4.I2) COMT - 205; (Job.1.S4.I3)
COMT - 230; (Job.1.S4.I4) COMT - 187 : 204.5
Job # 2
(Job.2.S1.I1) COMT - 240; (Job.2.S1.I2) COMT - 240; (Job.2.S1.I3) COMT - 99;
(Job.2.S1.I4) COMT - 123 : 181.5 (Job.2.S2.I1) COMT - 144; (Job.2.S2.I2) COMT -
150; (Job.2.S2.I3) COMT - 151; (Job.2.S2.I4) COMT - 489 : 150.5 (Job.2.S3.I1)
COMT - 10; (Job.2.S3.I2) COMT - 13; (Job.2.S3.I3) COMT - 10; (Job.2.S3.I4)
COMT - 41 : 11.5 (Job.2.S4.I1) COMT - 143; (Job.2.S4.I2) COMT - 143; (Job.2.S4.I3)
COMT - 148; (Job.2.S4.I4) COMT - 149 : 145.5
Job # 3
(Job.3.S1.I1) COMT - 261; (Job.3.S1.I2) COMT - 393; (Job.3.S1.I3) COMT - 23;
(Job.3.S1.I4) COMT - 12 : 142.0 (Job.3.S2.I1) COMT - 2452; (Job.3.S2.I2) COMT -
2452; (Job.3.S2.I3) COMT - 2451; (Job.3.S2.I4) COMT - 2450 : 2451.5 (Job.3.S3.I1)
COMT - 951; (Job.3.S3.I2) COMT - 931; (Job.3.S3.I3) COMT - 947; (Job.3.S3.I4)
COMT - 951 : 949.0 (Job.3.S4.I1) COMT - 248; (Job.3.S4.I2) COMT - 215; (Job.3.S4.I3)
COMT - 295; (Job.3.S4.I4) COMT - 213 : 231.5
Job # 4
(Job.4.S1.I1) COMT - 214; (Job.4.S1.I2) COMT - 264; (Job.4.S1.I3) COMT - 256;
(Job.4.S1.I4) COMT - 426 : 260.0 (Job.4.S2.I1) COMT - 377; (Job.4.S2.I2) COMT
- 378; (Job.4.S2.I3) COMT - 417; (Job.4.S2.I4) COMT - 340 : 377.5 (Job.4.S3.I1)
COMT - 1000; (Job.4.S3.I2) COMT - 914; (Job.4.S3.I3) COMT - 918; (Job.4.S3.I4)
COMT - 146 : 916.0 (Job.4.S4.I1) COMT - 209; (Job.4.S4.I2) COMT - 177; (Job.4.S4.I3)
COMT - 187; (Job.4.S4.I4) COMT - 183 : 185.0
Best ranks of each set–island : 749 - 11 - 22 - 698 - 656 - 270 - 341 - 187 - 99 -
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144 - 10 - 143 - 12 - 2450 - 931 - 213 - 214 - 340 - 146 - 177 -
Median: 245.75
Median of best : 200.0
A.2.5 CYP2D6
Job # 0
(Job.0.S1.I1) CYP2D6 - 564; (Job.0.S1.I2) CYP2D6 - 727; (Job.0.S1.I3) CYP2D6 -
846; (Job.0.S1.I4) CYP2D6 - 845 : 786.0 (Job.0.S2.I1) CYP2D6 - 854; (Job.0.S2.I2)
CYP2D6 - 892; (Job.0.S2.I3) CYP2D6 - 885; (Job.0.S2.I4) CYP2D6 - 915 : 888.5
(Job.0.S3.I1) CYP2D6 - 137; (Job.0.S3.I2) CYP2D6 - 791; (Job.0.S3.I3) CYP2D6 -
779; (Job.0.S3.I4) CYP2D6 - 190 : 484.5 (Job.0.S4.I1) CYP2D6 - 766; (Job.0.S4.I2)
CYP2D6 - 764; (Job.0.S4.I3) CYP2D6 - 568; (Job.0.S4.I4) CYP2D6 - 576 : 670.0
Job # 1
(Job.1.S1.I1) CYP2D6 - 940; (Job.1.S1.I2) CYP2D6 - 949; (Job.1.S1.I3) CYP2D6 -
951; (Job.1.S1.I4) CYP2D6 - 929 : 944.5 (Job.1.S2.I1) CYP2D6 - 947; (Job.1.S2.I2)
CYP2D6 - 1501; (Job.1.S2.I3) CYP2D6 - 962; (Job.1.S2.I4) CYP2D6 - 944 : 954.5
(Job.1.S3.I1) CYP2D6 - 166; (Job.1.S3.I2) CYP2D6 - 162; (Job.1.S3.I3) CYP2D6 -
271; (Job.1.S3.I4) CYP2D6 - 170 : 168.0 (Job.1.S4.I1) CYP2D6 - 733; (Job.1.S4.I2)
CYP2D6 - 739; (Job.1.S4.I3) CYP2D6 - 979; (Job.1.S4.I4) CYP2D6 - 733 : 736.0
Job # 2
(Job.2.S1.I1) CYP2D6 - 253; (Job.2.S1.I2) CYP2D6 - 187; (Job.2.S1.I3) CYP2D6 -
277; (Job.2.S1.I4) CYP2D6 - 268 : 260.5 (Job.2.S2.I1) CYP2D6 - 1009; (Job.2.S2.I2)
CYP2D6 - 816; (Job.2.S2.I3) CYP2D6 - 1079; (Job.2.S2.I4) CYP2D6 - 1099 : 1044.0
(Job.2.S3.I1) CYP2D6 - 962; (Job.2.S3.I2) CYP2D6 - 825; (Job.2.S3.I3) CYP2D6 -
828; (Job.2.S3.I4) CYP2D6 - 943 : 885.5 (Job.2.S4.I1) CYP2D6 - 1961; (Job.2.S4.I2)
CYP2D6 - 1962; (Job.2.S4.I3) CYP2D6 - 1905; (Job.2.S4.I4) CYP2D6 - 1938 : 1949.5
Job # 3
(Job.3.S1.I1) CYP2D6 - 369; (Job.3.S1.I2) CYP2D6 - 369; (Job.3.S1.I3) CYP2D6 -
1361; (Job.3.S1.I4) CYP2D6 - 1704 : 865.0 (Job.3.S2.I1) CYP2D6 - 768; (Job.3.S2.I2)
CYP2D6 - 718; (Job.3.S2.I3) CYP2D6 - 744; (Job.3.S2.I4) CYP2D6 - 649 : 731.0
(Job.3.S3.I1) CYP2D6 - 952; (Job.3.S3.I2) CYP2D6 - 653; (Job.3.S3.I3) CYP2D6 -
957; (Job.3.S3.I4) CYP2D6 - 1503 : 954.5 (Job.3.S4.I1) CYP2D6 - 405; (Job.3.S4.I2)
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CYP2D6 - 405; (Job.3.S4.I3) CYP2D6 - 405; (Job.3.S4.I4) CYP2D6 - 405 : 405.0
Job # 4
(Job.4.S1.I1) CYP2D6 - 822; (Job.4.S1.I2) CYP2D6 - 1967; (Job.4.S1.I3) CYP2D6 -
1224; (Job.4.S1.I4) CYP2D6 - 1125 : 1174.5 (Job.4.S2.I1) CYP2D6 - 890; (Job.4.S2.I2)
CYP2D6 - 926; (Job.4.S2.I3) CYP2D6 - 926; (Job.4.S2.I4) CYP2D6 - 938 : 926.0
(Job.4.S3.I1) CYP2D6 - 978; (Job.4.S3.I2) CYP2D6 - 990; (Job.4.S3.I3) CYP2D6 -
981; (Job.4.S3.I4) CYP2D6 - 978 : 979.5 (Job.4.S4.I1) CYP2D6 - 370; (Job.4.S4.I2)
CYP2D6 - 540; (Job.4.S4.I3) CYP2D6 - 515; (Job.4.S4.I4) CYP2D6 - 382 : 448.5
Best ranks of each set–island : 564 - 854 - 137 - 568 - 929 - 944 - 162 - 733 - 187
- 816 - 825 - 1905 - 369 - 649 - 653 - 405 - 822 - 890 - 978 - 370 -
Median: 875.25
Median of best : 693.0
A.2.6 DRD2
Job # 0
(Job.0.S1.I1) DRD2 - 605; (Job.0.S1.I2) DRD2 - 431; (Job.0.S1.I3) DRD2 - 608;
(Job.0.S1.I4) DRD2 - 609 : 606.5 (Job.0.S2.I1) DRD2 - 110; (Job.0.S2.I2) DRD2 -
108; (Job.0.S2.I3) DRD2 - 106; (Job.0.S2.I4) DRD2 - 104 : 107.0 (Job.0.S3.I1) DRD2
- 933; (Job.0.S3.I2) DRD2 - 931; (Job.0.S3.I3) DRD2 - 545; (Job.0.S3.I4) DRD2 - 933
: 932.0 (Job.0.S4.I1) DRD2 - 106; (Job.0.S4.I2) DRD2 - 109; (Job.0.S4.I3) DRD2 -
109; (Job.0.S4.I4) DRD2 - 106 : 107.5
Job # 1
(Job.1.S1.I1) DRD2 - 850; (Job.1.S1.I2) DRD2 - 807; (Job.1.S1.I3) DRD2 - 162;
(Job.1.S1.I4) DRD2 - 789 : 798.0 (Job.1.S2.I1) DRD2 - 201; (Job.1.S2.I2) DRD2 -
213; (Job.1.S2.I3) DRD2 - 210; (Job.1.S2.I4) DRD2 - 215 : 211.5 (Job.1.S3.I1) DRD2
- 864; (Job.1.S3.I2) DRD2 - 398; (Job.1.S3.I3) DRD2 - 863; (Job.1.S3.I4) DRD2 - 825
: 844.0 (Job.1.S4.I1) DRD2 - 962; (Job.1.S4.I2) DRD2 - 1021; (Job.1.S4.I3) DRD2 -
985; (Job.1.S4.I4) DRD2 - 894 : 973.5
Job # 2
(Job.2.S1.I1) DRD2 - 1118; (Job.2.S1.I2) DRD2 - 113; (Job.2.S1.I3) DRD2 - 1115;
(Job.2.S1.I4) DRD2 - 888 : 1001.5 (Job.2.S2.I1) DRD2 - 334; (Job.2.S2.I2) DRD2
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- 325; (Job.2.S2.I3) DRD2 - 514; (Job.2.S2.I4) DRD2 - 324 : 329.5 (Job.2.S3.I1)
DRD2 - 86; (Job.2.S3.I2) DRD2 - 86; (Job.2.S3.I3) DRD2 - 86; (Job.2.S3.I4) DRD2 -
86 : 86.0 (Job.2.S4.I1) DRD2 - 144; (Job.2.S4.I2) DRD2 - 144; (Job.2.S4.I3) DRD2
- 184; (Job.2.S4.I4) DRD2 - 190 : 164.0
Job # 3
(Job.3.S1.I1) DRD2 - 947; (Job.3.S1.I2) DRD2 - 945; (Job.3.S1.I3) DRD2 - 969;
(Job.3.S1.I4) DRD2 - 948 : 947.5 (Job.3.S2.I1) DRD2 - 107; (Job.3.S2.I2) DRD2 -
107; (Job.3.S2.I3) DRD2 - 107; (Job.3.S2.I4) DRD2 - 107 : 107.0 (Job.3.S3.I1) DRD2
- 199; (Job.3.S3.I2) DRD2 - 395; (Job.3.S3.I3) DRD2 - 144; (Job.3.S3.I4) DRD2 - 199
: 199.0 (Job.3.S4.I1) DRD2 - 545; (Job.3.S4.I2) DRD2 - 533; (Job.3.S4.I3) DRD2 -
543; (Job.3.S4.I4) DRD2 - 532 : 538.0
Job # 4
(Job.4.S1.I1) DRD2 - 316; (Job.4.S1.I2) DRD2 - 203; (Job.4.S1.I3) DRD2 - 134;
(Job.4.S1.I4) DRD2 - 134 : 168.5 (Job.4.S2.I1) DRD2 - 333; (Job.4.S2.I2) DRD2 -
331; (Job.4.S2.I3) DRD2 - 349; (Job.4.S2.I4) DRD2 - 347 : 340.0 (Job.4.S3.I1) DRD2
- 910; (Job.4.S3.I2) DRD2 - 798; (Job.4.S3.I3) DRD2 - 798; (Job.4.S3.I4) DRD2 - 912
: 854.0 (Job.4.S4.I1) DRD2 - 612; (Job.4.S4.I2) DRD2 - 564; (Job.4.S4.I3) DRD2 -
571; (Job.4.S4.I4) DRD2 - 564 : 567.5
Best ranks of each set–island : 431 - 104 - 545 - 106 - 162 - 201 - 398 - 894 - 113
- 324 - 86 - 144 - 945 - 107 - 144 - 532 - 134 - 331 - 798 - 564 -
Median: 439.0
Median of best : 262.5
A.2.7 GAK
Job # 0
(Job.0.S1.I1) GAK - 303; (Job.0.S1.I2) GAK - 335; (Job.0.S1.I3) GAK - 298; (Job.0.S1.I4)
GAK - 245 : 300.5 (Job.0.S2.I1) GAK - 53; (Job.0.S2.I2) GAK - 122; (Job.0.S2.I3)
GAK - 122; (Job.0.S2.I4) GAK - 385 : 122.0 (Job.0.S3.I1) GAK - 307; (Job.0.S3.I2)
GAK - 230; (Job.0.S3.I3) GAK - 284; (Job.0.S3.I4) GAK - 241 : 262.5 (Job.0.S4.I1)
GAK - 63; (Job.0.S4.I2) GAK - 46; (Job.0.S4.I3) GAK - 82; (Job.0.S4.I4) GAK - 60
: 61.5
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Job # 1
(Job.1.S1.I1) GAK - 588; (Job.1.S1.I2) GAK - 538; (Job.1.S1.I3) GAK - 591; (Job.1.S1.I4)
GAK - 594 : 589.5 (Job.1.S2.I1) GAK - 153; (Job.1.S2.I2) GAK - 153; (Job.1.S2.I3)
GAK - 160; (Job.1.S2.I4) GAK - 277 : 156.5 (Job.1.S3.I1) GAK - 191; (Job.1.S3.I2)
GAK - 215; (Job.1.S3.I3) GAK - 222; (Job.1.S3.I4) GAK - 218 : 216.5 (Job.1.S4.I1)
GAK - 319; (Job.1.S4.I2) GAK - 319; (Job.1.S4.I3) GAK - 319; (Job.1.S4.I4) GAK -
318 : 319.0
Job # 2
(Job.2.S1.I1) GAK - 449; (Job.2.S1.I2) GAK - 425; (Job.2.S1.I3) GAK - 847; (Job.2.S1.I4)
GAK - 847 : 648.0 (Job.2.S2.I1) GAK - 506; (Job.2.S2.I2) GAK - 506; (Job.2.S2.I3)
GAK - 507; (Job.2.S2.I4) GAK - 506 : 506.0 (Job.2.S3.I1) GAK - 462; (Job.2.S3.I2)
GAK - 262; (Job.2.S3.I3) GAK - 256; (Job.2.S3.I4) GAK - 256 : 259.0 (Job.2.S4.I1)
GAK - 748; (Job.2.S4.I2) GAK - 748; (Job.2.S4.I3) GAK - 748; (Job.2.S4.I4) GAK -
876 : 748.0
Job # 3
(Job.3.S1.I1) GAK - 837; (Job.3.S1.I2) GAK - 862; (Job.3.S1.I3) GAK - 862; (Job.3.S1.I4)
GAK - 837 : 849.5 (Job.3.S2.I1) GAK - 935; (Job.3.S2.I2) GAK - 935; (Job.3.S2.I3)
GAK - 935; (Job.3.S2.I4) GAK - 935 : 935.0 (Job.3.S3.I1) GAK - 561; (Job.3.S3.I2)
GAK - 561; (Job.3.S3.I3) GAK - 558; (Job.3.S3.I4) GAK - 574 : 561.0 (Job.3.S4.I1)
GAK - 213; (Job.3.S4.I2) GAK - 225; (Job.3.S4.I3) GAK - 225; (Job.3.S4.I4) GAK -
222 : 223.5
Job # 4
(Job.4.S1.I1) GAK - 185; (Job.4.S1.I2) GAK - 188; (Job.4.S1.I3) GAK - 139; (Job.4.S1.I4)
GAK - 153 : 169.0 (Job.4.S2.I1) GAK - 151; (Job.4.S2.I2) GAK - 113; (Job.4.S2.I3)
GAK - 130; (Job.4.S2.I4) GAK - 133 : 131.5 (Job.4.S3.I1) GAK - 152; (Job.4.S3.I2)
GAK - 150; (Job.4.S3.I3) GAK - 157; (Job.4.S3.I4) GAK - 148 : 151.0 (Job.4.S4.I1)
GAK - 909; (Job.4.S4.I2) GAK - 808; (Job.4.S4.I3) GAK - 857; (Job.4.S4.I4) GAK -
709 : 832.5
Best ranks of each set–island : 245 - 53 - 230 - 46 - 538 - 153 - 191 - 318 - 425 -
506 - 256 - 748 - 837 - 935 - 558 - 213 - 139 - 113 - 148 - 709 -
Median: 281.5
Median of best : 250.5
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A.2.8 GBA
Job # 0
(Job.0.S1.I1) GBA - 1716; (Job.0.S1.I2) GBA - 1961; (Job.0.S1.I3) GBA - 2379;
(Job.0.S1.I4) GBA - 1660 : 1838.5 (Job.0.S2.I1) GBA - 1454; (Job.0.S2.I2) GBA
- 1911; (Job.0.S2.I3) GBA - 1434; (Job.0.S2.I4) GBA - 1454 : 1454.0 (Job.0.S3.I1)
GBA - 1754; (Job.0.S3.I2) GBA - 1759; (Job.0.S3.I3) GBA - 1759; (Job.0.S3.I4) GBA
- 1823 : 1759.0 (Job.0.S4.I1) GBA - 1855; (Job.0.S4.I2) GBA - 1794; (Job.0.S4.I3)
GBA - 1872; (Job.0.S4.I4) GBA - 1866 : 1860.5
Job # 1
(Job.1.S1.I1) GBA - 1920; (Job.1.S1.I2) GBA - 1920; (Job.1.S1.I3) GBA - 1920;
(Job.1.S1.I4) GBA - 1920 : 1920.0 (Job.1.S2.I1) GBA - 1179; (Job.1.S2.I2) GBA
- 1177; (Job.1.S2.I3) GBA - 1131; (Job.1.S2.I4) GBA - 1115 : 1154.0 (Job.1.S3.I1)
GBA - 1055; (Job.1.S3.I2) GBA - 1963; (Job.1.S3.I3) GBA - 1490; (Job.1.S3.I4) GBA
- 1036 : 1272.5 (Job.1.S4.I1) GBA - 1021; (Job.1.S4.I2) GBA - 2219; (Job.1.S4.I3)
GBA - 942; (Job.1.S4.I4) GBA - 928 : 981.5
Job # 2
(Job.2.S1.I1) GBA - 2235; (Job.2.S1.I2) GBA - 2221; (Job.2.S1.I3) GBA - 2221;
(Job.2.S1.I4) GBA - 2221 : 2221.0 (Job.2.S2.I1) GBA - 2270; (Job.2.S2.I2) GBA
- 2270; (Job.2.S2.I3) GBA - 1972; (Job.2.S2.I4) GBA - 2343 : 2270.0 (Job.2.S3.I1)
GBA - 2395; (Job.2.S3.I2) GBA - 2205; (Job.2.S3.I3) GBA - 2363; (Job.2.S3.I4) GBA
- 2216 : 2289.5 (Job.2.S4.I1) GBA - 997; (Job.2.S4.I2) GBA - 1787; (Job.2.S4.I3)
GBA - 1787; (Job.2.S4.I4) GBA - 1707 : 1747.0
Job # 3
(Job.3.S1.I1) GBA - 2351; (Job.3.S1.I2) GBA - 1784; (Job.3.S1.I3) GBA - 2338;
(Job.3.S1.I4) GBA - 2463 : 2344.5 (Job.3.S2.I1) GBA - 1954; (Job.3.S2.I2) GBA
- 1981; (Job.3.S2.I3) GBA - 1990; (Job.3.S2.I4) GBA - 1961 : 1971.0 (Job.3.S3.I1)
GBA - 2074; (Job.3.S3.I2) GBA - 1811; (Job.3.S3.I3) GBA - 2072; (Job.3.S3.I4) GBA
- 1847 : 1959.5 (Job.3.S4.I1) GBA - 2013; (Job.3.S4.I2) GBA - 2013; (Job.3.S4.I3)
GBA - 1906; (Job.3.S4.I4) GBA - 1906 : 1959.5
Job # 4
(Job.4.S1.I1) GBA - 2676; (Job.4.S1.I2) GBA - 2409; (Job.4.S1.I3) GBA - 2409;
(Job.4.S1.I4) GBA - 2639 : 2524.0 (Job.4.S2.I1) GBA - 1836; (Job.4.S2.I2) GBA
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- 1840; (Job.4.S2.I3) GBA - 1869; (Job.4.S2.I4) GBA - 1946 : 1854.5 (Job.4.S3.I1)
GBA - 2278; (Job.4.S3.I2) GBA - 2481; (Job.4.S3.I3) GBA - 1132; (Job.4.S3.I4) GBA
- 2413 : 2345.5 (Job.4.S4.I1) GBA - 1329; (Job.4.S4.I2) GBA - 2221; (Job.4.S4.I3)
GBA - 1549; (Job.4.S4.I4) GBA - 1417 : 1483.0
Best ranks of each set–island : 1660 - 1434 - 1754 - 1794 - 1920 - 1115 - 1036 -
928 - 2221 - 1972 - 2205 - 997 - 1784 - 1954 - 1811 - 1906 - 2409 - 1836 - 1132 - 1329 -
Median: 1890.25
Median of best : 1789.0
A.2.9 LRRK2
Job # 0
(Job.0.S1.I1) LRRK2 - 204; (Job.0.S1.I2) LRRK2 - 182; (Job.0.S1.I3) LRRK2 - 204;
(Job.0.S1.I4) LRRK2 - 204 : 204.0 (Job.0.S2.I1) LRRK2 - 641; (Job.0.S2.I2) LRRK2
- 612; (Job.0.S2.I3) LRRK2 - 615; (Job.0.S2.I4) LRRK2 - 616 : 615.5 (Job.0.S3.I1)
LRRK2 - 179; (Job.0.S3.I2) LRRK2 - 176; (Job.0.S3.I3) LRRK2 - 179; (Job.0.S3.I4)
LRRK2 - 179 : 179.0 (Job.0.S4.I1) LRRK2 - 867; (Job.0.S4.I2) LRRK2 - 870;
(Job.0.S4.I3) LRRK2 - 832; (Job.0.S4.I4) LRRK2 - 825 : 849.5
Job # 1
(Job.1.S1.I1) LRRK2 - 251; (Job.1.S1.I2) LRRK2 - 251; (Job.1.S1.I3) LRRK2 - 251;
(Job.1.S1.I4) LRRK2 - 326 : 251.0 (Job.1.S2.I1) LRRK2 - 717; (Job.1.S2.I2) LRRK2
- 717; (Job.1.S2.I3) LRRK2 - 724; (Job.1.S2.I4) LRRK2 - 713 : 717.0 (Job.1.S3.I1)
LRRK2 - 494; (Job.1.S3.I2) LRRK2 - 931; (Job.1.S3.I3) LRRK2 - 886; (Job.1.S3.I4)
LRRK2 - 626 : 756.0 (Job.1.S4.I1) LRRK2 - 479; (Job.1.S4.I2) LRRK2 - 840;
(Job.1.S4.I3) LRRK2 - 833; (Job.1.S4.I4) LRRK2 - 485 : 659.0
Job # 2
(Job.2.S1.I1) LRRK2 - 650; (Job.2.S1.I2) LRRK2 - 2408; (Job.2.S1.I3) LRRK2 - 619;
(Job.2.S1.I4) LRRK2 - 636 : 643.0 (Job.2.S2.I1) LRRK2 - 743; (Job.2.S2.I2) LRRK2
- 855; (Job.2.S2.I3) LRRK2 - 877; (Job.2.S2.I4) LRRK2 - 733 : 799.0 (Job.2.S3.I1)
LRRK2 - 760; (Job.2.S3.I2) LRRK2 - 762; (Job.2.S3.I3) LRRK2 - 755; (Job.2.S3.I4)
LRRK2 - 760 : 760.0 (Job.2.S4.I1) LRRK2 - 905; (Job.2.S4.I2) LRRK2 - 906;
(Job.2.S4.I3) LRRK2 - 906; (Job.2.S4.I4) LRRK2 - 901 : 905.5
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Job # 3
(Job.3.S1.I1) LRRK2 - 439; (Job.3.S1.I2) LRRK2 - 438; (Job.3.S1.I3) LRRK2 - 439;
(Job.3.S1.I4) LRRK2 - 489 : 439.0 (Job.3.S2.I1) LRRK2 - 77; (Job.3.S2.I2) LRRK2 -
79; (Job.3.S2.I3) LRRK2 - 78; (Job.3.S2.I4) LRRK2 - 209 : 78.5 (Job.3.S3.I1) LRRK2
- 782; (Job.3.S3.I2) LRRK2 - 528; (Job.3.S3.I3) LRRK2 - 478; (Job.3.S3.I4) LRRK2
- 739 : 633.5 (Job.3.S4.I1) LRRK2 - 255; (Job.3.S4.I2) LRRK2 - 485; (Job.3.S4.I3)
LRRK2 - 485; (Job.3.S4.I4) LRRK2 - 255 : 370.0
Job # 4
(Job.4.S1.I1) LRRK2 - 309; (Job.4.S1.I2) LRRK2 - 308; (Job.4.S1.I3) LRRK2 - 221;
(Job.4.S1.I4) LRRK2 - 288 : 298.0 (Job.4.S2.I1) LRRK2 - 812; (Job.4.S2.I2) LRRK2
- 808; (Job.4.S2.I3) LRRK2 - 928; (Job.4.S2.I4) LRRK2 - 811 : 811.5 (Job.4.S3.I1)
LRRK2 - 721; (Job.4.S3.I2) LRRK2 - 330; (Job.4.S3.I3) LRRK2 - 736; (Job.4.S3.I4)
LRRK2 - 246 : 525.5 (Job.4.S4.I1) LRRK2 - 893; (Job.4.S4.I2) LRRK2 - 881;
(Job.4.S4.I3) LRRK2 - 881; (Job.4.S4.I4) LRRK2 - 880 : 881.0
Best ranks of each set–island : 182 - 612 - 176 - 825 - 251 - 713 - 494 - 479 - 619
- 733 - 755 - 901 - 438 - 77 - 478 - 255 - 221 - 808 - 246 - 880 -
Median: 638.25
Median of best : 486.5
A.2.10 MAOB
Job # 0
(Job.0.S1.I1) MAOB - 10; (Job.0.S1.I2) MAOB - 10; (Job.0.S1.I3) MAOB - 10;
(Job.0.S1.I4) MAOB - 14 : 10.0 (Job.0.S2.I1) MAOB - 37; (Job.0.S2.I2) MAOB
- 37; (Job.0.S2.I3) MAOB - 37; (Job.0.S2.I4) MAOB - 31 : 37.0 (Job.0.S3.I1) MAOB
- 24; (Job.0.S3.I2) MAOB - 23; (Job.0.S3.I3) MAOB - 24; (Job.0.S3.I4) MAOB - 28
: 24.0 (Job.0.S4.I1) MAOB - 46; (Job.0.S4.I2) MAOB - 426; (Job.0.S4.I3) MAOB -
426; (Job.0.S4.I4) MAOB - 426 : 426.0
Job # 1
(Job.1.S1.I1) MAOB - 62; (Job.1.S1.I2) MAOB - 648; (Job.1.S1.I3) MAOB - 785;
(Job.1.S1.I4) MAOB - 48 : 355.0 (Job.1.S2.I1) MAOB - 81; (Job.1.S2.I2) MAOB -
75; (Job.1.S2.I3) MAOB - 81; (Job.1.S2.I4) MAOB - 67 : 78.0 (Job.1.S3.I1) MAOB
- 49; (Job.1.S3.I2) MAOB - 49; (Job.1.S3.I3) MAOB - 28; (Job.1.S3.I4) MAOB - 49 :
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49.0 (Job.1.S4.I1) MAOB - 32; (Job.1.S4.I2) MAOB - 36; (Job.1.S4.I3) MAOB - 30;
(Job.1.S4.I4) MAOB - 32 : 32.0
Job # 2
(Job.2.S1.I1) MAOB - 73; (Job.2.S1.I2) MAOB - 73; (Job.2.S1.I3) MAOB - 37;
(Job.2.S1.I4) MAOB - 884 : 73.0 (Job.2.S2.I1) MAOB - 13; (Job.2.S2.I2) MAOB
- 12; (Job.2.S2.I3) MAOB - 13; (Job.2.S2.I4) MAOB - 13 : 13.0 (Job.2.S3.I1) MAOB
- 87; (Job.2.S3.I2) MAOB - 99; (Job.2.S3.I3) MAOB - 84; (Job.2.S3.I4) MAOB - 89
: 88.0 (Job.2.S4.I1) MAOB - 52; (Job.2.S4.I2) MAOB - 52; (Job.2.S4.I3) MAOB -
365; (Job.2.S4.I4) MAOB - 52 : 52.0
Job # 3
(Job.3.S1.I1) MAOB - 19; (Job.3.S1.I2) MAOB - 89; (Job.3.S1.I3) MAOB - 19;
(Job.3.S1.I4) MAOB - 235 : 54.0 (Job.3.S2.I1) MAOB - 171; (Job.3.S2.I2) MAOB -
70; (Job.3.S2.I3) MAOB - 109; (Job.3.S2.I4) MAOB - 70 : 89.5 (Job.3.S3.I1) MAOB
- 43; (Job.3.S3.I2) MAOB - 29; (Job.3.S3.I3) MAOB - 235; (Job.3.S3.I4) MAOB - 25
: 36.0 (Job.3.S4.I1) MAOB - 32; (Job.3.S4.I2) MAOB - 33; (Job.3.S4.I3) MAOB -
32; (Job.3.S4.I4) MAOB - 34 : 32.5
Job # 4
(Job.4.S1.I1) MAOB - 37; (Job.4.S1.I2) MAOB - 44; (Job.4.S1.I3) MAOB - 54;
(Job.4.S1.I4) MAOB - 44 : 44.0 (Job.4.S2.I1) MAOB - 67; (Job.4.S2.I2) MAOB
- 74; (Job.4.S2.I3) MAOB - 49; (Job.4.S2.I4) MAOB - 67 : 67.0 (Job.4.S3.I1) MAOB
- 103; (Job.4.S3.I2) MAOB - 84; (Job.4.S3.I3) MAOB - 79; (Job.4.S3.I4) MAOB - 96
: 90.0 (Job.4.S4.I1) MAOB - 28; (Job.4.S4.I2) MAOB - 28; (Job.4.S4.I3) MAOB -
28; (Job.4.S4.I4) MAOB - 28 : 28.0
Best ranks of each set–island : 10 - 31 - 23 - 46 - 48 - 67 - 28 - 30 - 37 - 12 - 84
- 52 - 19 - 70 - 25 - 32 - 37 - 49 - 79 - 28 -
Median: 50.5
Median of best : 34.5
A.2.11 MAPT
Job # 0
(Job.0.S1.I1) MAPT - 299; (Job.0.S1.I2) MAPT - 252; (Job.0.S1.I3) MAPT - 287;
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(Job.0.S1.I4) MAPT - 287 : 287.0 (Job.0.S2.I1) MAPT - 510; (Job.0.S2.I2) MAPT
- 510; (Job.0.S2.I3) MAPT - 510; (Job.0.S2.I4) MAPT - 510 : 510.0 (Job.0.S3.I1)
MAPT - 100; (Job.0.S3.I2) MAPT - 120; (Job.0.S3.I3) MAPT - 100; (Job.0.S3.I4)
MAPT - 196 : 110.0 (Job.0.S4.I1) MAPT - 119; (Job.0.S4.I2) MAPT - 119; (Job.0.S4.I3)
MAPT - 119; (Job.0.S4.I4) MAPT - 119 : 119.0
Job # 1
(Job.1.S1.I1) MAPT - 215; (Job.1.S1.I2) MAPT - 215; (Job.1.S1.I3) MAPT - 215;
(Job.1.S1.I4) MAPT - 50 : 215.0 (Job.1.S2.I1) MAPT - 656; (Job.1.S2.I2) MAPT
- 704; (Job.1.S2.I3) MAPT - 701; (Job.1.S2.I4) MAPT - 656 : 678.5 (Job.1.S3.I1)
MAPT - 25; (Job.1.S3.I2) MAPT - 550; (Job.1.S3.I3) MAPT - 553; (Job.1.S3.I4)
MAPT - 549 : 549.5 (Job.1.S4.I1) MAPT - 125; (Job.1.S4.I2) MAPT - 128; (Job.1.S4.I3)
MAPT - 120; (Job.1.S4.I4) MAPT - 317 : 126.5
Job # 2
(Job.2.S1.I1) MAPT - 103; (Job.2.S1.I2) MAPT - 120; (Job.2.S1.I3) MAPT - 108;
(Job.2.S1.I4) MAPT - 47 : 105.5 (Job.2.S2.I1) MAPT - 798; (Job.2.S2.I2) MAPT
- 801; (Job.2.S2.I3) MAPT - 805; (Job.2.S2.I4) MAPT - 797 : 799.5 (Job.2.S3.I1)
MAPT - 880; (Job.2.S3.I2) MAPT - 805; (Job.2.S3.I3) MAPT - 542; (Job.2.S3.I4)
MAPT - 865 : 835.0 (Job.2.S4.I1) MAPT - 109; (Job.2.S4.I2) MAPT - 108; (Job.2.S4.I3)
MAPT - 109; (Job.2.S4.I4) MAPT - 643 : 109.0
Job # 3
(Job.3.S1.I1) MAPT - 589; (Job.3.S1.I2) MAPT - 307; (Job.3.S1.I3) MAPT - 307;
(Job.3.S1.I4) MAPT - 174 : 307.0 (Job.3.S2.I1) MAPT - 493; (Job.3.S2.I2) MAPT
- 435; (Job.3.S2.I3) MAPT - 459; (Job.3.S2.I4) MAPT - 478 : 468.5 (Job.3.S3.I1)
MAPT - 151; (Job.3.S3.I2) MAPT - 155; (Job.3.S3.I3) MAPT - 160; (Job.3.S3.I4)
MAPT - 161 : 157.5 (Job.3.S4.I1) MAPT - 452; (Job.3.S4.I2) MAPT - 452; (Job.3.S4.I3)
MAPT - 436; (Job.3.S4.I4) MAPT - 437 : 444.5
Job # 4
(Job.4.S1.I1) MAPT - 493; (Job.4.S1.I2) MAPT - 494; (Job.4.S1.I3) MAPT - 526;
(Job.4.S1.I4) MAPT - 759 : 510.0 (Job.4.S2.I1) MAPT - 618; (Job.4.S2.I2) MAPT
- 616; (Job.4.S2.I3) MAPT - 326; (Job.4.S2.I4) MAPT - 613 : 614.5 (Job.4.S3.I1)
MAPT - 132; (Job.4.S3.I2) MAPT - 138; (Job.4.S3.I3) MAPT - 149; (Job.4.S3.I4)
MAPT - 801 : 143.5 (Job.4.S4.I1) MAPT - 764; (Job.4.S4.I2) MAPT - 928; (Job.4.S4.I3)
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MAPT - 593; (Job.4.S4.I4) MAPT - 770 : 767.0
Best ranks of each set–island : 252 - 510 - 100 - 119 - 50 - 656 - 25 - 120 - 47 -
797 - 542 - 108 - 174 - 435 - 151 - 436 - 493 - 326 - 132 - 593 -
Median: 375.75
Median of best : 213.0
A.2.12 PARK2
Job # 0
(Job.0.S1.I1) PARK2 - 4; (Job.0.S1.I2) PARK2 - 4; (Job.0.S1.I3) PARK2 - 4; (Job.0.S1.I4)
PARK2 - 4 : 4.0 (Job.0.S2.I1) PARK2 - 5; (Job.0.S2.I2) PARK2 - 5; (Job.0.S2.I3)
PARK2 - 5; (Job.0.S2.I4) PARK2 - 4 : 5.0 (Job.0.S3.I1) PARK2 - 33; (Job.0.S3.I2)
PARK2 - 2; (Job.0.S3.I3) PARK2 - 4; (Job.0.S3.I4) PARK2 - 4 : 4.0 (Job.0.S4.I1)
PARK2 - 4; (Job.0.S4.I2) PARK2 - 4; (Job.0.S4.I3) PARK2 - 1; (Job.0.S4.I4) PARK2
- 4 : 4.0
Job # 1
(Job.1.S1.I1) PARK2 - 5; (Job.1.S1.I2) PARK2 - 5; (Job.1.S1.I3) PARK2 - 5; (Job.1.S1.I4)
PARK2 - 35 : 5.0 (Job.1.S2.I1) PARK2 - 4; (Job.1.S2.I2) PARK2 - 4; (Job.1.S2.I3)
PARK2 - 4; (Job.1.S2.I4) PARK2 - 4 : 4.0 (Job.1.S3.I1) PARK2 - 2; (Job.1.S3.I2)
PARK2 - 2; (Job.1.S3.I3) PARK2 - 4; (Job.1.S3.I4) PARK2 - 5 : 3.0 (Job.1.S4.I1)
PARK2 - 5; (Job.1.S4.I2) PARK2 - 6; (Job.1.S4.I3) PARK2 - 6; (Job.1.S4.I4) PARK2
- 5 : 5.5
Job # 2
(Job.2.S1.I1) PARK2 - 12; (Job.2.S1.I2) PARK2 - 13; (Job.2.S1.I3) PARK2 - 20;
(Job.2.S1.I4) PARK2 - 9 : 12.5 (Job.2.S2.I1) PARK2 - 5; (Job.2.S2.I2) PARK2 -
5; (Job.2.S2.I3) PARK2 - 5; (Job.2.S2.I4) PARK2 - 5 : 5.0 (Job.2.S3.I1) PARK2
- 5; (Job.2.S3.I2) PARK2 - 5; (Job.2.S3.I3) PARK2 - 5; (Job.2.S3.I4) PARK2 - 5 :
5.0 (Job.2.S4.I1) PARK2 - 25; (Job.2.S4.I2) PARK2 - 25; (Job.2.S4.I3) PARK2 - 25;
(Job.2.S4.I4) PARK2 - 22 : 25.0
Job # 3
(Job.3.S1.I1) PARK2 - 5; (Job.3.S1.I2) PARK2 - 5; (Job.3.S1.I3) PARK2 - 4; (Job.3.S1.I4)
PARK2 - 5 : 5.0 (Job.3.S2.I1) PARK2 - 4; (Job.3.S2.I2) PARK2 - 4; (Job.3.S2.I3)
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PARK2 - 6; (Job.3.S2.I4) PARK2 - 4 : 4.0 (Job.3.S3.I1) PARK2 - 4; (Job.3.S3.I2)
PARK2 - 4; (Job.3.S3.I3) PARK2 - 4; (Job.3.S3.I4) PARK2 - 4 : 4.0 (Job.3.S4.I1)
PARK2 - 94; (Job.3.S4.I2) PARK2 - 95; (Job.3.S4.I3) PARK2 - 115; (Job.3.S4.I4)
PARK2 - 94 : 94.5
Job # 4
(Job.4.S1.I1) PARK2 - 32; (Job.4.S1.I2) PARK2 - 32; (Job.4.S1.I3) PARK2 - 15;
(Job.4.S1.I4) PARK2 - 3 : 23.5 (Job.4.S2.I1) PARK2 - 15; (Job.4.S2.I2) PARK2 - 6;
(Job.4.S2.I3) PARK2 - 15; (Job.4.S2.I4) PARK2 - 15 : 15.0 (Job.4.S3.I1) PARK2 -
11; (Job.4.S3.I2) PARK2 - 11; (Job.4.S3.I3) PARK2 - 18; (Job.4.S3.I4) PARK2 - 15
: 13.0 (Job.4.S4.I1) PARK2 - 21; (Job.4.S4.I2) PARK2 - 9; (Job.4.S4.I3) PARK2 -
12; (Job.4.S4.I4) PARK2 - 11 : 11.5
Best ranks of each set–island : 4 - 4 - 2 - 1 - 5 - 4 - 2 - 5 - 9 - 5 - 5 - 22 - 4 - 4
- 4 - 94 - 3 - 6 - 11 - 9 -
Median: 5.0
Median of best : 4.5
A.2.13 PINK1
Job # 0
(Job.0.S1.I1) PINK1 - 2; (Job.0.S1.I2) PINK1 - 1; (Job.0.S1.I3) PINK1 - 2; (Job.0.S1.I4)
PINK1 - 2 : 2.0 (Job.0.S2.I1) PINK1 - 823; (Job.0.S2.I2) PINK1 - 5; (Job.0.S2.I3)
PINK1 - 812; (Job.0.S2.I4) PINK1 - 868 : 817.5 (Job.0.S3.I1) PINK1 - 4; (Job.0.S3.I2)
PINK1 - 4; (Job.0.S3.I3) PINK1 - 5; (Job.0.S3.I4) PINK1 - 4 : 4.0 (Job.0.S4.I1)
PINK1 - 6; (Job.0.S4.I2) PINK1 - 5; (Job.0.S4.I3) PINK1 - 8; (Job.0.S4.I4) PINK1 -
5 : 5.5
Job # 1
(Job.1.S1.I1) PINK1 - 6; (Job.1.S1.I2) PINK1 - 6; (Job.1.S1.I3) PINK1 - 4; (Job.1.S1.I4)
PINK1 - 6 : 6.0 (Job.1.S2.I1) PINK1 - 37; (Job.1.S2.I2) PINK1 - 30; (Job.1.S2.I3)
PINK1 - 11; (Job.1.S2.I4) PINK1 - 35 : 32.5 (Job.1.S3.I1) PINK1 - 4; (Job.1.S3.I2)
PINK1 - 4; (Job.1.S3.I3) PINK1 - 4; (Job.1.S3.I4) PINK1 - 9 : 4.0 (Job.1.S4.I1)
PINK1 - 4; (Job.1.S4.I2) PINK1 - 4; (Job.1.S4.I3) PINK1 - 4; (Job.1.S4.I4) PINK1 -
57 : 4.0
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Job # 2
(Job.2.S1.I1) PINK1 - 64; (Job.2.S1.I2) PINK1 - 63; (Job.2.S1.I3) PINK1 - 64;
(Job.2.S1.I4) PINK1 - 61 : 63.5 (Job.2.S2.I1) PINK1 - 41; (Job.2.S2.I2) PINK1 -
33; (Job.2.S2.I3) PINK1 - 41; (Job.2.S2.I4) PINK1 - 36 : 38.5 (Job.2.S3.I1) PINK1
- 1; (Job.2.S3.I2) PINK1 - 4; (Job.2.S3.I3) PINK1 - 4; (Job.2.S3.I4) PINK1 - 4 :
4.0 (Job.2.S4.I1) PINK1 - 4; (Job.2.S4.I2) PINK1 - 4; (Job.2.S4.I3) PINK1 - 4;
(Job.2.S4.I4) PINK1 - 4 : 4.0
Job # 3
(Job.3.S1.I1) PINK1 - 6; (Job.3.S1.I2) PINK1 - 6; (Job.3.S1.I3) PINK1 - 6; (Job.3.S1.I4)
PINK1 - 4 : 6.0 (Job.3.S2.I1) PINK1 - 5; (Job.3.S2.I2) PINK1 - 5; (Job.3.S2.I3)
PINK1 - 29; (Job.3.S2.I4) PINK1 - 29 : 17.0 (Job.3.S3.I1) PINK1 - 13; (Job.3.S3.I2)
PINK1 - 38; (Job.3.S3.I3) PINK1 - 38; (Job.3.S3.I4) PINK1 - 34 : 36.0 (Job.3.S4.I1)
PINK1 - 6; (Job.3.S4.I2) PINK1 - 6; (Job.3.S4.I3) PINK1 - 4; (Job.3.S4.I4) PINK1 -
4 : 5.0
Job # 4
(Job.4.S1.I1) PINK1 - 5; (Job.4.S1.I2) PINK1 - 5; (Job.4.S1.I3) PINK1 - 5; (Job.4.S1.I4)
PINK1 - 5 : 5.0 (Job.4.S2.I1) PINK1 - 110; (Job.4.S2.I2) PINK1 - 111; (Job.4.S2.I3)
PINK1 - 90; (Job.4.S2.I4) PINK1 - 5 : 100.0 (Job.4.S3.I1) PINK1 - 5; (Job.4.S3.I2)
PINK1 - 5; (Job.4.S3.I3) PINK1 - 4; (Job.4.S3.I4) PINK1 - 5 : 5.0 (Job.4.S4.I1)
PINK1 - 60; (Job.4.S4.I2) PINK1 - 62; (Job.4.S4.I3) PINK1 - 64; (Job.4.S4.I4) PINK1
- 62 : 62.0
Best ranks of each set–island : 1 - 5 - 4 - 5 - 4 - 11 - 4 - 4 - 61 - 33 - 1 - 4 - 4 -
5 - 13 - 4 - 5 - 5 - 4 - 60 -
Median: 5.75
Median of best : 4.5
A.2.14 PON1
Job # 0
(Job.0.S1.I1) PON1 - 34; (Job.0.S1.I2) PON1 - 36; (Job.0.S1.I3) PON1 - 34; (Job.0.S1.I4)
PON1 - 35 : 34.5 (Job.0.S2.I1) PON1 - 36; (Job.0.S2.I2) PON1 - 32; (Job.0.S2.I3)
PON1 - 32; (Job.0.S2.I4) PON1 - 62 : 34.0 (Job.0.S3.I1) PON1 - 790; (Job.0.S3.I2)
PON1 - 670; (Job.0.S3.I3) PON1 - 682; (Job.0.S3.I4) PON1 - 847 : 736.0 (Job.0.S4.I1)
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PON1 - 52; (Job.0.S4.I2) PON1 - 39; (Job.0.S4.I3) PON1 - 39; (Job.0.S4.I4) PON1 -
52 : 45.5
Job # 1
(Job.1.S1.I1) PON1 - 40; (Job.1.S1.I2) PON1 - 55; (Job.1.S1.I3) PON1 - 82; (Job.1.S1.I4)
PON1 - 39 : 47.5 (Job.1.S2.I1) PON1 - 342; (Job.1.S2.I2) PON1 - 342; (Job.1.S2.I3)
PON1 - 274; (Job.1.S2.I4) PON1 - 305 : 323.5 (Job.1.S3.I1) PON1 - 37; (Job.1.S3.I2)
PON1 - 28; (Job.1.S3.I3) PON1 - 31; (Job.1.S3.I4) PON1 - 30 : 30.5 (Job.1.S4.I1)
PON1 - 34; (Job.1.S4.I2) PON1 - 34; (Job.1.S4.I3) PON1 - 47; (Job.1.S4.I4) PON1 -
35 : 34.5
Job # 2
(Job.2.S1.I1) PON1 - 56; (Job.2.S1.I2) PON1 - 49; (Job.2.S1.I3) PON1 - 52; (Job.2.S1.I4)
PON1 - 30 : 50.5 (Job.2.S2.I1) PON1 - 64; (Job.2.S2.I2) PON1 - 28; (Job.2.S2.I3)
PON1 - 101; (Job.2.S2.I4) PON1 - 64 : 64.0 (Job.2.S3.I1) PON1 - 81; (Job.2.S3.I2)
PON1 - 65; (Job.2.S3.I3) PON1 - 63; (Job.2.S3.I4) PON1 - 69 : 67.0 (Job.2.S4.I1)
PON1 - 26; (Job.2.S4.I2) PON1 - 99; (Job.2.S4.I3) PON1 - 98; (Job.2.S4.I4) PON1 -
79 : 88.5
Job # 3
(Job.3.S1.I1) PON1 - 366; (Job.3.S1.I2) PON1 - 136; (Job.3.S1.I3) PON1 - 380;
(Job.3.S1.I4) PON1 - 428 : 373.0 (Job.3.S2.I1) PON1 - 36; (Job.3.S2.I2) PON1 -
37; (Job.3.S2.I3) PON1 - 36; (Job.3.S2.I4) PON1 - 33 : 36.0 (Job.3.S3.I1) PON1
- 35; (Job.3.S3.I2) PON1 - 36; (Job.3.S3.I3) PON1 - 36; (Job.3.S3.I4) PON1 - 28 :
35.5 (Job.3.S4.I1) PON1 - 36; (Job.3.S4.I2) PON1 - 36; (Job.3.S4.I3) PON1 - 36;
(Job.3.S4.I4) PON1 - 36 : 36.0
Job # 4
(Job.4.S1.I1) PON1 - 76; (Job.4.S1.I2) PON1 - 77; (Job.4.S1.I3) PON1 - 77; (Job.4.S1.I4)
PON1 - 66 : 76.5 (Job.4.S2.I1) PON1 - 65; (Job.4.S2.I2) PON1 - 66; (Job.4.S2.I3)
PON1 - 77; (Job.4.S2.I4) PON1 - 47 : 65.5 (Job.4.S3.I1) PON1 - 71; (Job.4.S3.I2)
PON1 - 80; (Job.4.S3.I3) PON1 - 72; (Job.4.S3.I4) PON1 - 49 : 71.5 (Job.4.S4.I1)
PON1 - 35; (Job.4.S4.I2) PON1 - 31; (Job.4.S4.I3) PON1 - 35; (Job.4.S4.I4) PON1 -
35 : 35.0
Best ranks of each set–island : 34 - 32 - 670 - 39 - 39 - 274 - 28 - 34 - 30 - 28 -
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63 - 26 - 136 - 33 - 28 - 36 - 66 - 47 - 49 - 31 -
Median: 49.0
Median of best : 35.0
A.2.15 SNCA
Job # 0
(Job.0.S1.I1) SNCA - 191; (Job.0.S1.I2) SNCA - 4; (Job.0.S1.I3) SNCA - 2; (Job.0.S1.I4)
SNCA - 5 : 4.5 (Job.0.S2.I1) SNCA - 357; (Job.0.S2.I2) SNCA - 469; (Job.0.S2.I3)
SNCA - 480; (Job.0.S2.I4) SNCA - 468 : 468.5 (Job.0.S3.I1) SNCA - 17; (Job.0.S3.I2)
SNCA - 17; (Job.0.S3.I3) SNCA - 18; (Job.0.S3.I4) SNCA - 17 : 17.0 (Job.0.S4.I1)
SNCA - 4; (Job.0.S4.I2) SNCA - 4; (Job.0.S4.I3) SNCA - 4; (Job.0.S4.I4) SNCA -
2693 : 4.0
Job # 1
(Job.1.S1.I1) SNCA - 5; (Job.1.S1.I2) SNCA - 6; (Job.1.S1.I3) SNCA - 6; (Job.1.S1.I4)
SNCA - 5 : 5.5 (Job.1.S2.I1) SNCA - 83; (Job.1.S2.I2) SNCA - 23; (Job.1.S2.I3)
SNCA - 66; (Job.1.S2.I4) SNCA - 66 : 66.0 (Job.1.S3.I1) SNCA - 4; (Job.1.S3.I2)
SNCA - 3; (Job.1.S3.I3) SNCA - 4; (Job.1.S3.I4) SNCA - 3 : 3.5 (Job.1.S4.I1) SNCA
- 4; (Job.1.S4.I2) SNCA - 4; (Job.1.S4.I3) SNCA - 4; (Job.1.S4.I4) SNCA - 4 : 4.0
Job # 2
(Job.2.S1.I1) SNCA - 22; (Job.2.S1.I2) SNCA - 78; (Job.2.S1.I3) SNCA - 109; (Job.2.S1.I4)
SNCA - 24 : 51.0 (Job.2.S2.I1) SNCA - 17; (Job.2.S2.I2) SNCA - 17; (Job.2.S2.I3)
SNCA - 24; (Job.2.S2.I4) SNCA - 16 : 17.0 (Job.2.S3.I1) SNCA - 3; (Job.2.S3.I2)
SNCA - 4; (Job.2.S3.I3) SNCA - 3; (Job.2.S3.I4) SNCA - 4 : 3.5 (Job.2.S4.I1) SNCA
- 11; (Job.2.S4.I2) SNCA - 136; (Job.2.S4.I3) SNCA - 23; (Job.2.S4.I4) SNCA - 107
: 65.0
Job # 3
(Job.3.S1.I1) SNCA - 901; (Job.3.S1.I2) SNCA - 904; (Job.3.S1.I3) SNCA - 901;
(Job.3.S1.I4) SNCA - 901 : 901.0 (Job.3.S2.I1) SNCA - 3; (Job.3.S2.I2) SNCA - 2;
(Job.3.S2.I3) SNCA - 3; (Job.3.S2.I4) SNCA - 3 : 3.0 (Job.3.S3.I1) SNCA - 136;
(Job.3.S3.I2) SNCA - 196; (Job.3.S3.I3) SNCA - 874; (Job.3.S3.I4) SNCA - 3 : 166.0
(Job.3.S4.I1) SNCA - 395; (Job.3.S4.I2) SNCA - 424; (Job.3.S4.I3) SNCA - 428;
(Job.3.S4.I4) SNCA - 395 : 409.5
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Job # 4
(Job.4.S1.I1) SNCA - 43; (Job.4.S1.I2) SNCA - 403; (Job.4.S1.I3) SNCA - 337;
(Job.4.S1.I4) SNCA - 25 : 190.0 (Job.4.S2.I1) SNCA - 497; (Job.4.S2.I2) SNCA
- 453; (Job.4.S2.I3) SNCA - 505; (Job.4.S2.I4) SNCA - 3 : 475.0 (Job.4.S3.I1) SNCA
- 40; (Job.4.S3.I2) SNCA - 24; (Job.4.S3.I3) SNCA - 15; (Job.4.S3.I4) SNCA - 25
: 24.5 (Job.4.S4.I1) SNCA - 3; (Job.4.S4.I2) SNCA - 3; (Job.4.S4.I3) SNCA - 4;
(Job.4.S4.I4) SNCA - 3 : 3.0
Best ranks of each set–island : 2 - 357 - 17 - 4 - 5 - 23 - 3 - 4 - 22 - 16 - 3 - 11
- 901 - 2 - 3 - 395 - 25 - 3 - 15 - 3 -
Median: 20.75
Median of best : 8.0
